PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 26027838-3 2015 In this study, we evaluated the skin barrier function of hairless mice with colon carcinoma that was induced by azoxymethane (AOM) and dextran sodium sulfate (DSS). Azoxymethane 112-124 lysine demethylase and nuclear receptor corepressor Mus musculus 57-65 25277138-0 2014 Activation of intestinal human pregnane X receptor protects against azoxymethane/dextran sulfate sodium-induced colon cancer. Azoxymethane 68-80 nuclear receptor subfamily 1 group I member 2 Homo sapiens 31-50 26397238-5 2015 QD655-VEGFR2 was applied to the colon of azoxymethane (AOM-) or saline-treated control mice in vivo via lavage. Azoxymethane 41-53 kinase insert domain protein receptor Mus musculus 6-12 26397238-5 2015 QD655-VEGFR2 was applied to the colon of azoxymethane (AOM-) or saline-treated control mice in vivo via lavage. Azoxymethane 55-58 kinase insert domain protein receptor Mus musculus 6-12 25218594-0 2014 Aldose reductase inhibition suppresses azoxymethane-induced colonic premalignant lesions in C57BL/KsJ-db/db mice. Azoxymethane 39-51 aldo-keto reductase family 1, member B3 (aldose reductase) Mus musculus 0-16 25218594-2 2014 In the present study, we examined the effects of polyol pathway enzyme aldose reductase (AR) inhibitor, fidarestat, on the development of azoxymethane (AOM)-induced colonic premalignant lesions in C57BL/KsJ-db/db obese mice. Azoxymethane 138-150 aldo-keto reductase family 1, member B3 (aldose reductase) Mus musculus 89-91 25216325-4 2014 METHODS: In vivo molecular imaging was performed to examine colon tumorigenesis in Lgr5-EGFP mice treated with azoxymethane and dextran sodium sulfate. Azoxymethane 111-123 leucine rich repeat containing G protein coupled receptor 5 Mus musculus 83-87 25085247-5 2014 Similarly, Hur(IKO) mice subjected to an inflammatory colon carcinogenesis protocol [azoxymethane and dextran sodium sulfate (AOM-DSS) administration] exhibited a two-fold decrease in tumor burden. Azoxymethane 85-97 ELAV (embryonic lethal, abnormal vision)-like 1 (Hu antigen R) Mus musculus 11-14 25155760-4 2014 METHODS: FASN expression (IHC) in the colonic epithelium from azoxymethane and polyposis in rat colon (Pirc) models of colorectal cancer was studied. Azoxymethane 62-74 fatty acid synthase Rattus norvegicus 9-13 25155760-6 2014 RESULTS: FASN expression progressively increased from premalignant to malignant stage in the azoxymethane model (1.9- to 2.5-fold; P < 0.0001) and was also higher in the adenomas compared with adjacent uninvolved mucosa (1.8- to 3.4-fold; P < 0.001) in the Pirc model. Azoxymethane 93-105 fatty acid synthase Homo sapiens 9-13 25212605-1 2014 PURPOSE: We previously showed that EGF receptor (EGFR) promotes tumorigenesis in the azoxymethane/dextran sulfate sodium (AOM/DSS) model, whereas vitamin D suppresses tumorigenesis. Azoxymethane 85-97 epidermal growth factor receptor Mus musculus 35-47 25212605-1 2014 PURPOSE: We previously showed that EGF receptor (EGFR) promotes tumorigenesis in the azoxymethane/dextran sulfate sodium (AOM/DSS) model, whereas vitamin D suppresses tumorigenesis. Azoxymethane 85-97 epidermal growth factor receptor Mus musculus 49-53 25212605-1 2014 PURPOSE: We previously showed that EGF receptor (EGFR) promotes tumorigenesis in the azoxymethane/dextran sulfate sodium (AOM/DSS) model, whereas vitamin D suppresses tumorigenesis. Azoxymethane 122-125 epidermal growth factor receptor Mus musculus 35-47 25212605-1 2014 PURPOSE: We previously showed that EGF receptor (EGFR) promotes tumorigenesis in the azoxymethane/dextran sulfate sodium (AOM/DSS) model, whereas vitamin D suppresses tumorigenesis. Azoxymethane 122-125 epidermal growth factor receptor Mus musculus 49-53 24532706-0 2014 Luteolin inhibits matrix metalloproteinase 9 and 2 in azoxymethane-induced colon carcinogenesis. Azoxymethane 54-66 matrix metallopeptidase 9 Mus musculus 18-50 24532706-1 2014 The present investigation deals with the antimetastatic role of luteolin (LUT) by inhibiting matrix metalloproteinase (MMP)-9 and -2 in azoxymethane (AOM)-induced colon carcinogenesis in Balb/C mice. Azoxymethane 136-148 matrix metallopeptidase 9 Mus musculus 93-132 24532706-1 2014 The present investigation deals with the antimetastatic role of luteolin (LUT) by inhibiting matrix metalloproteinase (MMP)-9 and -2 in azoxymethane (AOM)-induced colon carcinogenesis in Balb/C mice. Azoxymethane 150-153 matrix metallopeptidase 9 Mus musculus 93-132 25104409-3 2014 The resulting QD655-VEGFR2 contrast agent was applied in vivo to the colon of azoxymethane (AOM) treated mice via lavage and allowed to incubate. Azoxymethane 78-90 kinase insert domain protein receptor Mus musculus 20-26 24827115-3 2014 Specifically, decoloring of the azoxymethane-treated rat colon after scoring classical ACF (cACF) resulted in visualization of a subset of aberrant crypts that remained densely stained. Azoxymethane 32-44 ATP-dependent chromatin assembly factor large subunit Drosophila melanogaster 87-90 24710407-3 2014 Remarkably, imposing a modest 50% reduction in circulating prothrombin in fII+/- mice, a level that carries no significant bleeding risk, dramatically decreased adenoma formation following an azoxymethane/dextran sodium sulfate challenge. Azoxymethane 192-204 coagulation factor II Mus musculus 74-77 26484096-8 2014 Furthermore, we induced inflammation-driven colon tumors in Lgr5-EGFP-IRES-Cre-ERT2 mice via administration of azoxymethane and dextrane sodium sulfate. Azoxymethane 111-123 leucine rich repeat containing G protein coupled receptor 5 Mus musculus 60-64 26484096-8 2014 Furthermore, we induced inflammation-driven colon tumors in Lgr5-EGFP-IRES-Cre-ERT2 mice via administration of azoxymethane and dextrane sodium sulfate. Azoxymethane 111-123 mitogen-activated protein kinase 3 Mus musculus 79-83 24867956-4 2014 In a murine model of colorectal cancer induced by azoxymethane, NLRX1-/- mice developed fewer tumors than wild type mice. Azoxymethane 50-62 NLR family member X1 Mus musculus 64-69 24867956-5 2014 In contrast, in a colitis-associated cancer model combining azoxymethane and dextran sulfate sodium, NLRX1-/- mice developed a more severe pathology likely due to the increased sensitivity to dextran sulfate sodium colitis. Azoxymethane 60-72 NLR family member X1 Mus musculus 101-106 24694019-9 2014 RESULTS: Azoxymethane-treated Chrm3-/- mice had fewer and smaller colon tumors than wild-type mice. Azoxymethane 9-21 cholinergic receptor, muscarinic 3, cardiac Mus musculus 30-35 24686242-7 2014 Moreover, in the azoxymethane-dextran sodium sulfate model, CEA-specific CAR Tregs significantly decreased the subsequent colorectal tumor burden. Azoxymethane 17-29 carcinoembryonic antigen gene family Mus musculus 60-63 24366884-4 2014 Herein, we demonstrated that colonic epithelial cells (CEC) were a major cellular source of GM-CSF and its production was significantly augmented when CAC model was established by administration of azoxymethane and dextran sulfate sodium. Azoxymethane 198-210 colony stimulating factor 2 Homo sapiens 92-98 24282287-4 2014 Additionally, we exposed Lgr5-EGFP-IRES-CreERT2 mice to azoxymethane/dextrane sodium sulfate (AOM/DSS), which induces inflammation-driven colon tumors. Azoxymethane 56-68 leucine rich repeat containing G protein coupled receptor 5 Mus musculus 25-29 24282287-4 2014 Additionally, we exposed Lgr5-EGFP-IRES-CreERT2 mice to azoxymethane/dextrane sodium sulfate (AOM/DSS), which induces inflammation-driven colon tumors. Azoxymethane 94-97 leucine rich repeat containing G protein coupled receptor 5 Mus musculus 25-29 24024667-0 2014 Luteolin, a bioflavonoid inhibits Azoxymethane-induced colorectal cancer through activation of Nrf2 signaling. Azoxymethane 34-46 nuclear factor, erythroid derived 2, like 2 Mus musculus 95-99 24377586-7 2014 Mitochondrial enzymes such as isocitrate dehydrogenase (ICDH), alpha-keto dehydrogenase (alpha-KDH), succinate dehydrogenase (SDH) and the activities of respiratory chain enzymes NADH dehydrogenase and cytochrome c oxidase were found to be elevated in AOM-treated animals. Azoxymethane 252-255 aminoadipate-semialdehyde synthase Mus musculus 126-129 25036966-0 2014 Bovine milk-derived alpha-lactalbumin inhibits colon inflammation and carcinogenesis in azoxymethane and dextran sodium sulfate-treated mice. Azoxymethane 88-100 lactalbumin, alpha Mus musculus 20-37 24140386-0 2013 Repair and removal of azoxymethane-induced O6-methylguanine in rat colon by O6-methylguanine DNA methyltransferase and apoptosis. Azoxymethane 22-34 O-6-methylguanine-DNA methyltransferase Rattus norvegicus 76-114 24140386-4 2013 In rats given AOM (10 mg/kg), the formation of O(6)meG occurs within 2 h of exposure, accompanied by rapid depletion of MGMT activity and followed by the induction of an acute apoptotic response that peaks at 6-8 h. MGMT repair and apoptosis are dependent on AOM dose and O(6)meG load. Azoxymethane 14-17 O-6-methylguanine-DNA methyltransferase Rattus norvegicus 120-124 24140386-4 2013 In rats given AOM (10 mg/kg), the formation of O(6)meG occurs within 2 h of exposure, accompanied by rapid depletion of MGMT activity and followed by the induction of an acute apoptotic response that peaks at 6-8 h. MGMT repair and apoptosis are dependent on AOM dose and O(6)meG load. Azoxymethane 14-17 O-6-methylguanine-DNA methyltransferase Rattus norvegicus 216-220 24140386-4 2013 In rats given AOM (10 mg/kg), the formation of O(6)meG occurs within 2 h of exposure, accompanied by rapid depletion of MGMT activity and followed by the induction of an acute apoptotic response that peaks at 6-8 h. MGMT repair and apoptosis are dependent on AOM dose and O(6)meG load. Azoxymethane 259-262 O-6-methylguanine-DNA methyltransferase Rattus norvegicus 216-220 24140386-6 2013 AOM, 10 mg/kg, overwhelms MGMT repair for about 96 h and renewed MGMT activity is only observed once O(6)meG is no longer detectable. Azoxymethane 0-3 O-6-methylguanine-DNA methyltransferase Rattus norvegicus 26-30 24140386-6 2013 AOM, 10 mg/kg, overwhelms MGMT repair for about 96 h and renewed MGMT activity is only observed once O(6)meG is no longer detectable. Azoxymethane 0-3 O-6-methylguanine-DNA methyltransferase Rattus norvegicus 65-69 24025712-3 2013 EXPERIMENTAL DESIGN: The azoxymethane/dextran sodium sulfate mouse model of sporadic colon cancer represents an adequate source for the isolation of CAFs and normal fibroblasts. Azoxymethane 25-37 T-box transcription factor 1 Homo sapiens 149-153 24617038-0 2013 Inhibition of beta-catenin and KRAS expressions by Piper betle in azoxymethane-induced colon cancer of male Fischer 344 rats. Azoxymethane 66-78 catenin beta 1 Rattus norvegicus 14-26 24617038-0 2013 Inhibition of beta-catenin and KRAS expressions by Piper betle in azoxymethane-induced colon cancer of male Fischer 344 rats. Azoxymethane 66-78 KRAS proto-oncogene, GTPase Rattus norvegicus 31-35 24251703-4 2013 Other studies have investigated the effect of adiponectin under the normal and high-fat diet conditions in a mouse model of azoxymethane-induced colon cancer. Azoxymethane 124-136 adiponectin, C1Q and collagen domain containing Mus musculus 46-57 23784800-6 2013 Furthermore, dietary P40 at 10-30% significantly suppressed azoxymethane-induced formation of aberrant crypt foci in the colons of CF-1 mice in conjunction with, at least in part, a lesser proliferative PCNA and a greater apoptotic caspase-3 expression in the colon mucosal epithelial cells. Azoxymethane 60-72 interleukin 9 Mus musculus 21-24 23784800-6 2013 Furthermore, dietary P40 at 10-30% significantly suppressed azoxymethane-induced formation of aberrant crypt foci in the colons of CF-1 mice in conjunction with, at least in part, a lesser proliferative PCNA and a greater apoptotic caspase-3 expression in the colon mucosal epithelial cells. Azoxymethane 60-72 caspase 3 Mus musculus 232-241 23784081-2 2013 Azoxymethane-induced aberrant crypt focus (ACF; 6 weeks) and tumours (32 weeks) were analysed in wild-type (WT) BALB/c mice, as well as in IL-4Ralpha (-) (/-) , IL-13 (-/-) and "double-knockout" (DKO) animals. Azoxymethane 0-12 interleukin 13 Mus musculus 161-166 23027128-2 2013 Disruption of Ptk6 decreases azoxymethane-induced colon tumorigenesis in mice by preventing signal transducer and activator of transcription 3 activation. Azoxymethane 29-41 PTK6 protein tyrosine kinase 6 Mus musculus 14-18 23027128-2 2013 Disruption of Ptk6 decreases azoxymethane-induced colon tumorigenesis in mice by preventing signal transducer and activator of transcription 3 activation. Azoxymethane 29-41 signal transducer and activator of transcription 3 Mus musculus 92-142 23977205-0 2013 Deletion of glutathione peroxidase-2 inhibits azoxymethane-induced colon cancer development. Azoxymethane 46-58 glutathione peroxidase 2 Mus musculus 12-36 23824743-5 2013 Isorhamnetin inhibited AOM/DSS-induced oncogenic c-Src activation and beta-catenin nuclear translocation, while promoting the expression of C-terminal Src kinase (CSK), a negative regulator of Src family of tyrosine kinases. Azoxymethane 23-26 SRC proto-oncogene, non-receptor tyrosine kinase Homo sapiens 49-54 23824743-5 2013 Isorhamnetin inhibited AOM/DSS-induced oncogenic c-Src activation and beta-catenin nuclear translocation, while promoting the expression of C-terminal Src kinase (CSK), a negative regulator of Src family of tyrosine kinases. Azoxymethane 23-26 catenin beta 1 Homo sapiens 70-82 23824743-5 2013 Isorhamnetin inhibited AOM/DSS-induced oncogenic c-Src activation and beta-catenin nuclear translocation, while promoting the expression of C-terminal Src kinase (CSK), a negative regulator of Src family of tyrosine kinases. Azoxymethane 23-26 SRC proto-oncogene, non-receptor tyrosine kinase Homo sapiens 51-54 22986531-5 2013 Immunohistochemistry revealed that HNF4alpha, unlike GATA6, exhibited a similar decrease to Cdx2 in genetic (Apc(min/+) and Apc(Delta14/+)) and chemically induced (Azoxymethane (AOM) treatment) models of intestinal tumors in mice. Azoxymethane 164-176 hepatic nuclear factor 4, alpha Mus musculus 35-44 23878224-6 2013 Here we demonstrate that azoxymethane (AOM) and dextran sulfate sodium (DSS)-induced inflammation-associated cancer is exacerbated in mice lacking Axl and Mer. Azoxymethane 25-37 AXL receptor tyrosine kinase Mus musculus 147-150 23878224-6 2013 Here we demonstrate that azoxymethane (AOM) and dextran sulfate sodium (DSS)-induced inflammation-associated cancer is exacerbated in mice lacking Axl and Mer. Azoxymethane 39-42 AXL receptor tyrosine kinase Mus musculus 147-150 23707755-0 2013 Effects of modulating M3 muscarinic receptor activity on azoxymethane-induced liver injury in mice. Azoxymethane 57-69 cholinergic receptor, muscarinic 3, cardiac Mus musculus 22-44 23598468-3 2013 We hypothesized that SPI and GEN induced epigenetic modifications on Sfrp2, Sfrp5 and Wnt5a genes, suppressing their gene expression induced by azoxymethane (AOM), a chemical carcinogen, to the similar level as that of pre-AOM period. Azoxymethane 144-156 secreted frizzled-related protein 2 Rattus norvegicus 69-74 23598468-3 2013 We hypothesized that SPI and GEN induced epigenetic modifications on Sfrp2, Sfrp5 and Wnt5a genes, suppressing their gene expression induced by azoxymethane (AOM), a chemical carcinogen, to the similar level as that of pre-AOM period. Azoxymethane 144-156 secreted frizzled-related protein 5 Rattus norvegicus 76-81 23598468-3 2013 We hypothesized that SPI and GEN induced epigenetic modifications on Sfrp2, Sfrp5 and Wnt5a genes, suppressing their gene expression induced by azoxymethane (AOM), a chemical carcinogen, to the similar level as that of pre-AOM period. Azoxymethane 144-156 Wnt family member 5A Rattus norvegicus 86-91 23660392-3 2013 MyD88 is also protective, for example in oncogenic virus carcinogenesis or, acting downstream of IL-18R to strengthen mucosal repair, in azoxymethane (AOM)/dextran sulfate sodium (DSS)-induced colon carcinogenesis. Azoxymethane 137-149 MYD88 innate immune signal transduction adaptor Homo sapiens 0-5 23660392-3 2013 MyD88 is also protective, for example in oncogenic virus carcinogenesis or, acting downstream of IL-18R to strengthen mucosal repair, in azoxymethane (AOM)/dextran sulfate sodium (DSS)-induced colon carcinogenesis. Azoxymethane 151-154 MYD88 innate immune signal transduction adaptor Homo sapiens 0-5 23922772-7 2013 Furthermore, FJX1 null mice develop significantly fewer colonic polyps than wild-type littermates after combined dextran sodium sulfate (DSS) and azoxymethane (AOM) treatment. Azoxymethane 146-158 four jointed box 1 Mus musculus 13-17 23669411-9 2013 RESULTS: C57Bl6 mice given pharmacologic inhibitors of IDO1 and IDO1-/- mice had lower tumor burdens and reduced proliferation in the neoplastic epithelium after administration of dextran sodium sulfate and azoxymethane than control mice. Azoxymethane 207-219 indoleamine 2,3-dioxygenase 1 Mus musculus 55-59 23669411-9 2013 RESULTS: C57Bl6 mice given pharmacologic inhibitors of IDO1 and IDO1-/- mice had lower tumor burdens and reduced proliferation in the neoplastic epithelium after administration of dextran sodium sulfate and azoxymethane than control mice. Azoxymethane 207-219 indoleamine 2,3-dioxygenase 1 Mus musculus 64-68 23708609-2 2013 Previously, we showed that the selective iNOS inhibitor S,S"-1,4-phenylenebis(1,2-ethanediyl)bis-isothiourea (PBIT) caused significant inhibition of colon carcinogenesis induced by azoxymethane (AOM), although it did not completely abrogate NO production due to the exogenous bioavailability of NO and NO generation by eNOS in tumor tissues. Azoxymethane 181-193 nitric oxide synthase 2 Rattus norvegicus 41-45 23708609-2 2013 Previously, we showed that the selective iNOS inhibitor S,S"-1,4-phenylenebis(1,2-ethanediyl)bis-isothiourea (PBIT) caused significant inhibition of colon carcinogenesis induced by azoxymethane (AOM), although it did not completely abrogate NO production due to the exogenous bioavailability of NO and NO generation by eNOS in tumor tissues. Azoxymethane 195-198 nitric oxide synthase 2 Rattus norvegicus 41-45 23707755-1 2013 Previously, we reported that azoxymethane (AOM)-induced liver injury is robustly exacerbated in M3 muscarinic receptor (M3R)-deficient mice. Azoxymethane 29-41 cholinergic receptor, muscarinic 3, cardiac Mus musculus 96-118 23707755-1 2013 Previously, we reported that azoxymethane (AOM)-induced liver injury is robustly exacerbated in M3 muscarinic receptor (M3R)-deficient mice. Azoxymethane 29-41 cholinergic receptor, muscarinic 3, cardiac Mus musculus 120-123 23707755-1 2013 Previously, we reported that azoxymethane (AOM)-induced liver injury is robustly exacerbated in M3 muscarinic receptor (M3R)-deficient mice. Azoxymethane 43-46 cholinergic receptor, muscarinic 3, cardiac Mus musculus 96-118 23707755-1 2013 Previously, we reported that azoxymethane (AOM)-induced liver injury is robustly exacerbated in M3 muscarinic receptor (M3R)-deficient mice. Azoxymethane 43-46 cholinergic receptor, muscarinic 3, cardiac Mus musculus 120-123 23707755-3 2013 Initial experiments confirmed that giving a selective M3R antagonist, darifenacin, to AOM-treated mice mimicked M3R gene ablation. Azoxymethane 86-89 cholinergic receptor, muscarinic 3, cardiac Mus musculus 54-57 23707755-3 2013 Initial experiments confirmed that giving a selective M3R antagonist, darifenacin, to AOM-treated mice mimicked M3R gene ablation. Azoxymethane 86-89 cholinergic receptor, muscarinic 3, cardiac Mus musculus 112-115 23554136-0 2013 Yerba mate tea and mate saponins prevented azoxymethane-induced inflammation of rat colon through suppression of NF-kappaB p65ser(311) signaling via IkappaB-alpha and GSK-3beta reduced phosphorylation. Azoxymethane 43-55 synaptotagmin 1 Rattus norvegicus 123-126 23554136-0 2013 Yerba mate tea and mate saponins prevented azoxymethane-induced inflammation of rat colon through suppression of NF-kappaB p65ser(311) signaling via IkappaB-alpha and GSK-3beta reduced phosphorylation. Azoxymethane 43-55 NFKB inhibitor alpha Rattus norvegicus 149-162 23554136-0 2013 Yerba mate tea and mate saponins prevented azoxymethane-induced inflammation of rat colon through suppression of NF-kappaB p65ser(311) signaling via IkappaB-alpha and GSK-3beta reduced phosphorylation. Azoxymethane 43-55 glycogen synthase kinase 3 beta Rattus norvegicus 167-176 23724067-6 2013 Furthermore, we observed that HDAC2 up-regulation is one of the earliest events in CRC carcinogenesis and observed this in human field carcinogenesis, the azoxymethane-treated rat model, and in more aggressive colon cancer cell lines. Azoxymethane 155-167 histone deacetylase 2 Homo sapiens 30-35 23430954-6 2013 Compared with Gas6(+/+) mice, Gas6(-/-) mice exhibited enhanced azoxymethane/dextran sulfate sodium (DSS)-induced tumorigenesis and had a shorter survival. Azoxymethane 64-76 growth arrest specific 6 Mus musculus 30-34 23393226-0 2013 Loss of sulfiredoxin renders mice resistant to azoxymethane/dextran sulfate sodium-induced colon carcinogenesis. Azoxymethane 47-59 sulfiredoxin 1 homolog (S. cerevisiae) Mus musculus 8-20 23338779-1 2013 The present study investigated whether a water-soluble extract from the culture medium of Ganoderma lucidum mycelia (Japanese: Reishi or Mannentake) (designated as MAK) exerted a protective effect against induction of aberrant crypt foci (ACF) by azoxymethane (AOM) and small-intestinal damage induced by the anticancer drug 5-FU. Azoxymethane 247-259 male germ cell-associated kinase Rattus norvegicus 164-167 22751125-4 2013 In mice, SMAC deficiency significantly increased the incidence and size of colon tumors induced by azoxymethane (AOM)/dextran sulfate sodium salt (DSS), and highly enriched beta-catenin hot spot mutations. Azoxymethane 99-111 diablo, IAP-binding mitochondrial protein Mus musculus 9-13 23567778-3 2013 METHODS: Colitis-associated cancer was induced by azoxymethane and dextran sodium sulfate in wild-type and in interleukin-1 receptor-associated kinase M (IRAK-M)-deficient mice with or without antibiotic (ATB) treatment. Azoxymethane 50-62 interleukin-1 receptor-associated kinase 3 Mus musculus 154-160 22323126-3 2012 However, GLP-2 increases colonic dysplasia in murine azoxymethane (AOM)-induced colon cancer. Azoxymethane 53-65 glucagon-like peptide 2 receptor Mus musculus 9-14 23354397-0 2012 A chemoprotective fish oil/pectin diet enhances apoptosis via Bcl-2 promoter methylation in rat azoxymethane-induced carcinomas. Azoxymethane 96-108 BCL2, apoptosis regulator Rattus norvegicus 62-67 22859375-0 2012 Tomato powder impedes the development of azoxymethane-induced colorectal cancer in rats through suppression of COX-2 expression via NF-kappaB and regulating Nrf2/HO-1 pathway. Azoxymethane 41-53 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 111-116 22859375-0 2012 Tomato powder impedes the development of azoxymethane-induced colorectal cancer in rats through suppression of COX-2 expression via NF-kappaB and regulating Nrf2/HO-1 pathway. Azoxymethane 41-53 heme oxygenase 1 Rattus norvegicus 162-166 21986945-4 2012 Genetic deletion of mPGES-1 significantly reduced both the total number and size of colorectal polyps at 18 weeks after azoxymethane administration with reduced nuclear translocation of beta-catenin, altered expression profiles of chemokines/cytokines and increased production of antitumorigenic PGs, prostaglandin D(2) and prostacyclin in tumor tissues. Azoxymethane 120-132 prostaglandin E synthase Mus musculus 20-27 22550081-2 2012 The present study shows reduced inflammatory responses and colorectal cancer in IEX-1 knockout (KO) mice treated with azoxymethane/dextran sulfate sodium (DSS). Azoxymethane 118-130 immediate early response 3 Mus musculus 80-85 22550081-5 2012 In accordance with this, T-helper 17 (T(H)17) cell differentiation was compromised in the absence of Galphai2, and deletion of Galphai2 in T cells alone aggravated colon inflammation and colorectal cancer development after azoxymethane/DSS treatment. Azoxymethane 223-235 guanine nucleotide binding protein (G protein), alpha inhibiting 2 Mus musculus 127-135 21630261-4 2012 In mice treated with azoxymethane (AOM) to model sporadic cancer, NTR-1 had a significant effect on tumor development with Ntsr1(+/+) mice developing over twofold more tumors than Ntsr1(-) (/-) mice (p = 0.04). Azoxymethane 21-33 neurotensin receptor 1 Mus musculus 66-71 23545937-0 2013 Extracellular calcium-sensing receptor/PTH knockout mice colons have increased Wnt/beta-catenin signaling, reduced non-canonical Wnt signaling, and increased susceptibility to azoxymethane-induced aberrant crypt foci. Azoxymethane 176-188 calcium-sensing receptor Mus musculus 0-38 23545937-2 2013 To understand a role of the colonic extracellular calcium-sensing receptor (CaSR) in calcium-mediated chemoprevention of colon cancer, we induced formation of aberrant crypt foci (ACF) caused by azoxymethane (AOM) injection in "rescued" CaSR-/PTH- (C-/P-) double knockout colons compared with colons from control CaSR+/PTH+ (C+/P+) mice. Azoxymethane 195-207 calcium-sensing receptor Mus musculus 76-80 23545937-2 2013 To understand a role of the colonic extracellular calcium-sensing receptor (CaSR) in calcium-mediated chemoprevention of colon cancer, we induced formation of aberrant crypt foci (ACF) caused by azoxymethane (AOM) injection in "rescued" CaSR-/PTH- (C-/P-) double knockout colons compared with colons from control CaSR+/PTH+ (C+/P+) mice. Azoxymethane 209-212 calcium-sensing receptor Mus musculus 76-80 23545937-9 2013 The loss of the colonic CaSR increased the number of ACF/cm(2) in response to AOM injection, suggesting colonic CaSR may mediate the chemoprotective effect of increased dietary calcium against colorectal cancer observed in humans. Azoxymethane 78-81 calcium sensing receptor Homo sapiens 24-28 23545937-9 2013 The loss of the colonic CaSR increased the number of ACF/cm(2) in response to AOM injection, suggesting colonic CaSR may mediate the chemoprotective effect of increased dietary calcium against colorectal cancer observed in humans. Azoxymethane 78-81 calcium sensing receptor Homo sapiens 112-116 23447577-4 2013 The membranous Hai-1/Spint1 immunoreactivity was decreased in murine Apc(Min/+) tumors and also in carcinogen (azoxymethane treatment followed by dextran sodium sulfate administration)-induced colon tumors compared with the adjacent non-neoplastic epithelium. Azoxymethane 111-123 serine protease inhibitor, Kunitz type 1 Mus musculus 15-20 23447577-4 2013 The membranous Hai-1/Spint1 immunoreactivity was decreased in murine Apc(Min/+) tumors and also in carcinogen (azoxymethane treatment followed by dextran sodium sulfate administration)-induced colon tumors compared with the adjacent non-neoplastic epithelium. Azoxymethane 111-123 serine protease inhibitor, Kunitz type 1 Mus musculus 21-27 22716201-0 2013 Genistein, a soya isoflavone, prevents azoxymethane-induced up-regulation of WNT/beta-catenin signalling and reduces colon pre-neoplasia in rats. Azoxymethane 39-51 Wnt family member 2 Rattus norvegicus 77-80 22716201-0 2013 Genistein, a soya isoflavone, prevents azoxymethane-induced up-regulation of WNT/beta-catenin signalling and reduces colon pre-neoplasia in rats. Azoxymethane 39-51 catenin beta 1 Rattus norvegicus 81-93 22716201-7 2013 AOM injection induced aberrant nuclear accumulation of beta-catenin in the CTL group but not in the SPI or GEN group. Azoxymethane 0-3 catenin beta 1 Rattus norvegicus 55-67 23803085-0 2013 Suppression of beta-catenin and cyclooxygenase-2 expression and cell proliferation in azoxymethane-induced colonic cancer in rats by rice bran phytic acid (PA). Azoxymethane 86-98 catenin beta 1 Rattus norvegicus 15-27 23803085-0 2013 Suppression of beta-catenin and cyclooxygenase-2 expression and cell proliferation in azoxymethane-induced colonic cancer in rats by rice bran phytic acid (PA). Azoxymethane 86-98 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 32-48 23555575-6 2013 Although Ptp4a3 is normally associated with late-stage cancer and metastasis, we observed increased Ptp4a3 expression in the colon of wildtype mice immediately following treatment with the carcinogen azoxymethane. Azoxymethane 200-212 protein tyrosine phosphatase 4a3 Mus musculus 100-106 23555575-10 2013 Ptp4a3-null mice developed 50% fewer colon tumors than wildtype mice after exposure to azoxymethane and dextran sodium sulfate. Azoxymethane 87-99 protein tyrosine phosphatase 4a3 Mus musculus 0-6 22916810-3 2012 The present study shows the results of molecular changes involved in the Tp53 pathway at an early stage in the distal colon tissue of azoxymethane (AOM)-induced colon cancer in rats evaluated by PCR array after exposure to diets containing the non-digestible fraction (NDF) of cooked bean (cultivar Bayo Madero). Azoxymethane 134-146 tumor protein p53 Rattus norvegicus 73-77 22320717-0 2012 Suppression of azoxymethane-induced colonic preneoplastic lesions in rats by 1-methyltryptophan, an inhibitor of indoleamine 2,3-dioxygenase. Azoxymethane 15-27 indoleamine 2,3-dioxygenase 1 Rattus norvegicus 113-140 22323126-3 2012 However, GLP-2 increases colonic dysplasia in murine azoxymethane (AOM)-induced colon cancer. Azoxymethane 67-70 glucagon-like peptide 2 receptor Mus musculus 9-14 22432057-9 2012 Six months following treatment with the alkylating carcinogen azoxymethane (AOM) at 10 mg/kg once a week for 6 weeks, XRCC1tp mice had a decrease in average colon tumor volume of 14+-3 mm(3) compared to 34+-4 mm(3) in WT littermates (p <= 0.03, N= 20/genotype). Azoxymethane 62-74 X-ray repair complementing defective repair in Chinese hamster cells 1 Mus musculus 118-123 22262168-8 2012 Enhanced CIN observed in SGO1-deficient mice resulted in an increase in formation of aberrant crypt foci (ACF) and accelerated development of tumors after exposure to azoxymethane (AOM), a colon carcinogen. Azoxymethane 167-179 shugoshin 1 Mus musculus 25-29 22262168-8 2012 Enhanced CIN observed in SGO1-deficient mice resulted in an increase in formation of aberrant crypt foci (ACF) and accelerated development of tumors after exposure to azoxymethane (AOM), a colon carcinogen. Azoxymethane 181-184 shugoshin 1 Mus musculus 25-29 22432057-9 2012 Six months following treatment with the alkylating carcinogen azoxymethane (AOM) at 10 mg/kg once a week for 6 weeks, XRCC1tp mice had a decrease in average colon tumor volume of 14+-3 mm(3) compared to 34+-4 mm(3) in WT littermates (p <= 0.03, N= 20/genotype). Azoxymethane 76-79 X-ray repair complementing defective repair in Chinese hamster cells 1 Mus musculus 118-123 21994466-2 2011 TNF receptor (TNFR) 2 expression is increased in inflammatory bowel diseases, the azoxymethane/dextran sodium sulfate (AOM/DSS) model of colitis-associated cancer, and by combined interleukin (IL) 6 and TNFalpha. Azoxymethane 82-94 TNF receptor superfamily member 1A Homo sapiens 0-12 23098518-3 2012 In the present study, we investigated the effect of pioglitazone on the development of azoxymethane-induced colon aberrant crypt foci (ACF) in KK-Ay obesity and diabetes model mice, and tried to clarify mechanisms by which the PPARgamma ligand inhibits ACF development. Azoxymethane 87-99 peroxisome proliferator activated receptor gamma Mus musculus 227-236 22199291-4 2011 MATERIALS AND METHODS: CD133 was evaluated by immunohistochemistry in a mouse model of colitis-related colon tumorigenesis induced by a combined treatment with azoxymethane (AOM) and dextran sodium sulphate (DSS). Azoxymethane 160-172 prominin 1 Mus musculus 23-28 21042865-4 2011 In this study, a novel single chain (sc)VEGF-based molecular probe is utilized in the azoxymethane (AOM)-treated mouse model of colorectal cancer to study delivery route and specificity for disease. Azoxymethane 86-98 vascular endothelial growth factor A Mus musculus 40-44 21042865-4 2011 In this study, a novel single chain (sc)VEGF-based molecular probe is utilized in the azoxymethane (AOM)-treated mouse model of colorectal cancer to study delivery route and specificity for disease. Azoxymethane 100-103 vascular endothelial growth factor A Mus musculus 40-44 21994466-2 2011 TNF receptor (TNFR) 2 expression is increased in inflammatory bowel diseases, the azoxymethane/dextran sodium sulfate (AOM/DSS) model of colitis-associated cancer, and by combined interleukin (IL) 6 and TNFalpha. Azoxymethane 82-94 TNF receptor superfamily member 1A Homo sapiens 14-18 21994466-2 2011 TNF receptor (TNFR) 2 expression is increased in inflammatory bowel diseases, the azoxymethane/dextran sodium sulfate (AOM/DSS) model of colitis-associated cancer, and by combined interleukin (IL) 6 and TNFalpha. Azoxymethane 119-122 TNF receptor superfamily member 1A Homo sapiens 0-12 21994466-2 2011 TNF receptor (TNFR) 2 expression is increased in inflammatory bowel diseases, the azoxymethane/dextran sodium sulfate (AOM/DSS) model of colitis-associated cancer, and by combined interleukin (IL) 6 and TNFalpha. Azoxymethane 119-122 TNF receptor superfamily member 1A Homo sapiens 14-18 21517784-4 2011 Consistent with the notion that PTPRT is a tumour suppressor, PTPRT knockout mice are hypersensitive to AOM (azoxymethane)-induced colon cancer. Azoxymethane 109-121 protein tyrosine phosphatase, receptor type, T Mus musculus 62-67 21987656-3 2011 IL-21 was increased in the gut of patients with UC-associated colon cancer, and in mice with CAC induced by azoxymethane (AOM) and dextran sulfate sodium (DSS). Azoxymethane 108-120 interleukin 21 Homo sapiens 0-5 21914785-6 2011 Using Pgc1alpha(-/-) and Pgc1alpha(+/+) mice, we show that loss of PGC1alpha protects mice from azoxymethane-induced colon carcinogenesis. Azoxymethane 96-108 peroxisome proliferative activated receptor, gamma, coactivator 1 alpha Mus musculus 67-76 21567095-4 2011 Although HGF stimulated proliferation of colonic epithelial cells in normal mucosa, the development of colorectal cancer induced by repeated injection of azoxymethane (AOM) was significantly inhibited by HGF treatment. Azoxymethane 154-166 hepatocyte growth factor Mus musculus 204-207 21741923-0 2011 Disruption of the mouse protein tyrosine kinase 6 gene prevents STAT3 activation and confers resistance to azoxymethane. Azoxymethane 107-119 PTK6 protein tyrosine kinase 6 Mus musculus 24-49 21741923-5 2011 METHODS: Ptk6+/+ and Ptk6-/- mice were injected with azoxymethane alone or in combination with dextran sodium sulfate; formation of aberrant crypt foci and colon tumors was examined. Azoxymethane 53-65 PTK6 protein tyrosine kinase 6 Mus musculus 9-13 21741923-5 2011 METHODS: Ptk6+/+ and Ptk6-/- mice were injected with azoxymethane alone or in combination with dextran sodium sulfate; formation of aberrant crypt foci and colon tumors was examined. Azoxymethane 53-65 PTK6 protein tyrosine kinase 6 Mus musculus 21-25 21741923-8 2011 RESULTS: Ptk6-/- mice developed fewer azoxymethane-induced aberrant crypt foci and tumors. Azoxymethane 38-50 PTK6 protein tyrosine kinase 6 Mus musculus 9-13 21741923-9 2011 Induction of PTK6 increased apoptosis, proliferation, and STAT3 activation in Ptk6+/+ mice injected with azoxymethane. Azoxymethane 105-117 PTK6 protein tyrosine kinase 6 Mus musculus 13-17 21741923-9 2011 Induction of PTK6 increased apoptosis, proliferation, and STAT3 activation in Ptk6+/+ mice injected with azoxymethane. Azoxymethane 105-117 signal transducer and activator of transcription 3 Mus musculus 58-63 21741923-9 2011 Induction of PTK6 increased apoptosis, proliferation, and STAT3 activation in Ptk6+/+ mice injected with azoxymethane. Azoxymethane 105-117 PTK6 protein tyrosine kinase 6 Mus musculus 78-82 21741923-10 2011 Disruption of Ptk6 impaired STAT3 activation following azoxymethane injection, and reduced active STAT3 levels in Ptk6-/- tumors. Azoxymethane 55-67 PTK6 protein tyrosine kinase 6 Mus musculus 14-18 21741923-13 2011 CONCLUSIONS: PTK6 promotes STAT3 activation in the colon following injection of the carcinogen azoxymethane and regulates STAT3 activity in mouse colon tumors and in the HCT116 and young adult mouse colon cell lines. Azoxymethane 95-107 PTK6 protein tyrosine kinase 6 Mus musculus 13-17 21741923-13 2011 CONCLUSIONS: PTK6 promotes STAT3 activation in the colon following injection of the carcinogen azoxymethane and regulates STAT3 activity in mouse colon tumors and in the HCT116 and young adult mouse colon cell lines. Azoxymethane 95-107 signal transducer and activator of transcription 3 Mus musculus 27-32 21741923-14 2011 Disruption of Ptk6 decreases azoxymethane-induced colon tumorigenesis in mice. Azoxymethane 29-41 PTK6 protein tyrosine kinase 6 Mus musculus 14-18 21576350-7 2011 mPGES-1 gene deletion results in an about 80% decrease in tumor multiplicity and up to a 90% reduction in tumor load in the distal colon of azoxymethane (AOM)-treated mice. Azoxymethane 140-152 prostaglandin E synthase Mus musculus 0-7 21576350-7 2011 mPGES-1 gene deletion results in an about 80% decrease in tumor multiplicity and up to a 90% reduction in tumor load in the distal colon of azoxymethane (AOM)-treated mice. Azoxymethane 154-157 prostaglandin E synthase Mus musculus 0-7 21567095-4 2011 Although HGF stimulated proliferation of colonic epithelial cells in normal mucosa, the development of colorectal cancer induced by repeated injection of azoxymethane (AOM) was significantly inhibited by HGF treatment. Azoxymethane 168-171 hepatocyte growth factor Mus musculus 204-207 21640075-3 2011 In the present study, we examined the effects of an angiotensin-converting enzyme (ACE) inhibitor and angiotensin-II type 1 receptor blocker (ARB), both of which inhibit the RAS, on the development of azoxymethane (AOM)-initiated colonic premalignant lesions in C57BL/KsJ-db/db (db/db) obese mice. Azoxymethane 201-213 angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Mus musculus 83-86 21653642-8 2011 These miRNAs were downregulated in azoxymethane and inflammation-associated colonic tumors from Egfr(wt) mice but upregulated in Egfr(wa2) tumors. Azoxymethane 35-47 epidermal growth factor receptor Mus musculus 96-100 21519141-3 2011 In this model, the induction of tumors using azoxymethane was accompanied by the coappearance of F4/80+CD11b(high)Gr1(low) M2 macrophages, cells that undergo polarization by IL-13 and are absent in tumors that lack high level IL-13 production. Azoxymethane 45-57 adhesion G protein-coupled receptor E1 Mus musculus 97-102 21370285-0 2011 Accumulation of K-Ras codon 12 mutations in the F344 rat distal colon following azoxymethane exposure. Azoxymethane 80-92 KRAS proto-oncogene, GTPase Rattus norvegicus 16-21 21519141-3 2011 In this model, the induction of tumors using azoxymethane was accompanied by the coappearance of F4/80+CD11b(high)Gr1(low) M2 macrophages, cells that undergo polarization by IL-13 and are absent in tumors that lack high level IL-13 production. Azoxymethane 45-57 integrin subunit alpha M Homo sapiens 103-108 21519141-3 2011 In this model, the induction of tumors using azoxymethane was accompanied by the coappearance of F4/80+CD11b(high)Gr1(low) M2 macrophages, cells that undergo polarization by IL-13 and are absent in tumors that lack high level IL-13 production. Azoxymethane 45-57 interleukin 13 Homo sapiens 174-179 21519141-3 2011 In this model, the induction of tumors using azoxymethane was accompanied by the coappearance of F4/80+CD11b(high)Gr1(low) M2 macrophages, cells that undergo polarization by IL-13 and are absent in tumors that lack high level IL-13 production. Azoxymethane 45-57 interleukin 13 Homo sapiens 226-231 20013030-0 2011 Luteolin inhibits cell proliferation during Azoxymethane-induced experimental colon carcinogenesis via Wnt/ beta-catenin pathway. Azoxymethane 44-56 catenin (cadherin associated protein), beta 1 Mus musculus 108-120 21355597-0 2011 Pterostilbene is more potent than resveratrol in preventing azoxymethane (AOM)-induced colon tumorigenesis via activation of the NF-E2-related factor 2 (Nrf2)-mediated antioxidant signaling pathway. Azoxymethane 60-72 nuclear factor, erythroid derived 2, like 2 Mus musculus 129-151 21355597-0 2011 Pterostilbene is more potent than resveratrol in preventing azoxymethane (AOM)-induced colon tumorigenesis via activation of the NF-E2-related factor 2 (Nrf2)-mediated antioxidant signaling pathway. Azoxymethane 60-72 nuclear factor, erythroid derived 2, like 2 Mus musculus 153-157 21355597-0 2011 Pterostilbene is more potent than resveratrol in preventing azoxymethane (AOM)-induced colon tumorigenesis via activation of the NF-E2-related factor 2 (Nrf2)-mediated antioxidant signaling pathway. Azoxymethane 74-77 nuclear factor, erythroid derived 2, like 2 Mus musculus 129-151 21355597-0 2011 Pterostilbene is more potent than resveratrol in preventing azoxymethane (AOM)-induced colon tumorigenesis via activation of the NF-E2-related factor 2 (Nrf2)-mediated antioxidant signaling pathway. Azoxymethane 74-77 nuclear factor, erythroid derived 2, like 2 Mus musculus 153-157 21355597-11 2011 This is also the first study to demonstrate that PS is a Nrf2 inducer and AR inhibitor in the AOM-treated colon carcinogenesis model. Azoxymethane 94-97 aldo-keto reductase family 1, member B3 (aldose reductase) Mus musculus 74-76 21425406-7 2011 Mice with Ets2-deficient intestinal cells develop more colon tumors in response to treatment with azoxymethane and dextran sulfate sodium. Azoxymethane 98-110 E26 avian leukemia oncogene 2, 3' domain Mus musculus 10-14 22523637-6 2011 We have also shown that in peripheral blood mononuclear cells (PBMC) and bone marrow (BM) cells collected from colon cancer patients and from azoxymethane-induced rats the expression and localization of NMT is altered. Azoxymethane 142-154 N-myristoyltransferase 1 Homo sapiens 203-206 21118981-3 2010 Using the azoxymethane and dextran sodium sulfate colitis-associated colorectal cancer model, we show that caspase-1-deficient (Casp1(-/-)) mice have enhanced tumor formation. Azoxymethane 10-22 caspase 1 Mus musculus 107-116 21303973-6 2011 We report that Mtgr1(-/-) mice were protected from tumorigenesis when injected with azoxymethane (AOM) and then subjected to repeated cycles of dextran sodium sulfate (DSS). Azoxymethane 84-96 CBFA2/RUNX1 translocation partner 2 Mus musculus 15-20 21721157-2 2011 It has been shown that ACA inhibited the development of azoxymethane-induced colon carcinogenesis through its suppression of cell proliferation in the colonic mucosa and its induction of glutathione S-transferase and quinone oxidoreductase 1 in vivo. Azoxymethane 56-68 hematopoietic prostaglandin D synthase Rattus norvegicus 187-212 21717373-8 2011 In contrast to these results obtained from DSS colitis, expression of claudin-1 was significantly downregulated, while expression of claudin-15 was upregulated in colitis-associated cancer tissues in the azoxymethane (AOM)/DSS model (Fig. Azoxymethane 204-216 claudin 15 Rattus norvegicus 133-143 21717373-8 2011 In contrast to these results obtained from DSS colitis, expression of claudin-1 was significantly downregulated, while expression of claudin-15 was upregulated in colitis-associated cancer tissues in the azoxymethane (AOM)/DSS model (Fig. Azoxymethane 218-221 claudin 1 Rattus norvegicus 70-79 21717373-8 2011 In contrast to these results obtained from DSS colitis, expression of claudin-1 was significantly downregulated, while expression of claudin-15 was upregulated in colitis-associated cancer tissues in the azoxymethane (AOM)/DSS model (Fig. Azoxymethane 218-221 claudin 15 Rattus norvegicus 133-143 21118981-3 2010 Using the azoxymethane and dextran sodium sulfate colitis-associated colorectal cancer model, we show that caspase-1-deficient (Casp1(-/-)) mice have enhanced tumor formation. Azoxymethane 10-22 caspase 1 Mus musculus 128-133 20855874-5 2010 In this study, we showed that mice deficient for Nlrp3 or the inflammasome effector caspase-1 were highly susceptible to azoxymethane/dextran sodium sulfate-induced inflammation and suffered from dramatically increased tumor burdens in the colon. Azoxymethane 121-133 NLR family, pyrin domain containing 3 Mus musculus 49-54 20732909-9 2010 With a single low dose of AOM (3 mg/kg) Aag-null mice showed an even stronger tumor response than Mgmt-null mice. Azoxymethane 26-29 N-methylpurine-DNA glycosylase Mus musculus 40-43 20732909-9 2010 With a single low dose of AOM (3 mg/kg) Aag-null mice showed an even stronger tumor response than Mgmt-null mice. Azoxymethane 26-29 O-6-methylguanine-DNA methyltransferase Mus musculus 98-102 21120281-0 2010 The role of Fas ligand protein in the oxidative stress induced by azoxymethane on crypt colon of rats. Azoxymethane 66-78 Fas ligand Rattus norvegicus 12-22 21120281-1 2010 PURPOSE: To study the protein Fas ligand (FasL) on the expression of apoptosis, using a model of oxidative stress induced by azoxymethane (AOM), in the crypt of colon in rats. Azoxymethane 125-137 Fas ligand Rattus norvegicus 30-40 21120281-1 2010 PURPOSE: To study the protein Fas ligand (FasL) on the expression of apoptosis, using a model of oxidative stress induced by azoxymethane (AOM), in the crypt of colon in rats. Azoxymethane 125-137 Fas ligand Rattus norvegicus 42-46 21120281-1 2010 PURPOSE: To study the protein Fas ligand (FasL) on the expression of apoptosis, using a model of oxidative stress induced by azoxymethane (AOM), in the crypt of colon in rats. Azoxymethane 139-142 Fas ligand Rattus norvegicus 30-40 21120281-1 2010 PURPOSE: To study the protein Fas ligand (FasL) on the expression of apoptosis, using a model of oxidative stress induced by azoxymethane (AOM), in the crypt of colon in rats. Azoxymethane 139-142 Fas ligand Rattus norvegicus 42-46 21120281-11 2010 CONCLUSION: Azoxymethane induce the oxidative stress and the significantly decrease of FasL expression, although there is no significant difference between basal and top of colon crypt linked to consumption-activation of Fas ligand. Azoxymethane 12-24 Fas ligand Rattus norvegicus 87-91 20855874-5 2010 In this study, we showed that mice deficient for Nlrp3 or the inflammasome effector caspase-1 were highly susceptible to azoxymethane/dextran sodium sulfate-induced inflammation and suffered from dramatically increased tumor burdens in the colon. Azoxymethane 121-133 caspase 1 Mus musculus 84-93 20823143-10 2010 Moreover, azoxymethane reduced insulin-like growth factor binding protein-3 protein level, which was enhanced by silibinin. Azoxymethane 10-22 insulin-like growth factor binding protein 3 Mus musculus 31-75 20518744-2 2010 We demonstrated previously that NEU3 is markedly up-regulated in various human cancers and showed that NEU3 transgenic mice developed a diabetic phenotype and were susceptible to azoxymethane-induced aberrant crypt foci in their colon tissues. Azoxymethane 179-191 neuraminidase 3 Homo sapiens 32-36 20518744-2 2010 We demonstrated previously that NEU3 is markedly up-regulated in various human cancers and showed that NEU3 transgenic mice developed a diabetic phenotype and were susceptible to azoxymethane-induced aberrant crypt foci in their colon tissues. Azoxymethane 179-191 neuraminidase 3 Homo sapiens 103-107 20624890-2 2010 In contrast, MyD88 signaling has a protective role in the development of azoxymethane (AOM)/dextran sodium sulfate (DSS) colitis-associated cancer (CAC). Azoxymethane 73-85 myeloid differentiation primary response gene 88 Mus musculus 13-18 20681671-8 2010 Furthermore, pterostilbene markedly inhibited AOM-induced activation of Ras, phosphatidylinositol 3 kinase/Akt, and EGFR signaling pathways. Azoxymethane 46-49 thymoma viral proto-oncogene 1 Mus musculus 107-110 20624890-2 2010 In contrast, MyD88 signaling has a protective role in the development of azoxymethane (AOM)/dextran sodium sulfate (DSS) colitis-associated cancer (CAC). Azoxymethane 87-90 myeloid differentiation primary response gene 88 Mus musculus 13-18 20133777-4 2010 PTPRT knockout mice that we generated exhibit increased levels of colonic paxillin phosphorylation at residue Y88 and are highly susceptible to carcinogen azoxymethane-induced colon tumor, providing critical in vivo evidence that PTPRT normally functions as a tumor suppressor. Azoxymethane 155-167 protein tyrosine phosphatase, receptor type, T Mus musculus 0-5 20197374-11 2010 Only AOM-treated Chrm3(-/-) mice developed ascites and had reduced survival compared with AOM-treated wild-type controls. Azoxymethane 5-8 cholinergic receptor, muscarinic 3, cardiac Mus musculus 17-22 20176658-8 2010 Mice null for IL4Ra and wild-type controls were treated with azoxymethane and dextran sulfate sodium to induce tumor formation. Azoxymethane 61-73 interleukin 4 receptor, alpha Mus musculus 14-19 20226691-6 2010 Together with their increased inflammatory response, the enhanced repair response of Casp12(-/-) mice rendered them more susceptible to colorectal cancer induced by azoxymethane (AOM)+DSS. Azoxymethane 165-177 caspase 12 Mus musculus 85-91 20226691-6 2010 Together with their increased inflammatory response, the enhanced repair response of Casp12(-/-) mice rendered them more susceptible to colorectal cancer induced by azoxymethane (AOM)+DSS. Azoxymethane 179-182 caspase 12 Mus musculus 85-91 19788889-3 2010 We observed that Nutlin-3 triggered a DNA damage response in azoxymethane-induced mouse AJ02-NM(0) colon cancer cells, characterized by the phosphorylation of H2AX (at Ser-139) and p53 (at Ser-15). Azoxymethane 61-73 H2A.X variant histone Mus musculus 159-163 19788889-3 2010 We observed that Nutlin-3 triggered a DNA damage response in azoxymethane-induced mouse AJ02-NM(0) colon cancer cells, characterized by the phosphorylation of H2AX (at Ser-139) and p53 (at Ser-15). Azoxymethane 61-73 transformation related protein 53, pseudogene Mus musculus 181-184 19931517-2 2010 We previously demonstrated that serum leptin levels are profoundly increased in mice which received azoxymethane (AOM) and dextran sulfate sodium (DSS) as tumor-initiator and -promoter, respectively, in a colon carcinogenesis model. Azoxymethane 100-112 leptin Mus musculus 38-44 19931517-2 2010 We previously demonstrated that serum leptin levels are profoundly increased in mice which received azoxymethane (AOM) and dextran sulfate sodium (DSS) as tumor-initiator and -promoter, respectively, in a colon carcinogenesis model. Azoxymethane 114-117 leptin Mus musculus 38-44 21189690-11 2010 In addition, mice heterozygous for a SF1 knockout allele show enhanced susceptibility to azoxymethane-induced colon tumorigenesis adding BBP/SF1 to the growing list of RNA processing factors implicated in genetic disease. Azoxymethane 89-101 splicing factor 1 Mus musculus 37-40 21189690-11 2010 In addition, mice heterozygous for a SF1 knockout allele show enhanced susceptibility to azoxymethane-induced colon tumorigenesis adding BBP/SF1 to the growing list of RNA processing factors implicated in genetic disease. Azoxymethane 89-101 splicing factor 1 Mus musculus 137-140 21189690-11 2010 In addition, mice heterozygous for a SF1 knockout allele show enhanced susceptibility to azoxymethane-induced colon tumorigenesis adding BBP/SF1 to the growing list of RNA processing factors implicated in genetic disease. Azoxymethane 89-101 splicing factor 1 Mus musculus 141-144 19931338-5 2010 Significant increases in interleukin-1beta and tumor necrosis factor-alpha mRNA were observed in the frontal cortex of azoxymethane-treated wild-type mice at coma stages of encephalopathy. Azoxymethane 119-131 interleukin 1 beta Mus musculus 25-42 19737566-11 2010 Intestinal tumorigenesis increased after administration of azoxymethane to Gucy2c(-/-) mice, compared with wild-type mice, but was eliminated in Gucy2c(-/-)Akt1(-/-) mice. Azoxymethane 59-71 guanylate cyclase 2c Mus musculus 75-81 19931338-5 2010 Significant increases in interleukin-1beta and tumor necrosis factor-alpha mRNA were observed in the frontal cortex of azoxymethane-treated wild-type mice at coma stages of encephalopathy. Azoxymethane 119-131 tumor necrosis factor Mus musculus 47-74 19931338-9 2010 These results demonstrate that toxic liver injury resulting from exposure to azoxymethane is associated with selective induction of proinflammatory cytokines in the brain and that deletion of tumor necrosis factor receptor-1 or interlukin-1 type 1 receptor delays the onset of coma and brain edema in this model of acute liver failure. Azoxymethane 77-89 tumor necrosis factor receptor superfamily, member 1a Mus musculus 192-224 19903783-0 2009 Epidermal growth factor receptor is required for colonic tumor promotion by dietary fat in the azoxymethane/dextran sulfate sodium model: roles of transforming growth factor-{alpha} and PTGS2. Azoxymethane 95-107 epidermal growth factor receptor Mus musculus 0-32 20574917-0 2010 Freeze-dried ham promotes azoxymethane-induced mucin-depleted foci and aberrant crypt foci in rat colon. Azoxymethane 26-38 solute carrier family 13 member 2 Rattus norvegicus 47-52 20616616-0 2010 Dietary linoleic acid and glucose enhances azoxymethane-induced colon cancer and metastases via the expression of high-mobility group box 1. Azoxymethane 43-55 high mobility group box 1 Rattus norvegicus 114-139 20616616-2 2010 METHODS: We examined the significance of HMGB1 in causing colon carcinogenesis induced by azoxymethane (AOM) injection in Fischer 344 rats fed on a control diet (group C), a 15% linoleic acid (LA) diet (group L), a control diet with 10% glucose drink (group G), and a 15% LA diet with a 10% glucose drink (group L+G). Azoxymethane 90-102 high mobility group box 1 Rattus norvegicus 41-46 20616616-2 2010 METHODS: We examined the significance of HMGB1 in causing colon carcinogenesis induced by azoxymethane (AOM) injection in Fischer 344 rats fed on a control diet (group C), a 15% linoleic acid (LA) diet (group L), a control diet with 10% glucose drink (group G), and a 15% LA diet with a 10% glucose drink (group L+G). Azoxymethane 104-107 high mobility group box 1 Rattus norvegicus 41-46 19760669-0 2009 Genetic reduction of circulating insulin-like growth factor-1 inhibits azoxymethane-induced colon tumorigenesis in mice. Azoxymethane 71-83 insulin-like growth factor 1 Mus musculus 33-61 19760669-6 2009 We conducted a pilot study to assess the impact of liver-specific IGF-1 deficiency on azoxymethane (AOM)-induced colon tumors. Azoxymethane 86-98 insulin-like growth factor 1 Mus musculus 66-71 19760669-6 2009 We conducted a pilot study to assess the impact of liver-specific IGF-1 deficiency on azoxymethane (AOM)-induced colon tumors. Azoxymethane 100-103 insulin-like growth factor 1 Mus musculus 66-71 19903783-4 2009 Although we showed that epidermal growth factor receptors (EGFR) controlled azoxymethane tumorigenesis in standard fat conditions, the role of EGFR in tumor promotion by high dietary fat has not been examined. Azoxymethane 76-88 epidermal growth factor receptor Mus musculus 59-63 19652364-7 2009 Furthermore, in the azoxymethane mouse model of colorectal carcinogenesis, Cck2r deletion in human progastrin-overexpressing mice resulted in markedly decreased aberrant crypt foci formation and substantially reduced tumor size and multiplicity. Azoxymethane 20-32 cholecystokinin B receptor Mus musculus 75-80 19787264-8 2009 Normal-appearing rat colonic mucosa and azoxymethane (AOM)-induced colorectal adenocarcinoma tissue expressed a barely detectable amount of BRD8 protein, but aggressive colon tumors induced with AOM and dextran sodium sulfate expressed BRD8 at a significantly higher level, suggesting that BRD8 expression is associated with tumor progression toward advanced stages and may aid to gain growth advantage. Azoxymethane 40-52 bromodomain containing 8 Rattus norvegicus 140-144 19787264-8 2009 Normal-appearing rat colonic mucosa and azoxymethane (AOM)-induced colorectal adenocarcinoma tissue expressed a barely detectable amount of BRD8 protein, but aggressive colon tumors induced with AOM and dextran sodium sulfate expressed BRD8 at a significantly higher level, suggesting that BRD8 expression is associated with tumor progression toward advanced stages and may aid to gain growth advantage. Azoxymethane 40-52 bromodomain containing 8 Rattus norvegicus 236-240 19787264-8 2009 Normal-appearing rat colonic mucosa and azoxymethane (AOM)-induced colorectal adenocarcinoma tissue expressed a barely detectable amount of BRD8 protein, but aggressive colon tumors induced with AOM and dextran sodium sulfate expressed BRD8 at a significantly higher level, suggesting that BRD8 expression is associated with tumor progression toward advanced stages and may aid to gain growth advantage. Azoxymethane 40-52 bromodomain containing 8 Rattus norvegicus 236-240 19826045-2 2009 The present study explores the effects of p53-modulating agent CP-31398 alone and combined with celecoxib on azoxymethane-induced aberrant crypt foci (ACF) and colon adenocarcinomas in F344 rats. Azoxymethane 109-121 tumor protein p53 Rattus norvegicus 42-45 19614672-0 2009 Co-treatment with deoxycholic acid and azoxymethane accelerates secretion of HMGB1 in IEC6 intestinal epithelial cells. Azoxymethane 39-51 high mobility group box 1 Rattus norvegicus 77-82 19378291-0 2009 Epigenetic modulation of the retinoid X receptor alpha by green tea in the azoxymethane-Apc Min/+ mouse model of intestinal cancer. Azoxymethane 75-87 retinoid X receptor alpha Mus musculus 29-54 19694754-1 2009 To establish an efficient rat model for colitis-associated colorectal cancer, azoxymethane and dextran sodium sulfate (AOM/DSS)-induced colon carcinogenesis was applied to a novel adenomatous polyposis coli (Apc) mutant, the Kyoto Apc Delta (KAD) rat. Azoxymethane 78-90 APC regulator of WNT signaling pathway Rattus norvegicus 208-211 19694754-1 2009 To establish an efficient rat model for colitis-associated colorectal cancer, azoxymethane and dextran sodium sulfate (AOM/DSS)-induced colon carcinogenesis was applied to a novel adenomatous polyposis coli (Apc) mutant, the Kyoto Apc Delta (KAD) rat. Azoxymethane 78-90 APC regulator of WNT signaling pathway Rattus norvegicus 231-234 20021465-4 2009 Further, mice deficient in GCC signaling are more susceptible to colon cancer induced by Apc mutations or the carcinogen azoxymethane. Azoxymethane 121-133 guanylate cyclase 2c Mus musculus 27-30 19343039-6 2009 In vivo, pharmacological blockade of p38alpha inhibits CRC growth in xenografted nude mice and azoxymethane-treated Apc(Min) mice, achieving both a cytostatic and cytotoxic effect, associated with high nuclear expression of FoxO3A and increased expression of its target genes p21 and PTEN. Azoxymethane 95-107 mitogen-activated protein kinase 14 Mus musculus 37-45 19497974-0 2009 Carcinogenic effects of exogenous and endogenous glucagon-like peptide-2 in azoxymethane-treated mice. Azoxymethane 76-88 glucagon-like peptide 2 receptor Mus musculus 49-72 19497974-8 2009 At 10 or 46 wk after azoxymethane treatment, the numbers of aberrant crypt foci increased with h(Gly(2))GLP-2[1-33] (P < 0.001) and decreased with hGLP-2[3-33] (P < 0.01-0.05) treatment. Azoxymethane 21-33 glucagon-like peptide 2 receptor Mus musculus 104-109 19442760-0 2009 Detection of K-ras mutations in azoxymethane-induced aberrant crypt foci in mice using LNA-mediated real-time PCR clamping and mutant-specific probes. Azoxymethane 32-44 Kirsten rat sarcoma viral oncogene homolog Mus musculus 13-18 19627619-0 2009 Cyclophilin C-associated protein (CyCAP) knock-out mice spontaneously develop colonic mucosal hyperplasia and exaggerated tumorigenesis after treatment with carcinogen azoxymethane. Azoxymethane 168-180 lectin, galactoside-binding, soluble, 3 binding protein Mus musculus 0-32 19627619-0 2009 Cyclophilin C-associated protein (CyCAP) knock-out mice spontaneously develop colonic mucosal hyperplasia and exaggerated tumorigenesis after treatment with carcinogen azoxymethane. Azoxymethane 168-180 lectin, galactoside-binding, soluble, 3 binding protein Mus musculus 34-39 19627619-11 2009 The hyperplasia was even more pronounced in CyCAP-/- mice than in WT after challenge with azoxymethane (p = 0.005, T-test). Azoxymethane 90-102 lectin, galactoside-binding, soluble, 3 binding protein Mus musculus 44-49 19173288-0 2009 Fatty acid synthase is over-expressed in large aberrant crypt foci in rats treated with azoxymethane. Azoxymethane 88-100 fatty acid synthase Rattus norvegicus 0-19 19442760-1 2009 Azoxymethane, a rodent colon-specific carcinogen, induce DNA damage, and causes proto-oncogene K-ras point mutations and subsequent tumor formation if DNA damage is not repaired or removed. Azoxymethane 0-12 Kirsten rat sarcoma viral oncogene homolog Mus musculus 95-100 19442760-2 2009 The present study was designed to detect and characterize K-ras mutations in azoxymethane (AOM)-induced aberrant crypt foci (ACF) in mice, and determine whether dietary supplementation of selenium influences K-ras mutations frequency in ACF using a new PCR technique of locked nucleic acid-mediated real-time PCR clamping combined with mutant-specific probes. Azoxymethane 77-89 Kirsten rat sarcoma viral oncogene homolog Mus musculus 58-63 19442760-2 2009 The present study was designed to detect and characterize K-ras mutations in azoxymethane (AOM)-induced aberrant crypt foci (ACF) in mice, and determine whether dietary supplementation of selenium influences K-ras mutations frequency in ACF using a new PCR technique of locked nucleic acid-mediated real-time PCR clamping combined with mutant-specific probes. Azoxymethane 91-94 Kirsten rat sarcoma viral oncogene homolog Mus musculus 58-63 19141699-0 2009 Soy isoflavones modulate azoxymethane-induced rat colon carcinogenesis exposed pre- and postnatally and inhibit growth of DLD-1 human colon adenocarcinoma cells by increasing the expression of estrogen receptor-beta. Azoxymethane 25-37 estrogen receptor 2 Homo sapiens 193-215 19215228-0 2009 Plasma membrane-associated sialidase (NEU3) promotes formation of colonic aberrant crypt foci in azoxymethane-treated transgenic mice. Azoxymethane 97-109 neuraminidase 3 Mus musculus 0-42 19215228-3 2009 Mice were injected with azoxymethane (i.p., 15 mg/kg/week) for 6 weeks, and 4 weeks later ACF had formed in the NEU3 transgenic mice significantly more than in the control wild-type mice. Azoxymethane 24-36 neuraminidase 3 Mus musculus 112-116 19215228-7 2009 The results of this study provide the first evidence that NEU3 essentially increases azoxymethane-induced ACF formation in colon mucosa by suppression of apoptosis, possibly via activation of the EGF signaling pathway, and thus indicate that up-regulation of NEU3 is important to the promotion stage of colorectal carcinogenesis in vivo. Azoxymethane 85-97 neuraminidase 3 Mus musculus 58-62 19215228-7 2009 The results of this study provide the first evidence that NEU3 essentially increases azoxymethane-induced ACF formation in colon mucosa by suppression of apoptosis, possibly via activation of the EGF signaling pathway, and thus indicate that up-regulation of NEU3 is important to the promotion stage of colorectal carcinogenesis in vivo. Azoxymethane 85-97 neuraminidase 3 Mus musculus 259-263 18824518-7 2009 In the azoxymethane (AOM) murine model of colon cancer, SphK1 and S1P were significantly elevated in colon cancer tissues compared to normal mucosa. Azoxymethane 7-19 sphingosine kinase 1 Mus musculus 56-61 19221092-5 2009 We find that enzastaurin potently reduces azoxymethane-induced colon tumor initiation and progression by inhibiting PKCbetaII-mediated tumor cell proliferation and beta-catenin accumulation. Azoxymethane 42-54 protein kinase C, beta Mus musculus 116-125 19221092-5 2009 We find that enzastaurin potently reduces azoxymethane-induced colon tumor initiation and progression by inhibiting PKCbetaII-mediated tumor cell proliferation and beta-catenin accumulation. Azoxymethane 42-54 catenin (cadherin associated protein), beta 1 Mus musculus 164-176 18824518-7 2009 In the azoxymethane (AOM) murine model of colon cancer, SphK1 and S1P were significantly elevated in colon cancer tissues compared to normal mucosa. Azoxymethane 7-19 sphingosine-1-phosphate receptor 1 Mus musculus 66-69 19139018-0 2009 Estrogen receptor-beta as a potential target for colon cancer prevention: chemoprevention of azoxymethane-induced colon carcinogenesis by raloxifene in F344 rats. Azoxymethane 93-105 estrogen receptor 2 Rattus norvegicus 0-22 18790560-2 2009 But when treated with azoxymethane, a colon carcinogen, COX-2 mice had a higher tumor load compared to wild-type mice. Azoxymethane 22-34 cytochrome c oxidase II, mitochondrial Mus musculus 56-61 18790788-3 2008 We report herein the role of epidermal growth factor receptor (EGFR), a known mediator of Snail and overexpressed in approximately 80% of human colorectal cancers, on PEG-mediated antiproliferative and hence antineoplastic effects in azoxymethane (AOM) rats and HT-29 colon cancer cells. Azoxymethane 234-246 epidermal growth factor receptor Homo sapiens 29-61 19759415-0 2009 Pla2g2a attenuates colon tumorigenesis in azoxymethane-treated C57BL/6 mice; expression studies reveal Pla2g2a target genes and pathways. Azoxymethane 42-54 phospholipase A2, group IIA (platelets, synovial fluid) Mus musculus 0-7 19759415-4 2009 RESULTS: Pla2g2a strongly inhibited colon tumorigenesis in mice following treatment with the DNA alkylating agent azoxymethane (AOM). Azoxymethane 114-126 phospholipase A2, group IIA (platelets, synovial fluid) Mus musculus 9-16 19030198-0 2008 Adiponectin deficiency enhances colorectal carcinogenesis and liver tumor formation induced by azoxymethane in mice. Azoxymethane 95-107 adiponectin, C1Q and collagen domain containing Mus musculus 0-11 19138982-9 2008 Silibinin dose-dependently decreased AOM-induced colonic cell proliferation, evidenced by proliferative cell nuclear antigen and cyclin D1 immunohistochemical staining, and induced apoptosis in these colon tissues, evidenced by terminal deoxyribonucleotidyl transferase-mediated dUTP nick end labeling staining and cleaved poly(ADP-ribose) polymerase. Azoxymethane 37-40 cyclin D1 Rattus norvegicus 129-138 19138982-9 2008 Silibinin dose-dependently decreased AOM-induced colonic cell proliferation, evidenced by proliferative cell nuclear antigen and cyclin D1 immunohistochemical staining, and induced apoptosis in these colon tissues, evidenced by terminal deoxyribonucleotidyl transferase-mediated dUTP nick end labeling staining and cleaved poly(ADP-ribose) polymerase. Azoxymethane 37-40 poly (ADP-ribose) polymerase 1 Rattus norvegicus 323-350 19138982-10 2008 Furthermore, silibinin significantly decreased AOM-induced inducible nitric oxide synthase- and cyclooxygenase-2-positive cells in colon tissues. Azoxymethane 47-50 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 96-112 18521082-1 2008 Mice overexpressing progastrin (PG) in intestinal mucosa (fatty acid-binding protein (Fabp)-PG mice) are at an increased risk of proximal colon carcinogenesis in response to azoxymethane. Azoxymethane 174-186 glutamatic-oxaloacetic transaminase 2, mitochondrial Mus musculus 58-84 18521082-1 2008 Mice overexpressing progastrin (PG) in intestinal mucosa (fatty acid-binding protein (Fabp)-PG mice) are at an increased risk of proximal colon carcinogenesis in response to azoxymethane. Azoxymethane 174-186 glutamatic-oxaloacetic transaminase 2, mitochondrial Mus musculus 86-90 19727435-4 2008 In addition, in colons of mice carrying mutations in Apc (Apc(Min) (/+)) or exposed to the carcinogen azoxymethane, elimination of GCC increased tumor initiation and promotion by disrupting genomic integrity and releasing cell cycle restriction. Azoxymethane 102-114 guanylate cyclase 2c Mus musculus 131-134 18790788-3 2008 We report herein the role of epidermal growth factor receptor (EGFR), a known mediator of Snail and overexpressed in approximately 80% of human colorectal cancers, on PEG-mediated antiproliferative and hence antineoplastic effects in azoxymethane (AOM) rats and HT-29 colon cancer cells. Azoxymethane 234-246 epidermal growth factor receptor Homo sapiens 63-67 18790788-3 2008 We report herein the role of epidermal growth factor receptor (EGFR), a known mediator of Snail and overexpressed in approximately 80% of human colorectal cancers, on PEG-mediated antiproliferative and hence antineoplastic effects in azoxymethane (AOM) rats and HT-29 colon cancer cells. Azoxymethane 234-246 snail family transcriptional repressor 1 Homo sapiens 90-95 21479479-0 2008 Effects of synthetic and natural in vivo inhibitors of beta-glucuronidase on azoxymethane-induced colon carcinogenesis in rats. Azoxymethane 77-89 glucuronidase, beta Rattus norvegicus 55-73 19138955-4 2008 Azoxymethane/DSS-treated Nrf2 knockout mice had increased incidence, multiplicity, and size of all colorectal tumors, including adenomas, versus treated wild-type (WT) mice, and the proportion of tumors that were adenocarcinoma was much higher in knockout (80%) versus WT (29%) mice. Azoxymethane 0-12 nuclear factor, erythroid derived 2, like 2 Mus musculus 25-29 18271008-4 2008 Transgenic mice in which an oncogenic K-ras(G12D) allele is activated in the colonic epithelium by sporadic recombination (K-rasLA2 mice) develop spontaneous ACF that are morphologically indistinguishable from those induced by the colon carcinogen azoxymethane (AOM). Azoxymethane 248-260 Kirsten rat sarcoma viral oncogene homolog Mus musculus 38-43 18681964-0 2008 Dark Aberrant Crypt Foci with activated Wnt pathway are related to tumorigenesis in the colon of AOM-treated rat. Azoxymethane 97-100 Wnt family member 2 Rattus norvegicus 40-43 18543083-1 2008 We previously demonstrated that angiotensin II (Ang II) receptor signaling is involved in azoxymethane-induced mouse colon tumorigenesis. Azoxymethane 90-102 angiotensinogen Rattus norvegicus 32-46 18543083-1 2008 We previously demonstrated that angiotensin II (Ang II) receptor signaling is involved in azoxymethane-induced mouse colon tumorigenesis. Azoxymethane 90-102 angiotensinogen Rattus norvegicus 48-54 18326560-8 2008 Following azoxymethane and dextran sodium sulfate (DSS) treatment, fewer total tumours were observed in the ILK knockout animals, which were mosaic with respect to ILK expression. Azoxymethane 10-22 integrin linked kinase Mus musculus 108-111 18644992-3 2008 In the azoxymethane-treated rat model of experimental colon carcinogenesis, sulindac treatment markedly induced Csk with a corresponding increase in inhibitory phosphorylation of Src (Tyr(527)). Azoxymethane 7-19 C-terminal Src kinase Rattus norvegicus 112-115 18644992-3 2008 In the azoxymethane-treated rat model of experimental colon carcinogenesis, sulindac treatment markedly induced Csk with a corresponding increase in inhibitory phosphorylation of Src (Tyr(527)). Azoxymethane 7-19 SRC proto-oncogene, non-receptor tyrosine kinase Rattus norvegicus 179-182 18413814-0 2008 Epidermal growth factor receptor controls flat dysplastic aberrant crypt foci development and colon cancer progression in the rat azoxymethane model. Azoxymethane 130-142 epidermal growth factor receptor Rattus norvegicus 0-32 18220315-3 2008 Therefore, we investigated the effect of deletion of the IL-4R alpha gene on azoxymethane-induced colorectal aberrant crypt focus (ACF) multiplicity and size in Balb/c mice. Azoxymethane 77-89 interleukin 4 receptor, alpha Mus musculus 57-68 18307533-0 2008 Susceptibility of Snark-deficient mice to azoxymethane-induced colorectal tumorigenesis and the formation of aberrant crypt foci. Azoxymethane 42-54 NUAK family, SNF1-like kinase, 2 Mus musculus 18-23 18239060-3 2008 Here, we show that colonic FASN levels are reduced with dietary intake of soy protein isolate (SPI), compared with a control casein diet, in male Sprague-Dawley rats administered the colon carcinogen azoxymethane. Azoxymethane 200-212 fatty acid synthase Rattus norvegicus 27-31 18239060-4 2008 SPI consumption resulted in decreased serum insulin levels and decreased azoxymethane-induced tumor suppressor p53 phosphorylation in colon crypt epithelium. Azoxymethane 73-85 Wistar clone pR53P1 p53 pseudogene Rattus norvegicus 111-114 18220315-5 2008 There were significantly higher levels of IL-4 in serum from azoxymethane- and sham-treated IL-4R alpha(-/-) mice than WT animals, but no difference in serum IL-13 levels. Azoxymethane 61-73 interleukin 4 Mus musculus 42-46 18220315-8 2008 In summary, IL-4R alpha-dependent signalling has a protective, anti-neoplastic role during the post-initiation phase of azoxymethane-induced colorectal carcinogenesis in Balb/c mice. Azoxymethane 120-132 interleukin 4 receptor, alpha Mus musculus 12-23 18087038-5 2007 We exploited this increased IGF-II sensitivity to develop an in vivo chemopreventive strategy using the azoxymethane (AOM) mutagenesis model. Azoxymethane 104-116 insulin-like growth factor 2 Mus musculus 28-34 17900258-0 2007 Increased susceptibility of Sf1(+/-) mice to azoxymethane-induced colon tumorigenesis. Azoxymethane 45-57 splicing factor 1 Mus musculus 28-31 17900258-6 2007 Azoxymethane (AOM) was given at a dose of 10 mg/kg body weight once a week for 6 weeks to 7-week-old Sf1(+/-) and Sf1(+/+) mice. Azoxymethane 0-12 splicing factor 1 Mus musculus 101-104 17900258-6 2007 Azoxymethane (AOM) was given at a dose of 10 mg/kg body weight once a week for 6 weeks to 7-week-old Sf1(+/-) and Sf1(+/+) mice. Azoxymethane 0-12 splicing factor 1 Mus musculus 114-117 17900258-6 2007 Azoxymethane (AOM) was given at a dose of 10 mg/kg body weight once a week for 6 weeks to 7-week-old Sf1(+/-) and Sf1(+/+) mice. Azoxymethane 14-17 splicing factor 1 Mus musculus 101-104 17200374-10 2007 Importantly, dietary pterostilbene also suppressed azoxymethane-induced colonic cell proliferation and iNOS expression. Azoxymethane 51-63 nitric oxide synthase 2 Rattus norvegicus 103-107 17634405-6 2007 Here we show that endogenously increased tissue levels of n-3 PUFA in the fat-1 transgenic mouse model lower incidence and growth rate of colon tumors induced by inflammation (dextrane sodium sulfate) plus treatment with carcinogen (azoxymethane). Azoxymethane 233-245 pumilio RNA binding family member 3 Homo sapiens 62-66 17634405-6 2007 Here we show that endogenously increased tissue levels of n-3 PUFA in the fat-1 transgenic mouse model lower incidence and growth rate of colon tumors induced by inflammation (dextrane sodium sulfate) plus treatment with carcinogen (azoxymethane). Azoxymethane 233-245 FAT atypical cadherin 1 Mus musculus 74-79 17658518-2 2007 In the current study, we elucidate the mechanism of EIBS by assessing iNOS/nitric oxide axis in the histologically normal colonic mucosa of rats treated with the colon-specific carcinogen, azoxymethane. Azoxymethane 189-201 nitric oxide synthase 2 Rattus norvegicus 70-74 17616656-2 2007 Here, we report that Tir8-deficient mice exhibited a dramatic intestinal inflammation in response to dextran sulfate sodium salt (DSS) administration in terms of weight loss, intestinal bleeding, and mortality and showed increased susceptibility to carcinogenesis in response to azoxymethane and DSS. Azoxymethane 279-291 single immunoglobulin and toll-interleukin 1 receptor (TIR) domain Mus musculus 21-25 17194898-0 2007 Long-term feeding of various fat diets modulates azoxymethane-induced colon carcinogenesis through Wnt/beta-catenin signaling in rats. Azoxymethane 49-61 Wnt family member 2 Rattus norvegicus 99-102 17194898-0 2007 Long-term feeding of various fat diets modulates azoxymethane-induced colon carcinogenesis through Wnt/beta-catenin signaling in rats. Azoxymethane 49-61 catenin beta 1 Rattus norvegicus 103-115 17398123-3 2007 SIGIRR-deficient (Sigirr(-/-)) colonic epithelial cells displayed commensal bacteria-dependent homeostatic defects, as shown by constitutive upregulation of inflammatory genes, increased inflammatory responses to dextran sulfate sodium (DSS) challenge, and increased Azoxymethane (AOM)+DSS-induced colitis-associated tumorigenesis. Azoxymethane 267-279 single immunoglobulin and toll-interleukin 1 receptor (TIR) domain Mus musculus 0-6 17398123-3 2007 SIGIRR-deficient (Sigirr(-/-)) colonic epithelial cells displayed commensal bacteria-dependent homeostatic defects, as shown by constitutive upregulation of inflammatory genes, increased inflammatory responses to dextran sulfate sodium (DSS) challenge, and increased Azoxymethane (AOM)+DSS-induced colitis-associated tumorigenesis. Azoxymethane 267-279 single immunoglobulin and toll-interleukin 1 receptor (TIR) domain Mus musculus 18-24 17398123-3 2007 SIGIRR-deficient (Sigirr(-/-)) colonic epithelial cells displayed commensal bacteria-dependent homeostatic defects, as shown by constitutive upregulation of inflammatory genes, increased inflammatory responses to dextran sulfate sodium (DSS) challenge, and increased Azoxymethane (AOM)+DSS-induced colitis-associated tumorigenesis. Azoxymethane 281-284 single immunoglobulin and toll-interleukin 1 receptor (TIR) domain Mus musculus 0-6 17398123-3 2007 SIGIRR-deficient (Sigirr(-/-)) colonic epithelial cells displayed commensal bacteria-dependent homeostatic defects, as shown by constitutive upregulation of inflammatory genes, increased inflammatory responses to dextran sulfate sodium (DSS) challenge, and increased Azoxymethane (AOM)+DSS-induced colitis-associated tumorigenesis. Azoxymethane 281-284 single immunoglobulin and toll-interleukin 1 receptor (TIR) domain Mus musculus 18-24 17234795-0 2007 Epidermal growth factor receptor signaling is required for microadenoma formation in the mouse azoxymethane model of colonic carcinogenesis. Azoxymethane 95-107 epidermal growth factor receptor Mus musculus 0-32 17234795-4 2007 In the current study, we used a specific EGFR antagonist, gefitinib, to investigate this role of the receptor in azoxymethane colonic premalignancy. Azoxymethane 113-125 epidermal growth factor receptor Mus musculus 41-45 17234795-10 2007 Azoxymethane significantly induced pro-transforming growth factor-alpha (6.4+/-1.3-fold) and increased phospho-(active) EGFR (5.9+/-1.1-fold), phospho-(active) ErbB2 (2.3+/-0.2-fold), and phospho-(active) extracellular signal-regulated kinase (3.3+/-0.4-fold) in premalignant colonocytes. Azoxymethane 0-12 transforming growth factor alpha Mus musculus 35-71 17234795-10 2007 Azoxymethane significantly induced pro-transforming growth factor-alpha (6.4+/-1.3-fold) and increased phospho-(active) EGFR (5.9+/-1.1-fold), phospho-(active) ErbB2 (2.3+/-0.2-fold), and phospho-(active) extracellular signal-regulated kinase (3.3+/-0.4-fold) in premalignant colonocytes. Azoxymethane 0-12 epidermal growth factor receptor Mus musculus 120-124 17234795-10 2007 Azoxymethane significantly induced pro-transforming growth factor-alpha (6.4+/-1.3-fold) and increased phospho-(active) EGFR (5.9+/-1.1-fold), phospho-(active) ErbB2 (2.3+/-0.2-fold), and phospho-(active) extracellular signal-regulated kinase (3.3+/-0.4-fold) in premalignant colonocytes. Azoxymethane 0-12 erb-b2 receptor tyrosine kinase 2 Mus musculus 160-165 16619040-7 2006 However, when mice are treated with azoxymethane to induce colonic tumors, we find that Ceacam1-/- mice developed a significantly greater number of tumors than their littermate controls. Azoxymethane 36-48 carcinoembryonic antigen-related cell adhesion molecule 1 Mus musculus 88-95 17190766-0 2007 Effect of azoxymethane and curcumin on transcriptional levels of cyclooxygenase-1 and -2 during initiation of colon carcinogenesis. Azoxymethane 10-22 prostaglandin-endoperoxide synthase 1 Rattus norvegicus 65-88 17038629-0 2006 Azoxymethane protects intestinal stem cells and reduces crypt epithelial mitosis through a COX-1-dependent mechanism. Azoxymethane 0-12 cytochrome c oxidase I, mitochondrial Mus musculus 91-96 16949053-1 2006 The p53 tumor suppressor protein is sequence-normal in azoxymethane (AOM)-induced mouse colon tumors, making them a good model for human colon cancers that retain a wild type p53 gene. Azoxymethane 55-67 transformation related protein 53, pseudogene Mus musculus 4-7 16949053-1 2006 The p53 tumor suppressor protein is sequence-normal in azoxymethane (AOM)-induced mouse colon tumors, making them a good model for human colon cancers that retain a wild type p53 gene. Azoxymethane 69-72 transformation related protein 53, pseudogene Mus musculus 4-7 16984374-0 2006 Suppression of azoxymethane-induced colon cancer development in rats by a cyclooxygenase-1 selective inhibitor, mofezolac. Azoxymethane 15-27 prostaglandin-endoperoxide synthase 1 Rattus norvegicus 74-90 16984374-1 2006 We demonstrated recently that mofezolac, a cyclooxygenase-1 (COX-1) selective inhibitor, suppresses the development of azoxymethane (AOM)-induced colonic aberrant crypt foci in F344 rats and intestinal polyps in APC1309 mice. Azoxymethane 119-131 prostaglandin-endoperoxide synthase 1 Rattus norvegicus 61-66 16984374-1 2006 We demonstrated recently that mofezolac, a cyclooxygenase-1 (COX-1) selective inhibitor, suppresses the development of azoxymethane (AOM)-induced colonic aberrant crypt foci in F344 rats and intestinal polyps in APC1309 mice. Azoxymethane 133-136 prostaglandin-endoperoxide synthase 1 Rattus norvegicus 61-66 16880406-4 2006 Furthermore, 15-PGDH gene knockout abrogates the normal resistance of C57BL/6J mice to colon tumor induction by the carcinogen azoxymethane (AOM), conferring susceptibility to AOM-induced adenomas and carcinomas in situ. Azoxymethane 127-139 hydroxyprostaglandin dehydrogenase 15 (NAD) Mus musculus 13-20 16940160-3 2006 In prior studies in the azoxymethane model of colon cancer, we showed that PKC-zeta was down-regulated in rat colonic tumors. Azoxymethane 24-36 protein kinase C zeta Homo sapiens 75-83 16880406-4 2006 Furthermore, 15-PGDH gene knockout abrogates the normal resistance of C57BL/6J mice to colon tumor induction by the carcinogen azoxymethane (AOM), conferring susceptibility to AOM-induced adenomas and carcinomas in situ. Azoxymethane 141-144 hydroxyprostaglandin dehydrogenase 15 (NAD) Mus musculus 13-20 16880406-4 2006 Furthermore, 15-PGDH gene knockout abrogates the normal resistance of C57BL/6J mice to colon tumor induction by the carcinogen azoxymethane (AOM), conferring susceptibility to AOM-induced adenomas and carcinomas in situ. Azoxymethane 176-179 hydroxyprostaglandin dehydrogenase 15 (NAD) Mus musculus 13-20 16928827-2 2006 In this study, we assessed the ability of PEG to target cyclin D1-beta-catenin-mediated hyperproliferation in the azoxymethane-treated rat model and the human colorectal cancer cell line, HT-29. Azoxymethane 114-126 cyclin D1 Rattus norvegicus 56-65 16928827-2 2006 In this study, we assessed the ability of PEG to target cyclin D1-beta-catenin-mediated hyperproliferation in the azoxymethane-treated rat model and the human colorectal cancer cell line, HT-29. Azoxymethane 114-126 catenin beta 1 Rattus norvegicus 66-78 16928827-8 2006 PEG did not alter total beta-catenin expression but rather its nuclear localization, leading us to assess E-cadherin expression (a major determinant of beta-catenin subcellular localization), which was increased by 73% and 71% in the azoxymethane-rat and HT-29 cells, respectively. Azoxymethane 234-246 cadherin 1 Rattus norvegicus 106-116 16618765-3 2006 This hypothesis was examined by treating wild-type (Pparb+/+) and Pparb-/- with azoxymethane, coupled with a highly specific PPARbeta ligand, GW0742. Azoxymethane 80-92 peroxisome proliferator activator receptor delta Mus musculus 66-71 16886601-2 2006 The purpose of this study was to investigate the association between the mRNA expression level of the Mgmt gene and mutation of the beta-catenin gene in rat colon tumors induced by azoxymethane (AOM) plus dextran sulfate sodium (DSS). Azoxymethane 181-193 O-6-methylguanine-DNA methyltransferase Rattus norvegicus 102-106 16886601-2 2006 The purpose of this study was to investigate the association between the mRNA expression level of the Mgmt gene and mutation of the beta-catenin gene in rat colon tumors induced by azoxymethane (AOM) plus dextran sulfate sodium (DSS). Azoxymethane 181-193 catenin beta 1 Rattus norvegicus 132-144 16886601-2 2006 The purpose of this study was to investigate the association between the mRNA expression level of the Mgmt gene and mutation of the beta-catenin gene in rat colon tumors induced by azoxymethane (AOM) plus dextran sulfate sodium (DSS). Azoxymethane 195-198 O-6-methylguanine-DNA methyltransferase Rattus norvegicus 102-106 16886601-2 2006 The purpose of this study was to investigate the association between the mRNA expression level of the Mgmt gene and mutation of the beta-catenin gene in rat colon tumors induced by azoxymethane (AOM) plus dextran sulfate sodium (DSS). Azoxymethane 195-198 catenin beta 1 Rattus norvegicus 132-144 16331625-7 2006 When IFN-gamma(-/-) mice were treated with AOM and TNBS, significantly higher number of tumors were seen (8.4 +/- 1.7) than in WT (3.3 +/- 2.9) or IL-4(-/-) (3.1 +/- 3.4) mice, which received identical treatments. Azoxymethane 43-46 interferon gamma Mus musculus 5-14 16331625-7 2006 When IFN-gamma(-/-) mice were treated with AOM and TNBS, significantly higher number of tumors were seen (8.4 +/- 1.7) than in WT (3.3 +/- 2.9) or IL-4(-/-) (3.1 +/- 3.4) mice, which received identical treatments. Azoxymethane 43-46 interleukin 4 Mus musculus 147-151 16309164-1 2005 BACKGROUND: In Apc(Min/+) (Min; multiple intestinal neoplasia) mice two separate populations of aberrant crypt foci (ACF) develop in the colon after azoxymethane (AOM) exposure. Azoxymethane 149-161 APC, WNT signaling pathway regulator Mus musculus 15-25 16297463-9 2006 The numbers of aberrant crypt foci in the mid-colon, distal colon and rectum following treatment with azoxymethane were also significantly increased by infusion with amidated or glycine-extended gastrin-releasing peptide. Azoxymethane 102-114 gastrin releasing peptide Rattus norvegicus 195-220 16619513-1 2006 The activation of ketoprofen, which inhibits the outgrowth of azoxymethane-induced aberrant crypt foci in the rat colon, on the inhibition of arylamine N-acetyltransferase (NAT) activity (N-acetylation of substrates), gene expression (mRNA NAT) and 2-aminofluorene (AF)-DNA adduct formation was studied in a human colon tumor (adenocarcinoma) cell line (colo 205). Azoxymethane 62-74 bromodomain containing 2 Homo sapiens 152-171 16619513-1 2006 The activation of ketoprofen, which inhibits the outgrowth of azoxymethane-induced aberrant crypt foci in the rat colon, on the inhibition of arylamine N-acetyltransferase (NAT) activity (N-acetylation of substrates), gene expression (mRNA NAT) and 2-aminofluorene (AF)-DNA adduct formation was studied in a human colon tumor (adenocarcinoma) cell line (colo 205). Azoxymethane 62-74 N-acetyltransferase 1 Rattus norvegicus 173-176 16619513-1 2006 The activation of ketoprofen, which inhibits the outgrowth of azoxymethane-induced aberrant crypt foci in the rat colon, on the inhibition of arylamine N-acetyltransferase (NAT) activity (N-acetylation of substrates), gene expression (mRNA NAT) and 2-aminofluorene (AF)-DNA adduct formation was studied in a human colon tumor (adenocarcinoma) cell line (colo 205). Azoxymethane 62-74 N-acetyltransferase 1 Rattus norvegicus 240-243 16122953-1 2006 The expression of inducible nitric oxide synthase (iNOS) is markedly elevated in rat colon cancers induced by azoxymethane (AOM). Azoxymethane 110-122 nitric oxide synthase 2 Rattus norvegicus 18-49 16122953-1 2006 The expression of inducible nitric oxide synthase (iNOS) is markedly elevated in rat colon cancers induced by azoxymethane (AOM). Azoxymethane 110-122 nitric oxide synthase 2 Rattus norvegicus 51-55 16113056-9 2006 No significant differences were found among the groups in hepatic cytochrome P450 2E1 (CYP2E1) activity, the first enzyme involved in activation of azoxymethane. Azoxymethane 148-160 cytochrome P450, family 2, subfamily e, polypeptide 1 Rattus norvegicus 87-93 16319132-3 2006 Therefore, we examined the expression of SK1 and COX-2 in rat colon tumors induced by azoxymethane (AOM) and the relationship of these two proteins in normal and malignant intestinal epithelial cells. Azoxymethane 86-98 sphingosine kinase 1 Rattus norvegicus 41-44 16319132-3 2006 Therefore, we examined the expression of SK1 and COX-2 in rat colon tumors induced by azoxymethane (AOM) and the relationship of these two proteins in normal and malignant intestinal epithelial cells. Azoxymethane 100-103 sphingosine kinase 1 Rattus norvegicus 41-44 16094650-6 2006 In an in vitro carcinogenesis model, IEC6 cells, which had confirmed CYP2E1 expression and activity, were continuously treated with AOM and/or LA for 40 weeks. Azoxymethane 132-135 cytochrome P450, family 2, subfamily e, polypeptide 1 Rattus norvegicus 69-75 17293962-8 2006 CONCLUSION: The azoxymethane increase expression SOD1, while inositol hexaphosphate decreases in a significant way the expression of SOD1 promoted by the administration of the carcinogen azoxymethane. Azoxymethane 16-28 superoxide dismutase 1, soluble Mus musculus 49-53 17293962-8 2006 CONCLUSION: The azoxymethane increase expression SOD1, while inositol hexaphosphate decreases in a significant way the expression of SOD1 promoted by the administration of the carcinogen azoxymethane. Azoxymethane 187-199 superoxide dismutase 1, soluble Mus musculus 49-53 17293962-8 2006 CONCLUSION: The azoxymethane increase expression SOD1, while inositol hexaphosphate decreases in a significant way the expression of SOD1 promoted by the administration of the carcinogen azoxymethane. Azoxymethane 187-199 superoxide dismutase 1, soluble Mus musculus 133-137 17293967-6 2006 RESULTS: mean values of TGF-beta2 expression were 9.0 +/- 3.9% for group 4 (control), 12.7 +/- 4.0% for group 3 (IP6), 19.3 +/- 6.2% for group 2 (AOM), and 13.1 +/- 5.3% for group 1 (IP6+AOM). Azoxymethane 146-149 transforming growth factor, beta 2 Rattus norvegicus 24-33 16309164-1 2005 BACKGROUND: In Apc(Min/+) (Min; multiple intestinal neoplasia) mice two separate populations of aberrant crypt foci (ACF) develop in the colon after azoxymethane (AOM) exposure. Azoxymethane 163-166 APC, WNT signaling pathway regulator Mus musculus 15-25 15961079-2 2005 We report herein that prior to occurrence of neoplastic lesions in the azoxymethane-rat model of colon carcinogenesis; the tumor suppressor gene C-terminal Src kinase (Csk) was down-regulated with a concomitant increase in Src activity. Azoxymethane 71-83 C-terminal Src kinase Rattus norvegicus 145-166 15849741-0 2005 Sulindac corrects defective apoptosis and suppresses azoxymethane-induced colonic oncogenesis in p53 knockout mice. Azoxymethane 53-65 transformation related protein 53, pseudogene Mus musculus 97-100 15961079-2 2005 We report herein that prior to occurrence of neoplastic lesions in the azoxymethane-rat model of colon carcinogenesis; the tumor suppressor gene C-terminal Src kinase (Csk) was down-regulated with a concomitant increase in Src activity. Azoxymethane 71-83 C-terminal Src kinase Rattus norvegicus 168-171 15961079-2 2005 We report herein that prior to occurrence of neoplastic lesions in the azoxymethane-rat model of colon carcinogenesis; the tumor suppressor gene C-terminal Src kinase (Csk) was down-regulated with a concomitant increase in Src activity. Azoxymethane 71-83 SRC proto-oncogene, non-receptor tyrosine kinase Rattus norvegicus 156-159 16034162-0 2005 Inhibition of azoxymethane-induced aberrant crypt foci in rat by diphenylmethyl selenocyanate through downregulation of COX-2 and modulation of glutathione-S-transferase and lipid peroxidation. Azoxymethane 14-26 cytochrome c oxidase II, mitochondrial Rattus norvegicus 120-125 16034162-0 2005 Inhibition of azoxymethane-induced aberrant crypt foci in rat by diphenylmethyl selenocyanate through downregulation of COX-2 and modulation of glutathione-S-transferase and lipid peroxidation. Azoxymethane 14-26 hematopoietic prostaglandin D synthase Rattus norvegicus 144-169 15904466-0 2005 Suppression of azoxymethane-induced colon cancer development in rats by a prostaglandin E receptor EP1-selective antagonist. Azoxymethane 15-27 prostaglandin E receptor 1 Rattus norvegicus 99-102 15864814-1 2005 BACKGROUND: The authors recently reported that gastrin gene knockout (GAS-KO) mice had an increased risk for colon carcinogenesis in response to azoxymethane (AOM) compared with their wild type (WT) littermates. Azoxymethane 145-157 gastrin Mus musculus 47-54 15864814-1 2005 BACKGROUND: The authors recently reported that gastrin gene knockout (GAS-KO) mice had an increased risk for colon carcinogenesis in response to azoxymethane (AOM) compared with their wild type (WT) littermates. Azoxymethane 159-162 gastrin Mus musculus 47-54 15700305-0 2005 Absence of acute apoptotic response to genotoxic carcinogens in p53-deficient mice is associated with increased susceptibility to azoxymethane-induced colon tumours. Azoxymethane 130-142 transformation related protein 53, pseudogene Mus musculus 64-67 15723712-7 2005 Our findings indicate that lysophosphatidic acid significantly increased the incidence of peritoneal and/or pleural metastases from intestinal adenocarcinomas induced in rats by azoxymethane through RhoA activation. Azoxymethane 178-190 ras homolog family member A Rattus norvegicus 199-203 15805260-6 2005 In the following study, we evaluated the influence of genetic deletion of a key intracellular phospholipase, cytoplasmic PLA(2) (cPLA(2)), on azoxymethane-induced colon tumorigenesis. Azoxymethane 142-154 phospholipase A2, group IB, pancreas Mus musculus 121-127 15805260-6 2005 In the following study, we evaluated the influence of genetic deletion of a key intracellular phospholipase, cytoplasmic PLA(2) (cPLA(2)), on azoxymethane-induced colon tumorigenesis. Azoxymethane 142-154 phospholipase A2, group IVA (cytosolic, calcium-dependent) Mus musculus 129-136 15576447-1 2005 The cytochrome P450 (P450) CYP2E1 enzyme metabolizes and activates a wide array of toxicological substrates, including alcohols, the widely used analgesic acetaminophen, acetone, benzene, halothane, and carcinogens such as azoxymethane and dimethylhydrazine. Azoxymethane 223-235 cytochrome P450, family 2, subfamily e, polypeptide 1 Mus musculus 27-33 15486344-1 2005 Transgenic mice (hGAS) that overexpress human progastrin are more susceptible than wild-type mice (FVB/N) to the induction of colonic aberrant crypt foci (ACF) and adenomas by the chemical carcinogen azoxymethane. Azoxymethane 200-212 gastrin Homo sapiens 17-21 15192017-0 2004 Lactoferrin enhances Fas expression and apoptosis in the colon mucosa of azoxymethane-treated rats. Azoxymethane 73-85 lactotransferrin Rattus norvegicus 0-11 15297369-0 2004 Azoxymethane-induced pre-adipocyte factor 1 (Pref-1) functions as a differentiation inhibitor in colonic epithelial cells. Azoxymethane 0-12 delta like non-canonical Notch ligand 1 Mus musculus 21-43 15297369-0 2004 Azoxymethane-induced pre-adipocyte factor 1 (Pref-1) functions as a differentiation inhibitor in colonic epithelial cells. Azoxymethane 0-12 delta like non-canonical Notch ligand 1 Mus musculus 45-51 15522837-2 2004 The aim of this study was to investigate whether long-term dietary corn oil promotes colon cancer by inhibiting the tumor suppressor gene p53-mediated mitochondria-dependent apoptosis in azoxymethane (AOM)-treated rats. Azoxymethane 187-199 Wistar clone pR53P1 p53 pseudogene Rattus norvegicus 138-141 15522837-2 2004 The aim of this study was to investigate whether long-term dietary corn oil promotes colon cancer by inhibiting the tumor suppressor gene p53-mediated mitochondria-dependent apoptosis in azoxymethane (AOM)-treated rats. Azoxymethane 201-204 Wistar clone pR53P1 p53 pseudogene Rattus norvegicus 138-141 15684064-4 2005 Likewise, Lrh-1+/- mice are protected against the formation of aberrant crypt foci in the colon of mice exposed to the carcinogen azoxymethane. Azoxymethane 130-142 nuclear receptor subfamily 5, group A, member 2 Mus musculus 10-15 15617833-3 2005 However, in the azoxymethane-treated rat, where beta-catenin is frequently rendered GSK-3beta-insensitive, nabumetone failed to alter beta-catenin levels but did decrease beta-catenin nuclear localization and transcriptional activity as gauged by cyclin D1. Azoxymethane 16-28 catenin beta 1 Rattus norvegicus 48-60 15578539-0 2004 Leptin reduces the development of the initial precancerous lesions induced by azoxymethane in the rat colonic mucosa. Azoxymethane 78-90 leptin Rattus norvegicus 0-6 15322124-3 2004 Here we demonstrate that nullizygous PKCbeta (PKCbetaKO) mice are highly resistant to azoxymethane (AOM)-induced preneoplastic lesions, aberrant crypt foci. Azoxymethane 86-98 protein kinase C, beta Mus musculus 37-44 15377995-3 2004 We investigated susceptibility of p21-deficient mice to the colon carcinogen azoxymethane (AOM). Azoxymethane 77-89 cyclin-dependent kinase inhibitor 1A (P21) Mus musculus 34-37 15192017-1 2004 Bovine lactoferrin, a multifunctional glycoprotein, has been shown to strongly inhibit development of azoxymethane (AOM)-induced rat colon tumors. Azoxymethane 102-114 lactotransferrin Rattus norvegicus 7-18 15543947-2 2004 Intestinal epithelial cells have been found to modulate the relative levels of the p65-p50 and p50-p50 NF-kappaB complexes in a number of instances, and here we show that this ratio was altered in response to dietary fiber (wheat bran) and carcinogen exposure (azoxymethane). Azoxymethane 261-273 RELA proto-oncogene, NF-kB subunit Homo sapiens 83-86 15465771-0 2004 Beef meat and blood sausage promote the formation of azoxymethane-induced mucin-depleted foci and aberrant crypt foci in rat colons. Azoxymethane 53-65 solute carrier family 13 member 2 Rattus norvegicus 74-79 15543947-2 2004 Intestinal epithelial cells have been found to modulate the relative levels of the p65-p50 and p50-p50 NF-kappaB complexes in a number of instances, and here we show that this ratio was altered in response to dietary fiber (wheat bran) and carcinogen exposure (azoxymethane). Azoxymethane 261-273 nuclear factor kappa B subunit 1 Homo sapiens 95-98 15543947-2 2004 Intestinal epithelial cells have been found to modulate the relative levels of the p65-p50 and p50-p50 NF-kappaB complexes in a number of instances, and here we show that this ratio was altered in response to dietary fiber (wheat bran) and carcinogen exposure (azoxymethane). Azoxymethane 261-273 nuclear factor kappa B subunit 1 Homo sapiens 95-98 12370429-4 2002 Heterozygous loss of PPARgamma causes an increase in beta-catenin levels and a greater incidence of colon cancer when animals are treated with azoxymethane. Azoxymethane 143-155 peroxisome proliferator activated receptor gamma Mus musculus 21-30 15517863-0 2004 Loss of heterozygosity and nonsense mutation in Apc in azoxymethane-induced colonic tumours in min mice. Azoxymethane 55-67 APC, WNT signaling pathway regulator Mus musculus 48-51 15170673-0 2004 Dietary seed oil rich in conjugated linolenic acid from bitter melon inhibits azoxymethane-induced rat colon carcinogenesis through elevation of colonic PPARgamma expression and alteration of lipid composition. Azoxymethane 78-90 peroxisome proliferator-activated receptor gamma Rattus norvegicus 153-162 15373703-0 2004 Inhibition of azoxymethane-induced colon carcinogenesis in rats due to JTE-522, a selective cyclooxygenase-2 inhibitor. Azoxymethane 14-26 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 92-108 12927365-1 2003 We examined the p53 response following acute exposure of mice to the colon-specific carcinogen azoxymethane (AOM). Azoxymethane 95-107 transformation related protein 53, pseudogene Mus musculus 16-19 12824873-9 2003 Therefore, the results indicate that susceptibility to AOM-induced tumorigenesis in the colon and also in the liver is enhanced in Parp-1(-/-) mice, and Parp-1 could have a substantial role in colon and liver tumorigenesis. Azoxymethane 55-58 poly (ADP-ribose) polymerase family, member 1 Mus musculus 131-137 12750256-0 2003 Identification of mucin-depleted foci in the unsectioned colon of azoxymethane-treated rats: correlation with carcinogenesis. Azoxymethane 66-78 solute carrier family 13 member 2 Rattus norvegicus 18-23 12750256-5 2003 We defined these lesions as mucin-depleted foci (MDF), and they were visible in all azoxymethane-treated rats and correlated with tumor induction (MDF/colon: 8.2 +/- 0.9 and 3.8 +/- 0.9 in controls and synbiotic-fed rats, respectively, P < 0.01; crypts/MDF: 12.2 +/- 2 and 6.4 +/- 1 in controls and synbiotic-fed rats, respectively, P < 0.05, means +/- SE, n = 7). Azoxymethane 84-96 solute carrier family 13 member 2 Rattus norvegicus 28-33 15312680-0 2004 Lactoferrin modifies apoptosis-related gene expression in the colon of the azoxymethane-treated rat. Azoxymethane 75-87 lactotransferrin Rattus norvegicus 0-11 15312680-1 2004 Lactoferrin, an iron-binding glycoprotein, exhibits suppressive effects on development of azoxymethane (AOM)-induced tumors in the rat colon, but the mechanisms are largely unknown. Azoxymethane 90-102 lactotransferrin Rattus norvegicus 0-11 15312680-1 2004 Lactoferrin, an iron-binding glycoprotein, exhibits suppressive effects on development of azoxymethane (AOM)-induced tumors in the rat colon, but the mechanisms are largely unknown. Azoxymethane 104-107 lactotransferrin Rattus norvegicus 0-11 14762787-0 2004 Leptin reduces the development of the initial precancerous lesions induced by azoxymethane in the rat colonic mucosa. Azoxymethane 78-90 leptin Rattus norvegicus 0-6 14762787-3 2004 METHODS: Leptin (1 mg/kg/d) or vehicle was administered systemically by miniosmotic pump in Fischer 344 rats either for 7 days (BrdU-labeling indices study) or 23 days (azoxymethane-induced colonic lesions study). Azoxymethane 169-181 leptin Rattus norvegicus 9-15 14762787-6 2004 Unexpectedly, in azoxymethane-treated rats, leptin significantly inhibited aberrant crypt foci formation in the middle and distal colon compared with controls (P = 0.006). Azoxymethane 17-29 leptin Rattus norvegicus 44-50 12943528-4 2004 An increased expression of both eNOS and VEGF in colonic tissue from azoxymethane-treated rats compared with that from control rats was found. Azoxymethane 69-81 nitric oxide synthase 3 Rattus norvegicus 32-36 12943528-4 2004 An increased expression of both eNOS and VEGF in colonic tissue from azoxymethane-treated rats compared with that from control rats was found. Azoxymethane 69-81 vascular endothelial growth factor A Rattus norvegicus 41-45 12943528-7 2004 Expression of the VEGF receptor Flk-1, but not Flt-1, was increased in colonic tissue of azoxymethane-treated rats compared with control rats. Azoxymethane 89-101 vascular endothelial growth factor A Rattus norvegicus 18-22 12943528-7 2004 Expression of the VEGF receptor Flk-1, but not Flt-1, was increased in colonic tissue of azoxymethane-treated rats compared with control rats. Azoxymethane 89-101 kinase insert domain receptor Rattus norvegicus 32-37 12943528-9 2004 Aspirin treatment reduced Flk-1 expression in both control and azoxymethane-treated rats. Azoxymethane 63-75 kinase insert domain receptor Rattus norvegicus 26-31 12943528-10 2004 Caspase-3 activity, which has been considered as an apoptotic index, was almost undetectable in azoxymethane-treated rats. Azoxymethane 96-108 caspase 3 Rattus norvegicus 0-9 12943528-12 2004 Overexpression of eNOS, VEGF and its receptor Flk-1 occurred early after azoxymethane administration in rat colonic tissue, even before morphological changes associated with tumour generation were observed, and aspirin prevented the overexpression of both eNOS and VEGF receptor Flk-1. Azoxymethane 73-85 nitric oxide synthase 3 Rattus norvegicus 18-22 12943528-12 2004 Overexpression of eNOS, VEGF and its receptor Flk-1 occurred early after azoxymethane administration in rat colonic tissue, even before morphological changes associated with tumour generation were observed, and aspirin prevented the overexpression of both eNOS and VEGF receptor Flk-1. Azoxymethane 73-85 vascular endothelial growth factor A Rattus norvegicus 24-28 12943528-12 2004 Overexpression of eNOS, VEGF and its receptor Flk-1 occurred early after azoxymethane administration in rat colonic tissue, even before morphological changes associated with tumour generation were observed, and aspirin prevented the overexpression of both eNOS and VEGF receptor Flk-1. Azoxymethane 73-85 kinase insert domain receptor Rattus norvegicus 46-51 14727811-1 2003 The aim of the study reported here was to investigate whether the azoxymethane (AOM)-induced colon cancer rat model mimics the human situation with regard to microsatellite stability, changes in expression of beta-catenin, and/or changes in the sequence of the proto-oncogene Ki-ras. Azoxymethane 66-78 KRAS proto-oncogene, GTPase Homo sapiens 276-282 12970140-8 2003 However, azoxymethane treated Cdx2(+/-) mice developed tumours specifically in the distal colon 12 weeks after azoxymethane treatment whereas no tumours were found in wild-type littermates at this stage. Azoxymethane 9-21 caudal type homeobox 2 Mus musculus 30-34 12720300-0 2003 Defective processing of the transforming growth factor-beta1 in azoxymethane-induced mouse colon tumors. Azoxymethane 64-76 transforming growth factor, beta 1 Mus musculus 28-60 12579275-1 2003 The present study was designed to investigate the protective effect of a dietary water-soluble extract from cultured medium of Ganoderma lucidum (Rei-shi or Mannentake) mycelia (designated as MAK) on the induction and development of azoxymethane (AOM)-induced colon tumors in male F344/Du Crj rats. Azoxymethane 233-245 male germ cell-associated kinase Rattus norvegicus 192-195 12584182-2 2003 We evaluated the status of cPLA(2) in azoxymethane (AOM)-induced mouse colon tumors. Azoxymethane 38-50 phospholipase A2, group IVA (cytosolic, calcium-dependent) Mus musculus 27-34 12584182-2 2003 We evaluated the status of cPLA(2) in azoxymethane (AOM)-induced mouse colon tumors. Azoxymethane 52-55 phospholipase A2, group IVA (cytosolic, calcium-dependent) Mus musculus 27-34 12557142-0 2003 Peroxisome proliferator-activated receptor gamma ligands suppress colon carcinogenesis induced by azoxymethane in mice. Azoxymethane 98-110 peroxisome proliferator activated receptor gamma Mus musculus 0-48 12070019-0 2002 Factor VIII expression in azoxymethane-induced murine fulminant hepatic failure. Azoxymethane 26-38 coagulation factor VIII Mus musculus 0-11 12145805-0 2002 Deletion of functional gastrin gene markedly increases colon carcinogenesis in response to azoxymethane in mice. Azoxymethane 91-103 gastrin Mus musculus 23-30 12145805-1 2002 BACKGROUND & AIMS: We recently reported that transgenic mice overexpressing progastrin were at a higher risk for developing colon cancers in response to azoxymethane (AOM), whereas mice overexpressing gastrin-17 were at a reduced risk. Azoxymethane 157-169 gastrin Mus musculus 83-90 12145805-1 2002 BACKGROUND & AIMS: We recently reported that transgenic mice overexpressing progastrin were at a higher risk for developing colon cancers in response to azoxymethane (AOM), whereas mice overexpressing gastrin-17 were at a reduced risk. Azoxymethane 171-174 gastrin Mus musculus 83-90 12239600-5 2002 We have reported for the first time in rats treated with azoxymethane that NMT activity was higher in colonic epithelial neoplasms than in normal colonic tissue and that an increase in NMT activity appeared at an early stage in colonic carcinogenesis. Azoxymethane 57-69 N-myristoyltransferase 1 Homo sapiens 75-78 12239600-5 2002 We have reported for the first time in rats treated with azoxymethane that NMT activity was higher in colonic epithelial neoplasms than in normal colonic tissue and that an increase in NMT activity appeared at an early stage in colonic carcinogenesis. Azoxymethane 57-69 N-myristoyltransferase 1 Homo sapiens 185-188 12070019-4 2002 We compared the expression of factor VIII to other hepatic hemostatic factors in azoxymethane-induced murine FHF. Azoxymethane 81-93 coagulation factor VIII Mus musculus 30-41 12070019-6 2002 At the highest dose of azoxymethane (50 microg/g body weight), factor VIII activity in plasma decreased by 98% within 36 hours after treatment, which was associated with an 80% reduction in hepatic factor VIII messenger RNA (mRNA). Azoxymethane 23-35 coagulation factor VIII Mus musculus 63-74 12070019-6 2002 At the highest dose of azoxymethane (50 microg/g body weight), factor VIII activity in plasma decreased by 98% within 36 hours after treatment, which was associated with an 80% reduction in hepatic factor VIII messenger RNA (mRNA). Azoxymethane 23-35 coagulation factor VIII Mus musculus 198-209 12070019-7 2002 In contrast, factor VIII mRNA levels in spleen, kidney, and lung tissue of azoxymethane-treated mice were unchanged. Azoxymethane 75-87 coagulation factor VIII Mus musculus 13-24 11756242-6 2002 Moreover, in the rodent-carcinogen model, azoxymethane (AOM)-treatment induced AKT expression in premalignant rat colonocytes. Azoxymethane 42-54 AKT serine/threonine kinase 1 Rattus norvegicus 79-82 12117783-0 2002 Hemizygous mice for the angiotensin II type 2 receptor gene have attenuated susceptibility to azoxymethane-induced colon tumorigenesis. Azoxymethane 94-106 angiotensin II receptor, type 2 Mus musculus 24-54 12017282-0 2002 Effect of vaccination with mutant KRAS peptides on rat colon carcinogenesis induced by azoxymethane. Azoxymethane 87-99 KRAS proto-oncogene, GTPase Rattus norvegicus 34-38 11756242-6 2002 Moreover, in the rodent-carcinogen model, azoxymethane (AOM)-treatment induced AKT expression in premalignant rat colonocytes. Azoxymethane 56-59 AKT serine/threonine kinase 1 Rattus norvegicus 79-82 11782374-1 2002 The inducible isoforms of nitric oxide synthase (iNOS) and cyclooxygenase (COX-2) are overexpressed in colonic tumors of humans, as well as in colon tumors that develop in rats after the administration of the colon-specific carcinogen, azoxymethane (AOM). Azoxymethane 236-248 nitric oxide synthase 2 Homo sapiens 49-53 11743651-7 2002 Quantitative polymerase chain reaction demonstrated that PLK3 mRNA levels were significantly lower in carcinogen (azoxymethane)-induced rat colon tumors than their uninvolved normal colonic mucosa. Azoxymethane 114-126 polo-like kinase 3 Rattus norvegicus 57-61 11782374-1 2002 The inducible isoforms of nitric oxide synthase (iNOS) and cyclooxygenase (COX-2) are overexpressed in colonic tumors of humans, as well as in colon tumors that develop in rats after the administration of the colon-specific carcinogen, azoxymethane (AOM). Azoxymethane 236-248 mitochondrially encoded cytochrome c oxidase II Homo sapiens 75-80 11782374-1 2002 The inducible isoforms of nitric oxide synthase (iNOS) and cyclooxygenase (COX-2) are overexpressed in colonic tumors of humans, as well as in colon tumors that develop in rats after the administration of the colon-specific carcinogen, azoxymethane (AOM). Azoxymethane 250-253 nitric oxide synthase 2 Homo sapiens 49-53 11782374-1 2002 The inducible isoforms of nitric oxide synthase (iNOS) and cyclooxygenase (COX-2) are overexpressed in colonic tumors of humans, as well as in colon tumors that develop in rats after the administration of the colon-specific carcinogen, azoxymethane (AOM). Azoxymethane 250-253 mitochondrially encoded cytochrome c oxidase II Homo sapiens 75-80 11931531-0 2002 Effects of cyclooxygenase-2 inhibitor NS-398 on APC and c-myc expression in rat colon carcinogenesis induced by azoxymethane. Azoxymethane 112-124 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 11-27 12086401-2 2002 Our previous studies indicated that nimesulide and celecoxib, selective COX-2 inhibitors, show inhibitory effects of intestinal carcinogenesis in azoxymethane-treated rats and mice and in Min mice models. Azoxymethane 146-158 cytochrome c oxidase II, mitochondrial Rattus norvegicus 72-77 11931531-0 2002 Effects of cyclooxygenase-2 inhibitor NS-398 on APC and c-myc expression in rat colon carcinogenesis induced by azoxymethane. Azoxymethane 112-124 APC regulator of WNT signaling pathway Rattus norvegicus 48-51 11931531-0 2002 Effects of cyclooxygenase-2 inhibitor NS-398 on APC and c-myc expression in rat colon carcinogenesis induced by azoxymethane. Azoxymethane 112-124 MYC proto-oncogene, bHLH transcription factor Rattus norvegicus 56-61 11931531-2 2002 The aim of this study was to examine the effects of NSAIDs on the expression of the tumor suppressor APC gene and the c-myc oncogene in the colons of rats treated with a colon-specific carcinogen, azoxymethane (AOM). Azoxymethane 197-209 APC regulator of WNT signaling pathway Rattus norvegicus 101-104 11931531-4 2002 RESULTS: The group of rats simultaneously administered AOM and NS-398, a cyclooxygenase (COX)-2 inhibitor, showed a significant reduction in the number of preneoplastic lesions of colon cancer compared with that in the group of rats treated with AOM alone. Azoxymethane 55-58 cytochrome c oxidase II, mitochondrial Rattus norvegicus 73-95 11931531-4 2002 RESULTS: The group of rats simultaneously administered AOM and NS-398, a cyclooxygenase (COX)-2 inhibitor, showed a significant reduction in the number of preneoplastic lesions of colon cancer compared with that in the group of rats treated with AOM alone. Azoxymethane 246-249 cytochrome c oxidase II, mitochondrial Rattus norvegicus 73-95 11731424-1 2001 Methylazoxymethanol (MAM) and its chemical and metabolic precursor, azoxymethane (AOM), both strong colon carcinogens in rodents, can be metabolically activated by CYP2E1 in vitro. Azoxymethane 68-80 cytochrome P450, family 2, subfamily e, polypeptide 1 Mus musculus 164-170 11731424-0 2001 Differential effects of CYP2E1 status on the metabolic activation of the colon carcinogens azoxymethane and methylazoxymethanol. Azoxymethane 91-103 cytochrome P450, family 2, subfamily e, polypeptide 1 Mus musculus 24-30 11605062-1 2001 The modifying effects of a dietary water-soluble extract from cultured medium of Ganoderma lucidum (Rei-shi or Mannentake) mycelia (MAK) on the development of azoxymethane (AOM)-induced colonic aberrant crypt foci (ACF) were investigated in male F344 rats. Azoxymethane 159-171 male germ cell-associated kinase Rattus norvegicus 132-135 11745407-7 2001 The total number of aberrant crypt foci in intact rats treated with the procarcinogen azoxymethane plus glycine-extended gastrin(17) was increased by 48% compared to the value in controls treated with azoxymethane only (p = 0.01). Azoxymethane 201-213 gastrin Rattus norvegicus 121-128 11745407-8 2001 We conclude that short term administration of glycine-extended gastrin(17) to mature rats not only has a proliferative effect upon colonic mucosa, but also increases the number of aberrant crypt foci formed in the colorectal mucosa after treatment with azoxymethane. Azoxymethane 253-265 gastrin Rattus norvegicus 63-70 11536370-2 2001 We hypothesize that alterations in the TGF-beta pathway contribute to differential sensitivity of mice to the colon carcinogen azoxymethane (AOM). Azoxymethane 127-139 transforming growth factor, beta 1 Mus musculus 39-47 11509121-4 2001 Well-differentiated adenocarcinoma appeared 5 months after 5 administrations of azoxymethane (10 mg/kg weight) only in a few TCRd -gene knockout mice and the frequency of the carcinoma-bearing mice was increased at 7 and 9 months after the administration. Azoxymethane 80-92 T cell receptor delta chain Mus musculus 125-129 11532879-0 2001 High susceptibility of Scid mice to colon carcinogenesis induced by azoxymethane indicates a possible caretaker role for DNA-dependent protein kinase. Azoxymethane 68-80 protein kinase, DNA activated, catalytic polypeptide Mus musculus 23-27 11532879-3 2001 In the present study, the susceptibility of Scid mice to colon carcinogenesis due to administration of azoxymethane (AOM) was investigated. Azoxymethane 103-115 protein kinase, DNA activated, catalytic polypeptide Mus musculus 44-48 11536370-2 2001 We hypothesize that alterations in the TGF-beta pathway contribute to differential sensitivity of mice to the colon carcinogen azoxymethane (AOM). Azoxymethane 141-144 transforming growth factor, beta 1 Mus musculus 39-47 11142416-0 2000 Neonatal inoculation with the protein-bound polysaccharide PSK increases resistance of adult animals to challenge with syngeneic tumor cells and reduces azoxymethane-induced precancerous lesions in the colon. Azoxymethane 153-165 TAO kinase 2 Mus musculus 59-62 11429049-5 2001 Groups 1 - 3 were administered azoxymethane (AOM) s.c. at a dose of 15 mg / kg body weight, once weekly for 3 weeks to induce beta-catenin-accumulated crypts. Azoxymethane 31-43 catenin beta 1 Rattus norvegicus 126-138 11429049-5 2001 Groups 1 - 3 were administered azoxymethane (AOM) s.c. at a dose of 15 mg / kg body weight, once weekly for 3 weeks to induce beta-catenin-accumulated crypts. Azoxymethane 45-48 catenin beta 1 Rattus norvegicus 126-138 11245437-9 2001 Finally, transgenic mice expressing elevated PKC betaII in the colonic epithelium exhibit a trend toward increased colon tumor formation after exposure to azoxymethane. Azoxymethane 155-167 proline rich transmembrane protein 2 Homo sapiens 45-48 11431334-8 2001 In the present study, we treated Min/+ mice with 5 mg/kg body weight azoxymethane (AOM) at weeks 1 and 2 and demonstrated induction of both types of lesions. Azoxymethane 69-81 APC, WNT signaling pathway regulator Mus musculus 33-36 11431334-8 2001 In the present study, we treated Min/+ mice with 5 mg/kg body weight azoxymethane (AOM) at weeks 1 and 2 and demonstrated induction of both types of lesions. Azoxymethane 83-86 APC, WNT signaling pathway regulator Mus musculus 33-36 11142416-11 2000 In addition, neonatal injection of PSK significantly reduced the number of aberrant crypts and aberrant crypt foci, the precancerous lesions in the colon of F344 rats that received injections s.c. with azoxymethane after 7 weeks of age, to 47% of that of rats that received an injection with saline at the same age. Azoxymethane 202-214 TAO kinase 2 Mus musculus 35-38 11142416-16 2000 These findings suggest that neonatal injection of PSK induces resistance in adult mice to challenge by syngeneic tumor cells and reduces the azoxymethane-induced precancerous lesions in the colon of adult rats via the thymus functions. Azoxymethane 141-153 TAO kinase 2 Mus musculus 50-53 11076880-0 2000 Sulindac and a cyclooxygenase-2 inhibitor, etodolac, increase APC mRNA in the colon of rats treated with azoxymethane. Azoxymethane 105-117 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 15-31 11004662-0 2000 K-ras point mutation is associated with enhancement by deoxycholic acid of colon carcinogenesis induced by azoxymethane, but not with its attenuation by all-trans-retinoic acid. Azoxymethane 107-119 KRAS proto-oncogene, GTPase Rattus norvegicus 0-5 10969813-0 2000 Mutational and nonmutational activation of p21ras in rat colonic azoxymethane-induced tumors: effects on mitogen-activated protein kinase, cyclooxygenase-2, and cyclin D1. Azoxymethane 65-77 HRas proto-oncogene, GTPase Rattus norvegicus 43-49 10938397-0 2000 Expression of transforming growth factor beta1 and its type II receptor in mouse colon tumors induced by azoxymethane. Azoxymethane 105-117 transforming growth factor, beta 1 Mus musculus 14-46 10938397-2 2000 We postulated that TGF-beta1 and TbetaR-II alterations may also be involved in mouse colon tumorigenesis induced by the chemical carcinogen, azoxymethane (AOM). Azoxymethane 141-153 transforming growth factor, beta 1 Mus musculus 19-28 10938397-2 2000 We postulated that TGF-beta1 and TbetaR-II alterations may also be involved in mouse colon tumorigenesis induced by the chemical carcinogen, azoxymethane (AOM). Azoxymethane 141-153 transforming growth factor, beta receptor II Mus musculus 33-42 10969813-1 2000 Azoxymethane (AOM)-induced colonic carcinogenesis involves a number of mutations, including those in the K-ras gene and CTNNB1, that codes for beta-catenin. Azoxymethane 0-12 KRAS proto-oncogene, GTPase Rattus norvegicus 105-110 10969813-1 2000 Azoxymethane (AOM)-induced colonic carcinogenesis involves a number of mutations, including those in the K-ras gene and CTNNB1, that codes for beta-catenin. Azoxymethane 0-12 catenin beta 1 Rattus norvegicus 120-126 10969813-1 2000 Azoxymethane (AOM)-induced colonic carcinogenesis involves a number of mutations, including those in the K-ras gene and CTNNB1, that codes for beta-catenin. Azoxymethane 0-12 catenin beta 1 Rattus norvegicus 143-155 10969813-1 2000 Azoxymethane (AOM)-induced colonic carcinogenesis involves a number of mutations, including those in the K-ras gene and CTNNB1, that codes for beta-catenin. Azoxymethane 14-17 KRAS proto-oncogene, GTPase Rattus norvegicus 105-110 10969813-1 2000 Azoxymethane (AOM)-induced colonic carcinogenesis involves a number of mutations, including those in the K-ras gene and CTNNB1, that codes for beta-catenin. Azoxymethane 14-17 catenin beta 1 Rattus norvegicus 120-126 10969813-1 2000 Azoxymethane (AOM)-induced colonic carcinogenesis involves a number of mutations, including those in the K-ras gene and CTNNB1, that codes for beta-catenin. Azoxymethane 14-17 catenin beta 1 Rattus norvegicus 143-155 10874009-0 2000 Altered expression of beta-catenin, inducible nitric oxide synthase and cyclooxygenase-2 in azoxymethane-induced rat colon carcinogenesis. Azoxymethane 92-104 catenin beta 1 Rattus norvegicus 22-34 10874009-0 2000 Altered expression of beta-catenin, inducible nitric oxide synthase and cyclooxygenase-2 in azoxymethane-induced rat colon carcinogenesis. Azoxymethane 92-104 nitric oxide synthase 2 Rattus norvegicus 36-67 10874009-0 2000 Altered expression of beta-catenin, inducible nitric oxide synthase and cyclooxygenase-2 in azoxymethane-induced rat colon carcinogenesis. Azoxymethane 92-104 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 72-88 10874009-2 2000 We have described the frequent mutation and an altered cellular localization of beta-catenin in rat colon adenocarcinomas induced by azoxymethane (AOM), along with up-regulation of inducible nitric oxide synthase (iNOS) and cyclooxygenase (COX)-2. Azoxymethane 133-145 catenin beta 1 Rattus norvegicus 80-92 10942530-0 2000 Differential expression of p16(INK4a) in azoxymethane-induced mouse colon tumorigenesis. Azoxymethane 41-53 cyclin dependent kinase inhibitor 2A Mus musculus 27-30 10939592-7 2000 Yet tumors are similarly sized in animals of either genotype receiving azoxymethane for identical times, a finding attributable to the significantly higher number of apoptotic cells detected in GRP/GRP-R coexpressing cancers. Azoxymethane 71-83 gastrin releasing peptide Mus musculus 194-197 10939592-7 2000 Yet tumors are similarly sized in animals of either genotype receiving azoxymethane for identical times, a finding attributable to the significantly higher number of apoptotic cells detected in GRP/GRP-R coexpressing cancers. Azoxymethane 71-83 gastrin releasing peptide receptor Mus musculus 198-203 10942530-2 2000 We postulated that alterations in the p16(INK4a) gene may also be involved in mouse colon tumorigenesis induced by the chemical carcinogen azoxymethane (AOM). Azoxymethane 139-151 cyclin dependent kinase inhibitor 2A Mus musculus 38-41 10942530-0 2000 Differential expression of p16(INK4a) in azoxymethane-induced mouse colon tumorigenesis. Azoxymethane 41-53 cyclin dependent kinase inhibitor 2A Mus musculus 31-36 10942530-2 2000 We postulated that alterations in the p16(INK4a) gene may also be involved in mouse colon tumorigenesis induced by the chemical carcinogen azoxymethane (AOM). Azoxymethane 139-151 cyclin dependent kinase inhibitor 2A Mus musculus 42-47 10942530-2 2000 We postulated that alterations in the p16(INK4a) gene may also be involved in mouse colon tumorigenesis induced by the chemical carcinogen azoxymethane (AOM). Azoxymethane 153-156 cyclin dependent kinase inhibitor 2A Mus musculus 38-41 10836998-0 2000 Frequent mutations of the beta-catenin gene in mouse colon tumors induced by azoxymethane. Azoxymethane 77-89 catenin (cadherin associated protein), beta 1 Mus musculus 26-38 10942530-2 2000 We postulated that alterations in the p16(INK4a) gene may also be involved in mouse colon tumorigenesis induced by the chemical carcinogen azoxymethane (AOM). Azoxymethane 153-156 cyclin dependent kinase inhibitor 2A Mus musculus 42-47 10942530-8 2000 Whereas control colon epithelium was uniformly negative for p16(INK4a) immunoreactivity, p16(INK4a)-immunoreactive cells were markedly increased in preneoplastic lesions and adenomas isolated from AOM-treated mice. Azoxymethane 197-200 cyclin dependent kinase inhibitor 2A Mus musculus 93-98 11216473-2 2000 We found that the COX-2 selective inhibitor, nimesulide, reduces azoxymethane (AOM)-induced aberrant crypt foci (ACF) in rats and colon carcinogenesis in mice, as well as formation of intestinal polyps in Min mice. Azoxymethane 65-77 cytochrome c oxidase II, mitochondrial Rattus norvegicus 18-23 10708483-0 2000 Azoxymethane induces KI-ras activation in the tumor resistant AKR/J mouse colon. Azoxymethane 0-12 Kirsten rat sarcoma viral oncogene homolog Mus musculus 21-27 10677604-8 2000 The AOM-treated group showed a significantly reduced infarction volume (by 42.5%, p<0.001), a significantly greater number of p53 positive cells (by 12.0%, p<0. Azoxymethane 4-7 Wistar clone pR53P1 p53 pseudogene Rattus norvegicus 129-132 10657948-4 2000 The following study was undertaken to test the hypothesis that sPLA(2) plays an equivalent role in murine susceptibility to the colon carcinogen azoxymethane (AOM). Azoxymethane 145-157 phospholipase A2, group IIA (platelets, synovial fluid) Mus musculus 63-70 10657948-4 2000 The following study was undertaken to test the hypothesis that sPLA(2) plays an equivalent role in murine susceptibility to the colon carcinogen azoxymethane (AOM). Azoxymethane 159-162 phospholipase A2, group IIA (platelets, synovial fluid) Mus musculus 63-70 10648462-8 2000 CONCLUSIONS: These results indicate that COX-2 is expressed very early in the pathogenesis of colitis-associated tumors, and that the expression pattern is similar to that seen in tumors from azoxymethane-treated and Min/+ mice. Azoxymethane 192-204 cytochrome c oxidase II, mitochondrial Mus musculus 41-46 12716300-5 2000 Whey protein may also be beneficial, as shown by both animal and human studies, and experimental data have demonstrated that the major component bovine lactoferrin (bLF), inhibits colon carcinogenesis in the post-initiation stage in male F344 rats treated with azoxymethane (AOM) without any overt toxicity. Azoxymethane 261-273 lactotransferrin Bos taurus 152-163 10767634-5 2000 Whey protein may also be beneficial, as shown by both animal and human studies, and experimental data have demonstrated that the major component bovine lactoferrin (bLF), inhibits colon carcinogenesis in the post-initiation stage in male F344 rats treated with azoxymethane (AOM) without any overt toxicity. Azoxymethane 261-273 lactotransferrin Bos taurus 152-163 10767634-5 2000 Whey protein may also be beneficial, as shown by both animal and human studies, and experimental data have demonstrated that the major component bovine lactoferrin (bLF), inhibits colon carcinogenesis in the post-initiation stage in male F344 rats treated with azoxymethane (AOM) without any overt toxicity. Azoxymethane 275-278 lactotransferrin Bos taurus 152-163 10667579-4 2000 Our previous study has shown that celecoxib, an inhibitor of COX-2, while sparing COX-1, inhibited azoxymethane (AOM)-induced colon tumorigenesis when administered during both initiation and postinitiation stages, ie., celecoxib administered continuously before, during, and after carcinogen treatment. Azoxymethane 99-111 cytochrome c oxidase II, mitochondrial Rattus norvegicus 61-66 10667579-4 2000 Our previous study has shown that celecoxib, an inhibitor of COX-2, while sparing COX-1, inhibited azoxymethane (AOM)-induced colon tumorigenesis when administered during both initiation and postinitiation stages, ie., celecoxib administered continuously before, during, and after carcinogen treatment. Azoxymethane 113-116 cytochrome c oxidase II, mitochondrial Rattus norvegicus 61-66 10678579-12 2000 Nonselective NSAIDs, for instance aspirin, and selective COX-2 inhibitors such as celecoxib (SC-58635) and NS-398 suppress azoxymethane-induced colon carcinogenesis in rats. Azoxymethane 123-135 cytochrome c oxidase II, mitochondrial Rattus norvegicus 57-62 11216473-2 2000 We found that the COX-2 selective inhibitor, nimesulide, reduces azoxymethane (AOM)-induced aberrant crypt foci (ACF) in rats and colon carcinogenesis in mice, as well as formation of intestinal polyps in Min mice. Azoxymethane 79-82 cytochrome c oxidase II, mitochondrial Rattus norvegicus 18-23 10590233-0 1999 Inhibition of O(6)-methylguanine-DNA methyltransferase increases azoxymethane-induced colonic tumors in rats. Azoxymethane 65-77 O-6-methylguanine-DNA methyltransferase Rattus norvegicus 14-54 10680590-0 2000 Suppression of azoxymethane-induced colonic aberrant crypt foci by a nitric oxide synthase inhibitor. Azoxymethane 15-27 nitric oxide synthase 2 Homo sapiens 69-90 10537280-4 1999 Administration of 250, 500, or 1000 ppm of a novel selective EP1 antagonist, ONO-8711, in the diet to azoxymethane-treated C57BL/6J mice also resulted in a dose-dependent reduction of ACF formation. Azoxymethane 102-114 prostaglandin E receptor 1 (subtype EP1) Mus musculus 61-64 10636069-1 1999 BACKGROUND: We wanted to investigate the relationship between the fecal levels of granulocyte marker protein (GMP) and the presence of aberrant crypt foci (ACF) and colorectal cancer in rats given injections of azoxymethane (AOM) and fed either of two different diets, a basal diet plus 20% corn oil or 20% beef suet, respectively. Azoxymethane 211-223 5'-nucleotidase, cytosolic II Mus musculus 110-113 10709674-3 1999 As discussed above, all six potential chemopreventive agents, aspirin, 2-CPR, DFMO, 4-HPR, piroxicam, and 9-cis-retinoic acid, decreased the level of AOM-induced ACF. Azoxymethane 150-153 cytochrome p450 oxidoreductase Homo sapiens 73-76 10403547-0 1999 Expression of the cyclin D1 gene in rat colorectal aberrant crypt foci and tumors induced by azoxymethane. Azoxymethane 93-105 cyclin D1 Rattus norvegicus 18-27 10403547-2 1999 We examined overexpression of cyclin D1 in several stages of rat colorectal carcinogenesis induced by azoxymethane (AOM) treatment. Azoxymethane 102-114 cyclin D1 Rattus norvegicus 30-39 10462473-0 1999 Effects of beta-glucuronidase-deficient and lycopene-producing Escherichia coli strains on formation of azoxymethane-induced aberrant crypt foci in the rat colon. Azoxymethane 104-116 glucuronidase, beta Rattus norvegicus 11-29 10462473-1 1999 We tried to inhibit the formation of azoxymethane-induced aberrant crypt foci (ACF) in the rat intestine by feeding a culture of a beta-glucuronidase-deficient Escherichia coli strain or a cell suspension of a lycopene-producing E. coli strain. Azoxymethane 37-49 glucuronidase, beta Rattus norvegicus 131-149 10462473-6 1999 These results suggest that feeding of the beta-glucuronidase-deficient E. coli is not very effective in preventing colon carcinogenesis, although activity of the fecal beta-glucuronidase is associated with AOM-induced ACF formation, and that lycopene-producing intestinal bacteria can effectively prevent colon carcinogenesis. Azoxymethane 206-209 glucuronidase, beta Rattus norvegicus 168-186 10330400-3 1999 Transgenic PKC betaII mice exhibit hyperproliferation of the colonic epithelium and an increased susceptibility to azoxymethane-induced aberrant crypt foci, preneoplastic lesions in the colon. Azoxymethane 115-127 protein kinase C, beta Mus musculus 11-21 10069452-0 1999 Coordinate regulation of cyclooxygenase-2 and TGF-beta1 in replication error-positive colon cancer and azoxymethane-induced rat colonic tumors. Azoxymethane 103-115 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 25-41 10069452-0 1999 Coordinate regulation of cyclooxygenase-2 and TGF-beta1 in replication error-positive colon cancer and azoxymethane-induced rat colonic tumors. Azoxymethane 103-115 transforming growth factor, beta 1 Rattus norvegicus 46-55 10069452-2 1999 We evaluated the expression of COX-2 in replication error-positive (RER) colon cancers, colon cancers metastatic to liver and azoxymethane (AOM)-induced rat colonic tumors. Azoxymethane 140-143 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 31-36 10709674-3 1999 As discussed above, all six potential chemopreventive agents, aspirin, 2-CPR, DFMO, 4-HPR, piroxicam, and 9-cis-retinoic acid, decreased the level of AOM-induced ACF. Azoxymethane 150-153 ACF Homo sapiens 162-165 9855006-0 1998 Suppressive effects of nimesulide, a selective inhibitor of cyclooxygenase-2, on azoxymethane-induced colon carcinogenesis in mice. Azoxymethane 81-93 prostaglandin-endoperoxide synthase 2 Mus musculus 60-76 9855006-1 1998 The effects of nimesulide, a selective inhibitor of cyclooxygenase-2 (COX-2) on azoxymethane (AOM)-induced colon carcinogenesis were investigated in mice. Azoxymethane 80-92 prostaglandin-endoperoxide synthase 2 Mus musculus 70-75 9649126-0 1998 Mutations of the Apc gene in experimental colorectal carcinogenesis induced by azoxymethane in F344 rats. Azoxymethane 79-91 APC regulator of WNT signaling pathway Rattus norvegicus 17-20 9649126-2 1998 We analysed mutations in exon 15 of the rat Apc gene using in vitro synthesized protein assay in 66 ACF and in 28 colon tumours induced by azoxymethane. Azoxymethane 139-151 APC regulator of WNT signaling pathway Rattus norvegicus 44-47 9426055-0 1998 Beta-catenin is frequently mutated and demonstrates altered cellular location in azoxymethane-induced rat colon tumors. Azoxymethane 81-93 catenin beta 1 Rattus norvegicus 0-12 9684124-0 1998 Enhanced ligand-induced activation of EGF-receptor and overall tyrosine kinase and phospholipase C in colonocytes isolated from azoxymethane-treated rats. Azoxymethane 128-140 epidermal growth factor like 1 Rattus norvegicus 38-41 9600336-5 1998 In the azoxymethane (AOM) treated rats, overexpression and nuclear localization of beta-catenin was observed in all adenomas. Azoxymethane 7-19 catenin beta 1 Rattus norvegicus 83-95 9781370-0 1998 Inhibition of azoxymethane initiated colon tumor and aberrant crypt foci development by bovine lactoferrin administration in F344 rats. Azoxymethane 14-26 lactotransferrin Bos taurus 95-106 9426055-3 1998 In the present study, we examined the expression of beta-catenin in rat colon tumors induced by azoxymethane in comparison with adjacent normal colon mucosa by immunostaining and immunoblotting. Azoxymethane 96-108 catenin beta 1 Rattus norvegicus 52-64 9426055-7 1998 Such frequent mutations of the beta-catenin gene in azoxymethane-induced rat colon tumors suggest that consequent alterations in the stability and localization of the protein may play an important role in this colon carcinogenesis model. Azoxymethane 52-64 catenin beta 1 Rattus norvegicus 31-43 9311948-4 1997 Azoxymethane suppressed cytosolic PKC lambda protein levels compared with the saline controls at both time points, and this suppression was partially blocked by fish oil feeding at 15 wk and pectin at 37 wk. Azoxymethane 0-12 protein kinase C, gamma Rattus norvegicus 34-37 9439679-0 1997 Inhibitory effect of NS-398, a selective cyclooxygenase-2 inhibitor, on azoxymethane-induced aberrant crypt foci in colon carcinogenesis of F344 rats. Azoxymethane 72-84 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 41-57 9421213-15 1998 The mechanisms underlying these findings rest on the fact that azoxymethane is metabolized mainly by cytochrome P450 2E1, and this enzyme system is not affected by tea. Azoxymethane 63-75 cytochrome P450, family 2, subfamily e, polypeptide 1 Rattus norvegicus 101-120 9570361-0 1997 Inhibition of initiation and early stage development of aberrant crypt foci and enhanced natural killer activity in male rats administered bovine lactoferrin concomitantly with azoxymethane. Azoxymethane 177-189 lactotransferrin Bos taurus 146-157 9570361-1 1997 The influence of concomitant administration of bovine lactoferrin (bLF) on induction of aberrant crypt foci (ACF) by azoxymethane was investigated in male F344 rats. Azoxymethane 117-129 lactotransferrin Bos taurus 54-65 9311948-5 1997 Also, at 15 wk, azoxymethane-injected rats fed corn oil had higher levels of membrane PKC lambda relative to the other treatment groups. Azoxymethane 16-28 protein kinase C, gamma Rattus norvegicus 86-89 9210960-0 1997 Assessment of mutations in Ki-ras and p53 in colon cancers from azoxymethane- and dimethylhydrazine-treated rats. Azoxymethane 64-76 KRAS proto-oncogene, GTPase Rattus norvegicus 27-33 9263527-0 1997 Inhibition of azoxymethane-initiated colon tumor by bovine lactoferrin administration in F344 rats. Azoxymethane 14-26 lactotransferrin Bos taurus 59-70 9180925-0 1997 Expression of bcl-2, bax, and bcl-XL proteins in azoxymethane-induced rat colonic adenocarcinomas. Azoxymethane 49-61 BCL2, apoptosis regulator Rattus norvegicus 14-19 9180925-0 1997 Expression of bcl-2, bax, and bcl-XL proteins in azoxymethane-induced rat colonic adenocarcinomas. Azoxymethane 49-61 Bcl2-like 1 Rattus norvegicus 30-36 9180925-1 1997 Using western blotting and immunochemical analysis, we investigated alterations in the expression of the apoptosis-related proteins bcl-2, bax, and bcl-X in colonic adenocarcinomas induced by subcutaneous injection of azoxymethane (AOM) (15 mg/kg body weight weekly for 2 wk) into male Sprague-Dawley rats. Azoxymethane 218-230 BCL2, apoptosis regulator Rattus norvegicus 132-137 9180925-1 1997 Using western blotting and immunochemical analysis, we investigated alterations in the expression of the apoptosis-related proteins bcl-2, bax, and bcl-X in colonic adenocarcinomas induced by subcutaneous injection of azoxymethane (AOM) (15 mg/kg body weight weekly for 2 wk) into male Sprague-Dawley rats. Azoxymethane 218-230 Bcl2-like 1 Rattus norvegicus 148-153 8566864-0 1996 Cyclooxygenase-1 and cyclooxygenase-2 gene expression in human colorectal adenocarcinomas and in azoxymethane induced colonic tumours in rats. Azoxymethane 97-109 prostaglandin-endoperoxide synthase 2 Homo sapiens 21-37 9290120-0 1997 Modification of azoxymethane intestinal carcinogenesis in rats by feeding sucrose boluses, pasta, and glucose. Azoxymethane 16-28 solute carrier family 45, member 1 Rattus norvegicus 91-96 8625306-17 1996 Animals treated with saline or AOM and fed HFCO showed increased levels of DAG kinase and membrane PKC activities in the colonic mucosa when compared to LFCO and HFFO groups. Azoxymethane 31-34 protein kinase C, gamma Rattus norvegicus 99-102 8625444-0 1996 Azoxymethane enhances ligand-induced activation of EGF receptor tyrosine kinase in the colonic mucosa of rats. Azoxymethane 0-12 epidermal growth factor receptor Rattus norvegicus 51-63 8625444-2 1996 To assess the functional role of TGF-alpha in colonic carcinogenesis the present investigation examines the changes in TGF-alpha-and EGF-induced activation of intrinsic tyrosine kinase (Tyr-k) activity of EGFR in the colonic mucosa of rats after administration of the colonic carcinogen azoxymethane (AOM; 20 mg/kg body wt). Azoxymethane 287-299 transforming growth factor alpha Rattus norvegicus 119-128 8625444-2 1996 To assess the functional role of TGF-alpha in colonic carcinogenesis the present investigation examines the changes in TGF-alpha-and EGF-induced activation of intrinsic tyrosine kinase (Tyr-k) activity of EGFR in the colonic mucosa of rats after administration of the colonic carcinogen azoxymethane (AOM; 20 mg/kg body wt). Azoxymethane 287-299 epidermal growth factor receptor Rattus norvegicus 205-209 8625444-2 1996 To assess the functional role of TGF-alpha in colonic carcinogenesis the present investigation examines the changes in TGF-alpha-and EGF-induced activation of intrinsic tyrosine kinase (Tyr-k) activity of EGFR in the colonic mucosa of rats after administration of the colonic carcinogen azoxymethane (AOM; 20 mg/kg body wt). Azoxymethane 301-304 transforming growth factor alpha Rattus norvegicus 119-128 8625444-2 1996 To assess the functional role of TGF-alpha in colonic carcinogenesis the present investigation examines the changes in TGF-alpha-and EGF-induced activation of intrinsic tyrosine kinase (Tyr-k) activity of EGFR in the colonic mucosa of rats after administration of the colonic carcinogen azoxymethane (AOM; 20 mg/kg body wt). Azoxymethane 301-304 epidermal growth factor receptor Rattus norvegicus 205-209 8681445-2 1996 Animals were given three weekly subcutaneous injections of AOM (15 mg/kg body weight) to induce ACE. Azoxymethane 59-62 angiotensin I converting enzyme Rattus norvegicus 96-99 8766520-1 1996 Alterations of apoptosis and cell proliferation in the colonic epithelium of rats after exposure to azoxymethane (AOM) were estimated by means of the terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling (TUNEL) method, measurement of 5-bromo-2"-deoxyuridine (BrdU) incorporation, immunohistochemical staining for proliferating cell nuclear antigen (PCNA), and counting of mitotic cells. Azoxymethane 100-112 proliferating cell nuclear antigen Rattus norvegicus 337-371 8766520-1 1996 Alterations of apoptosis and cell proliferation in the colonic epithelium of rats after exposure to azoxymethane (AOM) were estimated by means of the terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling (TUNEL) method, measurement of 5-bromo-2"-deoxyuridine (BrdU) incorporation, immunohistochemical staining for proliferating cell nuclear antigen (PCNA), and counting of mitotic cells. Azoxymethane 100-112 proliferating cell nuclear antigen Rattus norvegicus 373-377 8766520-1 1996 Alterations of apoptosis and cell proliferation in the colonic epithelium of rats after exposure to azoxymethane (AOM) were estimated by means of the terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling (TUNEL) method, measurement of 5-bromo-2"-deoxyuridine (BrdU) incorporation, immunohistochemical staining for proliferating cell nuclear antigen (PCNA), and counting of mitotic cells. Azoxymethane 114-117 proliferating cell nuclear antigen Rattus norvegicus 337-371 8766520-1 1996 Alterations of apoptosis and cell proliferation in the colonic epithelium of rats after exposure to azoxymethane (AOM) were estimated by means of the terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling (TUNEL) method, measurement of 5-bromo-2"-deoxyuridine (BrdU) incorporation, immunohistochemical staining for proliferating cell nuclear antigen (PCNA), and counting of mitotic cells. Azoxymethane 114-117 proliferating cell nuclear antigen Rattus norvegicus 373-377 8613017-10 1996 CONCLUSIONS: COX-2 but not COX-1 gene expression is markedly elevated in most colonic tumors examined in azoxymethane-treated rodents. Azoxymethane 105-117 cytochrome c oxidase II, mitochondrial Rattus norvegicus 13-18 8566864-5 1996 It was found that cyclooxygenase-1 and cyclooxygenase-2 mRNA were increased in azoxymethane induced colonic tumours, compared with specimens taken adjacent to the tumours or from the macroscopically normal intestine distant from the tumours. Azoxymethane 79-91 prostaglandin-endoperoxide synthase 1 Homo sapiens 18-34 8566864-5 1996 It was found that cyclooxygenase-1 and cyclooxygenase-2 mRNA were increased in azoxymethane induced colonic tumours, compared with specimens taken adjacent to the tumours or from the macroscopically normal intestine distant from the tumours. Azoxymethane 79-91 prostaglandin-endoperoxide synthase 2 Homo sapiens 39-55 8566864-6 1996 Cyclooxygenase-1 and cyclooxygenase-2 mRNA were increased in specimens from the macroscopically normal intestine of azoxymethane treated animals, compared with colonic specimens from saline treated rats. Azoxymethane 116-128 prostaglandin-endoperoxide synthase 1 Rattus norvegicus 0-16 8566864-6 1996 Cyclooxygenase-1 and cyclooxygenase-2 mRNA were increased in specimens from the macroscopically normal intestine of azoxymethane treated animals, compared with colonic specimens from saline treated rats. Azoxymethane 116-128 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 21-37 7585585-11 1995 Furthermore, the ability of ursodeoxycholic acid to block AOM-induced increases in particulate PKC-alpha, -beta II, and -zeta, and/or inhibit down-regulation of PKC-zeta, may contribute to the chemopreventive effects of this bile acid. Azoxymethane 58-61 protein kinase C, alpha Rattus norvegicus 95-125 8601574-0 1996 Suppression of azoxymethane-induced aberrant crypt foci in rat colon by nimesulide, a selective inhibitor of cyclooxygenase 2. Azoxymethane 15-27 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 109-125 7621432-1 1995 The effects of combined administration of vasoactive intestinal peptide (VIP) and the ornithine decarboxylase (ODC) inhibitor, 1,3-diaminopropane (DAP), on development of colon tumors induced by azoxymethane (AOM), on ODC activity of the colon wall, and on the labelling index of colon epithelial cells were investigated in inbred Wistar rats. Azoxymethane 195-207 vasoactive intestinal peptide Rattus norvegicus 42-71 8526349-1 1995 Inhibition of expression of ras-p21 and p53 by sulindac during azoxymethane-induced colon carcinogenesis. Azoxymethane 63-75 tumor protein p53 Homo sapiens 40-43 7656228-5 1995 First, PLA2, activity in colon tumors produced using azoxymethane (AOM) in Fischer-344 rats was examined. Azoxymethane 53-65 phospholipase A2 Zea mays 7-11 7621432-1 1995 The effects of combined administration of vasoactive intestinal peptide (VIP) and the ornithine decarboxylase (ODC) inhibitor, 1,3-diaminopropane (DAP), on development of colon tumors induced by azoxymethane (AOM), on ODC activity of the colon wall, and on the labelling index of colon epithelial cells were investigated in inbred Wistar rats. Azoxymethane 195-207 ornithine decarboxylase 1 Rattus norvegicus 86-109 7727039-5 1995 The approximately 11% frequency of mutation in IQ-induced ACF is within the range of previous ACF studies of azoxymethane, which reported a 7-37% incidence of Ki-ras mutation. Azoxymethane 109-121 KRAS proto-oncogene, GTPase Rattus norvegicus 159-165 7789532-5 1995 The present studies demonstrate that dietary piroxicam selectively preserved the expression of protein kinase C-zeta in azoxymethane-induced tumors; suggesting that this is at least one mechanism involved in this agent"s chemopreventive actions in this organ. Azoxymethane 120-132 protein kinase C, zeta Rattus norvegicus 95-116 7705952-7 1995 Gastrin levels in rats with AOM-induced tumors were significantly higher than in controls. Azoxymethane 28-31 gastrin Rattus norvegicus 0-7 7789532-0 1995 Selective preservation of protein kinase C-zeta in the chemoprevention of azoxymethane-induced colonic tumors by piroxicam. Azoxymethane 74-86 protein kinase C, zeta Rattus norvegicus 26-47 8056450-0 1994 Ornithine decarboxylase inhibitor attenuates bombesin enhancement of intestinal carcinogenesis and metastasis induced by azoxymethane. Azoxymethane 121-133 ornithine decarboxylase 1 Rattus norvegicus 0-23 7697797-0 1995 Transgenic expression of human MGMT protects against azoxymethane-induced aberrant crypt foci and G to A mutations in the K-ras oncogene of mouse colon. Azoxymethane 53-65 O-6-methylguanine-DNA methyltransferase Homo sapiens 31-35 7697797-0 1995 Transgenic expression of human MGMT protects against azoxymethane-induced aberrant crypt foci and G to A mutations in the K-ras oncogene of mouse colon. Azoxymethane 53-65 Kirsten rat sarcoma viral oncogene homolog Mus musculus 122-127 7697797-2 1995 In this study we evaluated the ability of transgenic overexpression of MGMT in the colon to protect mice from the development of azoxymethane(AOM)-induced aberrant crypt foci (ACF) and mutations in K-ras. Azoxymethane 129-141 O-6-methylguanine-DNA methyltransferase Mus musculus 71-75 21607428-0 1994 Inhibition by calmodulin antagonist trifluoperazine of experimental carcinogenesis in rat colon induced by azoxymethane. Azoxymethane 107-119 calmodulin 1 Rattus norvegicus 14-24 8033306-1 1994 In our previous study, we demonstrated that azoxymethane (AOM) treatment significantly enhanced the expression of ras p21, the protein product of ras genes, and that the dietary administration of chemopreventive agents such as D,L-alpha-difluoromethylornithine (DFMO), a irreversible inhibitor of ornithine decarboxylase, and piroxicam, a non-steroidal anti-inflammatory drug (NSAID), exerted a significant inhibitory effect on AOM-induced ras p21 expression. Azoxymethane 44-56 KRAS proto-oncogene, GTPase Rattus norvegicus 118-121 8033306-1 1994 In our previous study, we demonstrated that azoxymethane (AOM) treatment significantly enhanced the expression of ras p21, the protein product of ras genes, and that the dietary administration of chemopreventive agents such as D,L-alpha-difluoromethylornithine (DFMO), a irreversible inhibitor of ornithine decarboxylase, and piroxicam, a non-steroidal anti-inflammatory drug (NSAID), exerted a significant inhibitory effect on AOM-induced ras p21 expression. Azoxymethane 44-56 ornithine decarboxylase 1 Rattus norvegicus 297-320 8033306-1 1994 In our previous study, we demonstrated that azoxymethane (AOM) treatment significantly enhanced the expression of ras p21, the protein product of ras genes, and that the dietary administration of chemopreventive agents such as D,L-alpha-difluoromethylornithine (DFMO), a irreversible inhibitor of ornithine decarboxylase, and piroxicam, a non-steroidal anti-inflammatory drug (NSAID), exerted a significant inhibitory effect on AOM-induced ras p21 expression. Azoxymethane 44-56 KRAS proto-oncogene, GTPase Rattus norvegicus 444-447 8033306-1 1994 In our previous study, we demonstrated that azoxymethane (AOM) treatment significantly enhanced the expression of ras p21, the protein product of ras genes, and that the dietary administration of chemopreventive agents such as D,L-alpha-difluoromethylornithine (DFMO), a irreversible inhibitor of ornithine decarboxylase, and piroxicam, a non-steroidal anti-inflammatory drug (NSAID), exerted a significant inhibitory effect on AOM-induced ras p21 expression. Azoxymethane 58-61 KRAS proto-oncogene, GTPase Rattus norvegicus 118-121 8033306-1 1994 In our previous study, we demonstrated that azoxymethane (AOM) treatment significantly enhanced the expression of ras p21, the protein product of ras genes, and that the dietary administration of chemopreventive agents such as D,L-alpha-difluoromethylornithine (DFMO), a irreversible inhibitor of ornithine decarboxylase, and piroxicam, a non-steroidal anti-inflammatory drug (NSAID), exerted a significant inhibitory effect on AOM-induced ras p21 expression. Azoxymethane 58-61 ornithine decarboxylase 1 Rattus norvegicus 297-320 8033306-1 1994 In our previous study, we demonstrated that azoxymethane (AOM) treatment significantly enhanced the expression of ras p21, the protein product of ras genes, and that the dietary administration of chemopreventive agents such as D,L-alpha-difluoromethylornithine (DFMO), a irreversible inhibitor of ornithine decarboxylase, and piroxicam, a non-steroidal anti-inflammatory drug (NSAID), exerted a significant inhibitory effect on AOM-induced ras p21 expression. Azoxymethane 58-61 KRAS proto-oncogene, GTPase Rattus norvegicus 444-447 8149495-0 1994 Sequential analysis of K-ras mutations in aberrant crypt foci and colonic tumors induced by azoxymethane in Fischer-344 rats on high-risk diet. Azoxymethane 92-104 KRAS proto-oncogene, GTPase Rattus norvegicus 23-28 1988118-0 1991 Enhancement by methionine enkephalin of colon carcinogenesis induced by azoxymethane. Azoxymethane 72-84 proenkephalin Rattus norvegicus 26-36 8149347-0 1994 Monoamine oxidase B inhibitor enhances experimental carcinogenesis in rat colon induced by azoxymethane. Azoxymethane 91-103 monoamine oxidase B Rattus norvegicus 0-19 7598792-0 1994 Histochemical studies of progressive p53 mutations during colonic carcinogenesis in Sprague-Dawley rats induced by N-methyl-N-nitro-nitrosoguanidine or azoxymethane. Azoxymethane 152-164 Wistar clone pR53P1 p53 pseudogene Rattus norvegicus 37-40 8242846-0 1993 Inhibition by dietary curcumin of azoxymethane-induced ornithine decarboxylase, tyrosine protein kinase, arachidonic acid metabolism and aberrant crypt foci formation in the rat colon. Azoxymethane 34-46 ornithine decarboxylase 1 Rattus norvegicus 55-78 8242846-8 1993 Dietary curcumin significantly decreased the levels of AOM-induced ODC activity in the liver and colon (P < 0.0001) and TPK activity in the liver and colon (P < 0.01-0.0001) and the formation of 5(S)-, 8(S)-, 12(S)- and 15(S)-hydroxyeicosatetraenoic acids (HETEs) in the liver and colon (P < 0.0001). Azoxymethane 55-58 ornithine decarboxylase 1 Rattus norvegicus 67-70 8339252-15 1993 Although other mechanisms are not excluded, inhibition of AOM-induced colon carcinogenesis by anethole trithione and diallyl disulfide may be associated, in part, with increased activities of phase II enzymes such as GST, NAD(P)H-dependent quinone reductase, and UDP-glucuronosyl transferase in the liver and colon. Azoxymethane 58-61 hematopoietic prostaglandin D synthase Rattus norvegicus 217-220 8386981-0 1993 Alpha 1-antitrypsin as a biomarker in azoxymethane induced intestinal tumors in F344 rats. Azoxymethane 38-50 serpin family A member 1 Homo sapiens 0-19 8422651-0 1993 Effect of restricted caloric intake on the development of the azoxymethane-induced glutathione S-transferase placental form positive hepatocellular foci in male F344 rats. Azoxymethane 62-74 hematopoietic prostaglandin D synthase Rattus norvegicus 83-108 8422651-1 1993 The modifying effect of 30% caloric restriction on the occurrence of azoxymethane (AOM)-induced glutathione S-transferase placental form (GST-P) positive hepatocellular foci was investigated in male F344 rats. Azoxymethane 69-81 glutathione S-transferase pi 1 Rattus norvegicus 96-143 8422651-1 1993 The modifying effect of 30% caloric restriction on the occurrence of azoxymethane (AOM)-induced glutathione S-transferase placental form (GST-P) positive hepatocellular foci was investigated in male F344 rats. Azoxymethane 83-86 glutathione S-transferase pi 1 Rattus norvegicus 96-143 8319499-2 1993 The expression of the mutant p53 gene product in aberrant crypt foci and in adenocarcinomas induced by azoxymethane was investigated immunohistochemically, using the rat model system. Azoxymethane 103-115 Wistar clone pR53P1 p53 pseudogene Rattus norvegicus 29-32 1997099-9 1991 Azoxymethane increased in CCPR, but this was suppressed by the high dose of EGF. Azoxymethane 0-12 epidermal growth factor like 1 Rattus norvegicus 76-79 1997099-10 1991 These results suggest that (1) luminal EGF and azoxymethane independently increase the colonic CCPR and their combined effect is not synergistic but antagonistic; (2) EGF may have a role in normal epithelial growth, but does not potentiate colonic carcinogenesis in this model. Azoxymethane 47-59 epidermal growth factor like 1 Rattus norvegicus 167-170 8403199-0 1993 K-ras mutations in aberrant crypt foci, adenomas and adenocarcinomas during azoxymethane-induced colon carcinogenesis. Azoxymethane 76-88 KRAS proto-oncogene, GTPase Rattus norvegicus 0-5 8403199-10 1993 These data suggest that K-ras mutations play a role during the stages of carcinogenesis in azoxymethane-induced rat colon cancer. Azoxymethane 91-103 KRAS proto-oncogene, GTPase Rattus norvegicus 24-29 20233899-4 2010 Contrary to our hypothesis, deletion of STAT2 inhibited azoxymethane/dextran sodium sulfate-induced colorectal carcinogenesis as measured by prolonged survival, lower adenoma incidence, smaller polyps, and less chronic inflammation. Azoxymethane 56-68 signal transducer and activator of transcription 2 Homo sapiens 40-45 2206944-0 1990 Enhancement by neurotensin of experimental carcinogenesis induced in rat colon by azoxymethane. Azoxymethane 82-94 neurotensin Rattus norvegicus 15-26 20233899-7 2010 Deletion of STAT2 decreased azoxymethane/dextran sodium sulfate-induced expression and release of proinflammatory mediators, such as interleukin-6 and CCL2, and decreased interleukin-6 release from skin carcinoma cells, which then decreased STAT3 activation. Azoxymethane 28-40 signal transducer and activator of transcription 3 Homo sapiens 241-246 20233899-7 2010 Deletion of STAT2 decreased azoxymethane/dextran sodium sulfate-induced expression and release of proinflammatory mediators, such as interleukin-6 and CCL2, and decreased interleukin-6 release from skin carcinoma cells, which then decreased STAT3 activation. Azoxymethane 28-40 signal transducer and activator of transcription 2 Homo sapiens 12-17 20233899-7 2010 Deletion of STAT2 decreased azoxymethane/dextran sodium sulfate-induced expression and release of proinflammatory mediators, such as interleukin-6 and CCL2, and decreased interleukin-6 release from skin carcinoma cells, which then decreased STAT3 activation. Azoxymethane 28-40 interleukin 6 Homo sapiens 133-146 20233899-7 2010 Deletion of STAT2 decreased azoxymethane/dextran sodium sulfate-induced expression and release of proinflammatory mediators, such as interleukin-6 and CCL2, and decreased interleukin-6 release from skin carcinoma cells, which then decreased STAT3 activation. Azoxymethane 28-40 C-C motif chemokine ligand 2 Homo sapiens 151-155 20233899-7 2010 Deletion of STAT2 decreased azoxymethane/dextran sodium sulfate-induced expression and release of proinflammatory mediators, such as interleukin-6 and CCL2, and decreased interleukin-6 release from skin carcinoma cells, which then decreased STAT3 activation. Azoxymethane 28-40 interleukin 6 Homo sapiens 171-184 9855016-0 1998 Altered expression of cyclin D1 and cyclin-dependent kinase 4 in azoxymethane-induced mouse colon tumorigenesis. Azoxymethane 65-77 cyclin D1 Mus musculus 22-31 9855016-0 1998 Altered expression of cyclin D1 and cyclin-dependent kinase 4 in azoxymethane-induced mouse colon tumorigenesis. Azoxymethane 65-77 cyclin-dependent kinase 4 Mus musculus 36-61 9855016-2 1998 We hypothesize that altered expression of cyclin D1 and Cdk4 may also be involved in mouse colon tumorigenesis induced by the chemical carcinogen, azoxymethane (AOM). Azoxymethane 147-159 cyclin D1 Mus musculus 42-51 9855016-2 1998 We hypothesize that altered expression of cyclin D1 and Cdk4 may also be involved in mouse colon tumorigenesis induced by the chemical carcinogen, azoxymethane (AOM). Azoxymethane 147-159 cyclin-dependent kinase 4 Mus musculus 56-60 9855016-2 1998 We hypothesize that altered expression of cyclin D1 and Cdk4 may also be involved in mouse colon tumorigenesis induced by the chemical carcinogen, azoxymethane (AOM). Azoxymethane 161-164 cyclin D1 Mus musculus 42-51 9855016-2 1998 We hypothesize that altered expression of cyclin D1 and Cdk4 may also be involved in mouse colon tumorigenesis induced by the chemical carcinogen, azoxymethane (AOM). Azoxymethane 161-164 cyclin-dependent kinase 4 Mus musculus 56-60 34914638-9 2022 Finally, the SOAT1 inhibitor (Avasimibe) showed the significant levels of therapeutic effects on both AOM/DSS-induced and ApcMin/+ spontaneous intestine cancer. Azoxymethane 102-105 sterol O-acyltransferase 1 Homo sapiens 13-18 34628032-8 2022 Moreover, colitis-associated colorectal cancer development was higher in GPR65 KO mice than WT mice when treated with AOM/DSS. Azoxymethane 118-121 G-protein coupled receptor 65 Mus musculus 73-78 33535870-9 2021 Mechanistically, tanshinone IIA downregulated the NF-kappaB signalling pathway in the colonic tumours of AOM/DSS-treated mice. Azoxymethane 105-108 ATPase, class II, type 9A Mus musculus 28-31 33535870-9 2021 Mechanistically, tanshinone IIA downregulated the NF-kappaB signalling pathway in the colonic tumours of AOM/DSS-treated mice. Azoxymethane 105-108 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 50-59 34702807-0 2021 The overexpression of Tipe2 in CRC cells suppresses survival while endogenous Tipe2 accelerates AOM/DSS induced-tumor initiation. Azoxymethane 96-99 tumor necrosis factor, alpha-induced protein 8-like 2 Mus musculus 78-83 34876395-0 2021 Correlation Between THSD7A Expression and Tumor Characteristics of Azoxymethane-Induced Colon Cancer Model in Rats. Azoxymethane 67-79 thrombospondin type 1 domain containing 7A Rattus norvegicus 20-26 34876395-2 2021 Thus, we investigated the correlation between THSD7A expression and pathologic determinants of azoxymethane (AOM)-induced CRC in a rat model. Azoxymethane 109-112 thrombospondin type 1 domain containing 7A Rattus norvegicus 46-52 34876395-11 2021 CONCLUSION: Negative staining for THSD7A seems to be linked to invasive pathologic determinants in AOM-induced CRC in rats. Azoxymethane 99-102 thrombospondin type 1 domain containing 7A Rattus norvegicus 34-40 34947813-6 2021 Interestingly, the knockout of CXCL13 inhibits benzo(a)pyrene-induced lung cancer and azoxymethane/dextran sodium sulfate-induced colorectal cancer in mice. Azoxymethane 86-98 chemokine (C-X-C motif) ligand 13 Mus musculus 31-37 34625710-3 2021 Here, we show that CCL11 is involved in the pathogenesis of DSS-induced colitis and in colon tumorigenesis in the azoxymethane (AOM)-DSS model of colitis-associated carcinogenesis (CAC). Azoxymethane 114-126 chemokine (C-C motif) ligand 11 Mus musculus 19-24 34625710-3 2021 Here, we show that CCL11 is involved in the pathogenesis of DSS-induced colitis and in colon tumorigenesis in the azoxymethane (AOM)-DSS model of colitis-associated carcinogenesis (CAC). Azoxymethane 128-131 chemokine (C-C motif) ligand 11 Mus musculus 19-24 34625710-7 2021 Studies in bone marrow chimera mice revealed that hematopoietic- and epithelial-cell-derived CCL11 were both important for tumorigenesis in the AOM-DSS model. Azoxymethane 144-147 chemokine (C-C motif) ligand 11 Mus musculus 93-98 34702807-10 2021 These data suggest strongly that the overexpressed Tipe2 suppresses tumor cells proliferation and survival, but endogenous Tipe2 promotes the initiation of tumorigenesis when exposure to dangerous environment such as AOM/DSS-related inflammation. Azoxymethane 217-220 tumor necrosis factor, alpha-induced protein 8-like 2 Mus musculus 123-128 34307147-2 2021 We previously reported that Nrf2 deficiency enhances the anti-tumorigenic effect of 17beta-estradiol (E2) in an azoxymethane (AOM)/dextran sodium sulfate (DSS) model of colitis-associated cancer (CAC). Azoxymethane 112-124 nuclear factor, erythroid derived 2, like 2 Mus musculus 28-32 34744741-4 2021 The results showed that 50 mg/kg SPS-1, an active fraction isolated from SPS, could significantly inhibit CRC induced by AOM/DSS and changed the polarization of macrophages to the M1 phenotype. Azoxymethane 121-124 selenophosphate synthetase 1 Mus musculus 33-38 34622729-8 2021 CONCLUSIONS: The inhibitory effects of piceatannol on AOM/DSS-induced colon tumor growth appear to be associated with reductions in colon MCP-1 and PD-1 levels through the downregulated expression of COX-2 in the tumor microenvironment. Azoxymethane 54-57 mast cell protease 1 Mus musculus 138-143 34622729-8 2021 CONCLUSIONS: The inhibitory effects of piceatannol on AOM/DSS-induced colon tumor growth appear to be associated with reductions in colon MCP-1 and PD-1 levels through the downregulated expression of COX-2 in the tumor microenvironment. Azoxymethane 54-57 programmed cell death 1 Mus musculus 148-152 34622729-8 2021 CONCLUSIONS: The inhibitory effects of piceatannol on AOM/DSS-induced colon tumor growth appear to be associated with reductions in colon MCP-1 and PD-1 levels through the downregulated expression of COX-2 in the tumor microenvironment. Azoxymethane 54-57 cytochrome c oxidase II, mitochondrial Mus musculus 200-205 34638991-2 2021 Our previous study showed that the deficiency of the 15 kDa selenoprotein (Selenof) significantly reduced the formation of aberrant crypt foci (ACF) in a mouse model of azoxymethane (AOM)-induced colon carcinogenesis. Azoxymethane 169-181 selenoprotein F Mus musculus 53-73 34638991-2 2021 Our previous study showed that the deficiency of the 15 kDa selenoprotein (Selenof) significantly reduced the formation of aberrant crypt foci (ACF) in a mouse model of azoxymethane (AOM)-induced colon carcinogenesis. Azoxymethane 169-181 selenoprotein F Mus musculus 75-82 34273909-7 2021 Tumor-associated proteins, including p65 and Ki-67, were downregulated by the IRAK1/4 inhibitor in AOM/DSS-treated mice. Azoxymethane 99-102 v-rel reticuloendotheliosis viral oncogene homolog A (avian) Mus musculus 37-40 34273909-7 2021 Tumor-associated proteins, including p65 and Ki-67, were downregulated by the IRAK1/4 inhibitor in AOM/DSS-treated mice. Azoxymethane 99-102 antigen identified by monoclonal antibody Ki 67 Mus musculus 45-50 34273909-7 2021 Tumor-associated proteins, including p65 and Ki-67, were downregulated by the IRAK1/4 inhibitor in AOM/DSS-treated mice. Azoxymethane 99-102 interleukin-1 receptor-associated kinase 1 Mus musculus 78-85 34352441-5 2021 The rat CRC model was induced by AOM/DSS, in which we verified activity in the Wnt/beta-catenin pathway by examining GSK3beta phosphorylation. Azoxymethane 33-36 catenin beta 1 Rattus norvegicus 83-95 34526999-14 2021 In the prophylactic setting, after immunization with CDC25B or COX2 peptides mice treated with AOM developed significantly fewer tumors as compared to controls (p<0.0002) with 50% of mice remaining tumor free in each antigen group. Azoxymethane 95-98 cell division cycle 25B Mus musculus 53-59 34160895-10 2021 Of note, TFAM knockout increased the susceptibility of mice to azoxymethane/DSS-induced CAC and TFAM overexpression protected mice from intestinal inflammation and colitis-associated tumorigenesis. Azoxymethane 63-75 transcription factor A, mitochondrial Mus musculus 9-13 34307147-2 2021 We previously reported that Nrf2 deficiency enhances the anti-tumorigenic effect of 17beta-estradiol (E2) in an azoxymethane (AOM)/dextran sodium sulfate (DSS) model of colitis-associated cancer (CAC). Azoxymethane 126-129 nuclear factor, erythroid derived 2, like 2 Mus musculus 28-32 34307147-6 2021 Based on Western blotting results, PD-L1 expression was reduced in Nrf2 knockout (KO) female and E2-treated male mice when compared with their wild-type counterparts, following AOM/DSS treatment; this supports the association of PD-L1 expression with tumor progression. Azoxymethane 177-180 CD274 antigen Mus musculus 35-40 34307147-6 2021 Based on Western blotting results, PD-L1 expression was reduced in Nrf2 knockout (KO) female and E2-treated male mice when compared with their wild-type counterparts, following AOM/DSS treatment; this supports the association of PD-L1 expression with tumor progression. Azoxymethane 177-180 nuclear factor, erythroid derived 2, like 2 Mus musculus 67-71 34307147-6 2021 Based on Western blotting results, PD-L1 expression was reduced in Nrf2 knockout (KO) female and E2-treated male mice when compared with their wild-type counterparts, following AOM/DSS treatment; this supports the association of PD-L1 expression with tumor progression. Azoxymethane 177-180 CD274 antigen Mus musculus 229-234 34118646-8 2021 KEY FINDINGS: Topiramate improved the body weight gain, decreased serum CEA, augmented the antioxidant defenses in the colonic tissues with significant amelioration of the inflammatory changes, decline in tissue VEGF and p-AKT/mTOR/MAP kinase signaling and increased Nrf2/HO-1 content in a dose-dependent manner when compared to rats treated with azoxymethane alone. Azoxymethane 347-359 NFE2 like bZIP transcription factor 2 Rattus norvegicus 267-271 34118646-8 2021 KEY FINDINGS: Topiramate improved the body weight gain, decreased serum CEA, augmented the antioxidant defenses in the colonic tissues with significant amelioration of the inflammatory changes, decline in tissue VEGF and p-AKT/mTOR/MAP kinase signaling and increased Nrf2/HO-1 content in a dose-dependent manner when compared to rats treated with azoxymethane alone. Azoxymethane 347-359 heme oxygenase 1 Rattus norvegicus 272-276 34099522-4 2021 To understand the role of DNA repair, especially homologous recombination (HR), in chemical carcinogen-induced CRC growth, we unraveled the role of RAD51AP1 (RAD51-Associated Protein 1), a protein involved in HR, in genotoxic carcinogen (Azoxymethane, AOM)-induced CRC. Azoxymethane 238-250 RAD51 associated protein 1 Mus musculus 148-156 34099522-4 2021 To understand the role of DNA repair, especially homologous recombination (HR), in chemical carcinogen-induced CRC growth, we unraveled the role of RAD51AP1 (RAD51-Associated Protein 1), a protein involved in HR, in genotoxic carcinogen (Azoxymethane, AOM)-induced CRC. Azoxymethane 238-250 RAD51 associated protein 1 Mus musculus 158-184 34099522-4 2021 To understand the role of DNA repair, especially homologous recombination (HR), in chemical carcinogen-induced CRC growth, we unraveled the role of RAD51AP1 (RAD51-Associated Protein 1), a protein involved in HR, in genotoxic carcinogen (Azoxymethane, AOM)-induced CRC. Azoxymethane 252-255 RAD51 associated protein 1 Mus musculus 148-156 34099522-4 2021 To understand the role of DNA repair, especially homologous recombination (HR), in chemical carcinogen-induced CRC growth, we unraveled the role of RAD51AP1 (RAD51-Associated Protein 1), a protein involved in HR, in genotoxic carcinogen (Azoxymethane, AOM)-induced CRC. Azoxymethane 252-255 RAD51 associated protein 1 Mus musculus 158-184 34099522-5 2021 Although AOM treatment alone significantly increased RAD51AP1 expression, the combination of AOM and Dextran Sulfate Sodium (DSS) treatment dramatically increased by several folds. Azoxymethane 9-12 RAD51 associated protein 1 Mus musculus 53-61 34154626-7 2021 Functionally, IMP3 promote the malignant biological process of CRC cells via MEKK1/MEK1/ERK signaling pathway both in vitro and in vivo, Moreover, IMP3-/- mice show decreased the expression of MEKK1 as well as colorectal tumors compared with wild-type mice after treatment with azoxymethane/dextran sodium sulfate. Azoxymethane 278-290 IMP3, U3 small nucleolar ribonucleoprotein Mus musculus 14-18 34154626-7 2021 Functionally, IMP3 promote the malignant biological process of CRC cells via MEKK1/MEK1/ERK signaling pathway both in vitro and in vivo, Moreover, IMP3-/- mice show decreased the expression of MEKK1 as well as colorectal tumors compared with wild-type mice after treatment with azoxymethane/dextran sodium sulfate. Azoxymethane 278-290 mitogen-activated protein kinase kinase 1 Mus musculus 77-82 34154626-7 2021 Functionally, IMP3 promote the malignant biological process of CRC cells via MEKK1/MEK1/ERK signaling pathway both in vitro and in vivo, Moreover, IMP3-/- mice show decreased the expression of MEKK1 as well as colorectal tumors compared with wild-type mice after treatment with azoxymethane/dextran sodium sulfate. Azoxymethane 278-290 mitogen-activated protein kinase kinase 1 Mus musculus 83-87 34154626-7 2021 Functionally, IMP3 promote the malignant biological process of CRC cells via MEKK1/MEK1/ERK signaling pathway both in vitro and in vivo, Moreover, IMP3-/- mice show decreased the expression of MEKK1 as well as colorectal tumors compared with wild-type mice after treatment with azoxymethane/dextran sodium sulfate. Azoxymethane 278-290 mitogen-activated protein kinase 1 Mus musculus 88-91 34154626-7 2021 Functionally, IMP3 promote the malignant biological process of CRC cells via MEKK1/MEK1/ERK signaling pathway both in vitro and in vivo, Moreover, IMP3-/- mice show decreased the expression of MEKK1 as well as colorectal tumors compared with wild-type mice after treatment with azoxymethane/dextran sodium sulfate. Azoxymethane 278-290 IMP3, U3 small nucleolar ribonucleoprotein Mus musculus 147-151 34154626-7 2021 Functionally, IMP3 promote the malignant biological process of CRC cells via MEKK1/MEK1/ERK signaling pathway both in vitro and in vivo, Moreover, IMP3-/- mice show decreased the expression of MEKK1 as well as colorectal tumors compared with wild-type mice after treatment with azoxymethane/dextran sodium sulfate. Azoxymethane 278-290 mitogen-activated protein kinase kinase 1 Mus musculus 193-198 34109174-3 2021 Here, based on the BRD7 knockout (BRD7-/-) and BRD7 flox/flox (BRD7+/+) mouse models constructed in our previous work, we established an azoxymethane/dextran sodium sulfate (AOM/DSS)-induced mouse model. Azoxymethane 137-149 bromodomain containing 7 Mus musculus 19-23 34109174-3 2021 Here, based on the BRD7 knockout (BRD7-/-) and BRD7 flox/flox (BRD7+/+) mouse models constructed in our previous work, we established an azoxymethane/dextran sodium sulfate (AOM/DSS)-induced mouse model. Azoxymethane 137-149 bromodomain containing 7 Mus musculus 34-38 34109174-3 2021 Here, based on the BRD7 knockout (BRD7-/-) and BRD7 flox/flox (BRD7+/+) mouse models constructed in our previous work, we established an azoxymethane/dextran sodium sulfate (AOM/DSS)-induced mouse model. Azoxymethane 137-149 bromodomain containing 7 Mus musculus 47-51 34109174-3 2021 Here, based on the BRD7 knockout (BRD7-/-) and BRD7 flox/flox (BRD7+/+) mouse models constructed in our previous work, we established an azoxymethane/dextran sodium sulfate (AOM/DSS)-induced mouse model. Azoxymethane 137-149 bromodomain containing 7 Mus musculus 63-67 34109174-3 2021 Here, based on the BRD7 knockout (BRD7-/-) and BRD7 flox/flox (BRD7+/+) mouse models constructed in our previous work, we established an azoxymethane/dextran sodium sulfate (AOM/DSS)-induced mouse model. Azoxymethane 174-177 bromodomain containing 7 Mus musculus 19-23 34109174-3 2021 Here, based on the BRD7 knockout (BRD7-/-) and BRD7 flox/flox (BRD7+/+) mouse models constructed in our previous work, we established an azoxymethane/dextran sodium sulfate (AOM/DSS)-induced mouse model. Azoxymethane 174-177 bromodomain containing 7 Mus musculus 34-38 34109174-3 2021 Here, based on the BRD7 knockout (BRD7-/-) and BRD7 flox/flox (BRD7+/+) mouse models constructed in our previous work, we established an azoxymethane/dextran sodium sulfate (AOM/DSS)-induced mouse model. Azoxymethane 174-177 bromodomain containing 7 Mus musculus 47-51 34109174-3 2021 Here, based on the BRD7 knockout (BRD7-/-) and BRD7 flox/flox (BRD7+/+) mouse models constructed in our previous work, we established an azoxymethane/dextran sodium sulfate (AOM/DSS)-induced mouse model. Azoxymethane 174-177 bromodomain containing 7 Mus musculus 63-67 34109174-4 2021 BRD7+/+ mice were found to be highly susceptible to AOM/DSS-induced colitis-associated CRC, and BRD7 significantly promoted cell proliferation and cell cycle G1/S transition but showed no significant effect on cell apoptosis. Azoxymethane 52-55 bromodomain containing 7 Mus musculus 0-4 34070183-8 2021 These results suggest that at one month after the end of the DSS or AOM inductions, a smouldering inflammation is present in both induced conditions, since the pro-inflammatory cytokines still exceed, in proportion, the local homeostatic regulation of which TGF-beta1 is a part (inflammatory threshold). Azoxymethane 68-71 transforming growth factor, beta 1 Rattus norvegicus 258-267 35631174-6 2022 FTH1 expression increased in the mice"s colons in the IC + AOM/DSS group compared with that observed in the ID and IOL + AOM/DSS groups. Azoxymethane 59-62 ferritin heavy polypeptide 1 Mus musculus 0-4 34087454-8 2021 Additionally, comparing to WT mice, IDO-/- mice treated with AOM/DSS exhibited fewer and smaller tumor burdens in colon, with less Treg and more CD8+ T cells infiltration, while Kyn administration abolished this regulation. Azoxymethane 61-64 indoleamine 2,3-dioxygenase 1 Mus musculus 36-39 35378414-9 2022 The administration of 10 mg/kg tetra- and pentahydroxyflavanones to AOM/DSS-treated mice also resulted in decreases of 59.5 and 42.5% in IL-10 levels and 58.1 and 93.9% in PD-1 levels, respectively, in the colon. Azoxymethane 68-71 interleukin 10 Mus musculus 137-142 35378414-9 2022 The administration of 10 mg/kg tetra- and pentahydroxyflavanones to AOM/DSS-treated mice also resulted in decreases of 59.5 and 42.5% in IL-10 levels and 58.1 and 93.9% in PD-1 levels, respectively, in the colon. Azoxymethane 68-71 programmed cell death 1 Mus musculus 172-176 35378414-10 2022 CONCLUSION: The inhibitory effects of tetra- and pentahydroxyflavanones on the growth of colon tumors in AOM/DSS-treated mice appear to be associated with decreases in the colon levels of IL-10 and PD-1 through the down-regulated expression of COX-2 and CD8+ T-cell exhaustion by TOX/TOX2 in the tumor microenvironment. Azoxymethane 105-108 interleukin 10 Mus musculus 188-193 35378414-10 2022 CONCLUSION: The inhibitory effects of tetra- and pentahydroxyflavanones on the growth of colon tumors in AOM/DSS-treated mice appear to be associated with decreases in the colon levels of IL-10 and PD-1 through the down-regulated expression of COX-2 and CD8+ T-cell exhaustion by TOX/TOX2 in the tumor microenvironment. Azoxymethane 105-108 programmed cell death 1 Mus musculus 198-202 35503250-8 2022 Finally, uncoupling MTG16:E protein interactions partially phenocopied the enhanced tumorigenicity of Mtg16-/- colon in the azoxymethane(AOM)/DSS-induced model of CAC, indicating that MTG16 protects from tumorigenesis through additional mechanisms. Azoxymethane 124-136 CBFA2/RUNX1 partner transcriptional co-repressor 3 Homo sapiens 20-25 35503250-8 2022 Finally, uncoupling MTG16:E protein interactions partially phenocopied the enhanced tumorigenicity of Mtg16-/- colon in the azoxymethane(AOM)/DSS-induced model of CAC, indicating that MTG16 protects from tumorigenesis through additional mechanisms. Azoxymethane 124-136 CBFA2/RUNX1 partner transcriptional co-repressor 3 Homo sapiens 102-107 35503250-8 2022 Finally, uncoupling MTG16:E protein interactions partially phenocopied the enhanced tumorigenicity of Mtg16-/- colon in the azoxymethane(AOM)/DSS-induced model of CAC, indicating that MTG16 protects from tumorigenesis through additional mechanisms. Azoxymethane 137-140 CBFA2/RUNX1 partner transcriptional co-repressor 3 Homo sapiens 20-25 35503250-8 2022 Finally, uncoupling MTG16:E protein interactions partially phenocopied the enhanced tumorigenicity of Mtg16-/- colon in the azoxymethane(AOM)/DSS-induced model of CAC, indicating that MTG16 protects from tumorigenesis through additional mechanisms. Azoxymethane 137-140 CBFA2/RUNX1 partner transcriptional co-repressor 3 Homo sapiens 102-107 35563010-2 2022 Methods: CA-CRC was induced in P2X7R+/+ and P2X7R-/- mice with azoxymethane (AOM) combined with dextran sodium sulfate (DSS). Azoxymethane 63-75 cation channel, sperm associated 3 Mus musculus 9-15 35563010-2 2022 Methods: CA-CRC was induced in P2X7R+/+ and P2X7R-/- mice with azoxymethane (AOM) combined with dextran sodium sulfate (DSS). Azoxymethane 63-75 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 31-36 35563010-2 2022 Methods: CA-CRC was induced in P2X7R+/+ and P2X7R-/- mice with azoxymethane (AOM) combined with dextran sodium sulfate (DSS). Azoxymethane 77-80 cation channel, sperm associated 3 Mus musculus 9-15 35563010-2 2022 Methods: CA-CRC was induced in P2X7R+/+ and P2X7R-/- mice with azoxymethane (AOM) combined with dextran sodium sulfate (DSS). Azoxymethane 77-80 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 31-36 35399505-6 2022 Further, we demonstrated that Vim-/- mice did not develop colitis-associated cancer model upon DSS treatment spontaneously but increased tumor numbers and size in the distal colon in the azoxymethane/DSS model comparing with WT mice. Azoxymethane 187-199 vimentin Mus musculus 30-33 35365782-5 2022 In Villin-ACKR3 transgenic mice with a high expression level of CKR3 in their intestinal epithelial cells, administration of AOM/DSS induced more severe colorectal tumorigenesis than their WT littermates. Azoxymethane 125-128 atypical chemokine receptor 3 Mus musculus 10-15 35365782-5 2022 In Villin-ACKR3 transgenic mice with a high expression level of CKR3 in their intestinal epithelial cells, administration of AOM/DSS induced more severe colorectal tumorigenesis than their WT littermates. Azoxymethane 125-128 chemokine (C-C motif) receptor 3 Mus musculus 64-68 35101901-3 2022 Consistent with these findings, TIPE2 deficiency significantly inhibited the development of CRC in mice treated with azoxymethane/dextran sodium sulfate and in Apcmin/+ mice. Azoxymethane 117-129 tumor necrosis factor, alpha-induced protein 8-like 2 Mus musculus 32-37 35359953-4 2022 Genetic deletion of IL25 inhibited tumor formation and growth and prolonged survival in AOM/DSS-treated mice. Azoxymethane 88-91 interleukin 25 Mus musculus 20-24 35232776-9 2022 In azoxymethane-induced CRC model, Sqle tg mice showed increased tumourigenesis compared with wild-type mice (p<0.01). Azoxymethane 3-15 squalene epoxidase Mus musculus 35-39 35163788-0 2022 T-Cell-Specific CerS4 Depletion Prolonged Inflammation and Enhanced Tumor Burden in the AOM/DSS-Induced CAC Model. Azoxymethane 88-91 ceramide synthase 4 Mus musculus 16-21 35205671-5 2022 Here, we found that IRF9 had an oncogenic effect in CRC; loss of IRF9 reduced tumorigenesis in both azoxymethane (AOM)/dextran sodium sulfate (DSS)-induced and spontaneous CRC models. Azoxymethane 100-112 interferon regulatory factor 9 Homo sapiens 20-24 35205671-5 2022 Here, we found that IRF9 had an oncogenic effect in CRC; loss of IRF9 reduced tumorigenesis in both azoxymethane (AOM)/dextran sodium sulfate (DSS)-induced and spontaneous CRC models. Azoxymethane 100-112 interferon regulatory factor 9 Homo sapiens 65-69 35205671-5 2022 Here, we found that IRF9 had an oncogenic effect in CRC; loss of IRF9 reduced tumorigenesis in both azoxymethane (AOM)/dextran sodium sulfate (DSS)-induced and spontaneous CRC models. Azoxymethane 114-117 interferon regulatory factor 9 Homo sapiens 20-24 35205671-5 2022 Here, we found that IRF9 had an oncogenic effect in CRC; loss of IRF9 reduced tumorigenesis in both azoxymethane (AOM)/dextran sodium sulfate (DSS)-induced and spontaneous CRC models. Azoxymethane 114-117 interferon regulatory factor 9 Homo sapiens 65-69 35163788-10 2022 The higher tumor incidence in CerS4 LCK/Cre mice and the toxic effect of AOM/DSS in CerS4 KO mice exhibited the importance of CerS4 in other tissues and revealed the complexity of general targeting CerS4. Azoxymethane 73-76 ceramide synthase 4 Mus musculus 84-89 35163788-10 2022 The higher tumor incidence in CerS4 LCK/Cre mice and the toxic effect of AOM/DSS in CerS4 KO mice exhibited the importance of CerS4 in other tissues and revealed the complexity of general targeting CerS4. Azoxymethane 73-76 ceramide synthase 4 Mus musculus 126-131 35163788-10 2022 The higher tumor incidence in CerS4 LCK/Cre mice and the toxic effect of AOM/DSS in CerS4 KO mice exhibited the importance of CerS4 in other tissues and revealed the complexity of general targeting CerS4. Azoxymethane 73-76 ceramide synthase 4 Mus musculus 198-203 35148799-10 2022 RESULTS: In preclinical settings, loss of EMILIN-2 associated with an increased number of tumor lesions upon AOM/DSS treatment. Azoxymethane 109-112 elastin microfibril interfacer 2 Homo sapiens 42-50 35163788-3 2022 CerS4 KO mice were highly sensitive to the toxic effect of AOM/DSS, leading to a high mortality rate. Azoxymethane 59-62 ceramide synthase 4 Mus musculus 0-5 35014688-7 2022 The obese Wistar rats exposed to azoxymethane to induce colon cancer exhibited a more severe colon tumor outcome, which was associated with significantly increased MACC1 levels compared with their non-obese littermates. Azoxymethane 33-45 MET transcriptional regulator MACC1 Rattus norvegicus 164-169 3621182-0 1987 Enhancement by vasoactive intestinal peptide of experimental carcinogenesis induced by azoxymethane in rat colon. Azoxymethane 87-99 vasoactive intestinal peptide Rattus norvegicus 15-44 2790802-0 1989 Attenuation of azoxymethane-induced colonic mucosal ornithine decarboxylase and tyrosine kinase activity by calcium in rats. Azoxymethane 15-27 ornithine decarboxylase 1 Rattus norvegicus 52-75 2493096-1 1989 During azoxymethane (AOM)-induced colonic carcinogenesis in rats, biphasic induction of ornithine decarboxylase (ODC) activity occurs in the colonic mucosa. Azoxymethane 7-19 ornithine decarboxylase 1 Rattus norvegicus 88-111 2493096-1 1989 During azoxymethane (AOM)-induced colonic carcinogenesis in rats, biphasic induction of ornithine decarboxylase (ODC) activity occurs in the colonic mucosa. Azoxymethane 7-19 ornithine decarboxylase 1 Rattus norvegicus 113-116 2493096-1 1989 During azoxymethane (AOM)-induced colonic carcinogenesis in rats, biphasic induction of ornithine decarboxylase (ODC) activity occurs in the colonic mucosa. Azoxymethane 21-24 ornithine decarboxylase 1 Rattus norvegicus 88-111 2493096-1 1989 During azoxymethane (AOM)-induced colonic carcinogenesis in rats, biphasic induction of ornithine decarboxylase (ODC) activity occurs in the colonic mucosa. Azoxymethane 21-24 ornithine decarboxylase 1 Rattus norvegicus 113-116 2752519-1 1989 In previous studies, we have shown that inositol hexaphosphate (InsP6), a constituent of cereal diet, inhibited azoxymethane-induced experimental large intestinal cancer (LIC) in Fischer 344 rats. Azoxymethane 112-124 inositol hexaphosphate kinase 1 Mus musculus 64-69 2501972-0 1989 Early alterations of rat intestinal diamine oxidase activity by azoxymethane, an intestinal carcinogen. Azoxymethane 64-76 amine oxidase, copper containing 1 Rattus norvegicus 36-51 2501972-3 1989 In vitro, azoxymethane was a very weak inhibitor of rat intestinal diamine oxidase activity. Azoxymethane 10-22 amine oxidase, copper containing 1 Rattus norvegicus 67-82 2501972-4 1989 In vivo, after subcutaneous injection of a single dose of azoxymethane, diamine oxidase activity was increased in the duodenum but was mainly inhibited in the colon. Azoxymethane 58-70 amine oxidase, copper containing 1 Rattus norvegicus 72-87 2501972-5 1989 Intestinal diamine oxidase activity may then be influenced by regulatory processes induced by azoxymethane rather than by a direct effect. Azoxymethane 94-106 amine oxidase, copper containing 1 Rattus norvegicus 11-26 3621182-1 1987 The effects of vasoactive intestinal peptide (VIP) on the incidence and histology of colonic tumors induced by azoxymethane (AOM) were investigated in Wistar rats. Azoxymethane 111-123 vasoactive intestinal peptide Rattus norvegicus 46-49 3731101-0 1986 Kinetic changes in mucosal ornithine decarboxylase activity during azoxymethane-induced colonic carcinogenesis in the rat. Azoxymethane 67-79 ornithine decarboxylase 1 Rattus norvegicus 27-50 2881630-0 1987 Effect of a long-acting analogue of somatostatin, SMS 201-995, on the development of intestinal tumours in azoxymethane-treated rats. Azoxymethane 107-119 somatostatin Rattus norvegicus 36-48 3568008-1 1987 Because the role of proteolytic enzymes in carcinogenesis is not yet well understood, we studied two arylamidases cleaving Boc-(Ala)2-p-nitroanilide and Bz-Lys-p-nitroanilide in the sera of rats during azoxymethane (AOM)-induced development of bowel carcinomas. Azoxymethane 202-214 BOC cell adhesion associated, oncogene regulated Rattus norvegicus 123-126 3568008-1 1987 Because the role of proteolytic enzymes in carcinogenesis is not yet well understood, we studied two arylamidases cleaving Boc-(Ala)2-p-nitroanilide and Bz-Lys-p-nitroanilide in the sera of rats during azoxymethane (AOM)-induced development of bowel carcinomas. Azoxymethane 216-219 BOC cell adhesion associated, oncogene regulated Rattus norvegicus 123-126 33564842-3 2021 When treated with azoxymethane and dextran sodium sulphate (AOM/DSS) as a model of IBD, Gsto1 -/- mice were highly sensitive to colitis and showed a significant increase in the size and number of colon tumours compared with wildtype mice (WT). Azoxymethane 18-30 glutathione S-transferase omega 1 Mus musculus 88-93 3862909-0 1985 Effect of different levels of dietary trans fat or corn oil on azoxymethane-induced colon carcinogenesis in F344 rats. Azoxymethane 63-75 FAT atypical cadherin 1 Rattus norvegicus 44-47 3862909-1 1985 The effect of various levels of dietary corn oil or trans fat on azoxymethane (AOM; CAS: 25843-45-2)-induced carcinogenesis was investigated in female F344 rats fed the AIN-76 semipurified diets. Azoxymethane 65-77 FAT atypical cadherin 1 Rattus norvegicus 58-61 34006646-5 2021 Mice lacking Gal-1 (Lgals1 -/- ) developed a lower number of tumors and showed a decreased frequency of a particular population of CD8+CD122+PD-1+ Tregs in the azoxymethane-dextran sodium sulfate model of colitis-associated CRC. Azoxymethane 160-172 lectin, galactose binding, soluble 1 Mus musculus 20-26 34006646-5 2021 Mice lacking Gal-1 (Lgals1 -/- ) developed a lower number of tumors and showed a decreased frequency of a particular population of CD8+CD122+PD-1+ Tregs in the azoxymethane-dextran sodium sulfate model of colitis-associated CRC. Azoxymethane 160-172 CD8a molecule Homo sapiens 131-134 33901495-9 2021 Although MondoA-deficient Tregs were less immune suppressive and selectively promoted Th1 responses in a subcutaneous MC38 tumor model, Treg-specific MondoA knockout mice were more susceptible to AOM-DSS-induced colorectal cancer. Azoxymethane 196-199 MLX interacting protein Homo sapiens 150-156 33861936-1 2021 The anticancer effects of Shinan (Shinan-South Korea) sea salts on azoxymethane (AOM)/dextran sodium sulfate (DSS) with high fat diet (HFD)-induced colon cancer and obesity in C57BL/6N mice were studied. Azoxymethane 67-79 sepia Mus musculus 54-57 33842405-0 2021 Nuclear Factor Erythroid 2-related Factor 2 Knockout Suppresses the Development of Aggressive Colorectal Cancer Formation Induced by Azoxymethane/Dextran Sulfate Sodium-Treatment in Female Mice. Azoxymethane 133-145 nuclear factor, erythroid derived 2, like 2 Mus musculus 0-43 32860065-3 2021 METHODS: We analyzed TRIM21 expression in tumor tissues from patients with colorectal cancer (CRC) and ulcerative colitis (UC)-associated cancer by immunohistochemistry and real-time polymerase chain reaction and established a CAC model in TRIM21-/- and wild type mice by azoxymethane (AOM) and dextran sodium sulfate (DSS). Azoxymethane 272-284 tripartite motif containing 21 Homo sapiens 21-27 7053860-0 1982 Effect of beta-glucuronidase inhibitor on azoxymethane-induced colonic carcinogenesis in rats. Azoxymethane 42-54 glucuronidase, beta Rattus norvegicus 10-28 621376-0 1978 The cytochemical demonstration of beta-glucuronidase in colon neoplasms of rats exposed to azoxymethane. Azoxymethane 91-103 glucuronidase, beta Rattus norvegicus 34-52 33564842-3 2021 When treated with azoxymethane and dextran sodium sulphate (AOM/DSS) as a model of IBD, Gsto1 -/- mice were highly sensitive to colitis and showed a significant increase in the size and number of colon tumours compared with wildtype mice (WT). Azoxymethane 60-63 glutathione S-transferase omega 1 Mus musculus 88-93 33564842-4 2021 Gsto1 -/- mice treated with AOM/DSS had significantly lower serum IL-1beta and IL-18 levels as well as significantly decreased IFN-gamma, decreased pSTAT1 and increased pSTAT3 levels in the distal colon compared to similarly treated WT mice. Azoxymethane 29-32 glutathione S-transferase omega 1 Mus musculus 0-5 33564842-4 2021 Gsto1 -/- mice treated with AOM/DSS had significantly lower serum IL-1beta and IL-18 levels as well as significantly decreased IFN-gamma, decreased pSTAT1 and increased pSTAT3 levels in the distal colon compared to similarly treated WT mice. Azoxymethane 29-32 interleukin 1 alpha Mus musculus 67-75 33564842-4 2021 Gsto1 -/- mice treated with AOM/DSS had significantly lower serum IL-1beta and IL-18 levels as well as significantly decreased IFN-gamma, decreased pSTAT1 and increased pSTAT3 levels in the distal colon compared to similarly treated WT mice. Azoxymethane 29-32 interleukin 18 Mus musculus 80-85 33564842-4 2021 Gsto1 -/- mice treated with AOM/DSS had significantly lower serum IL-1beta and IL-18 levels as well as significantly decreased IFN-gamma, decreased pSTAT1 and increased pSTAT3 levels in the distal colon compared to similarly treated WT mice. Azoxymethane 29-32 interferon gamma Mus musculus 128-137 33564842-5 2021 Histologically, AOM/DSS treated Gsto1 -/- mice showed increased active chronic inflammation with macrophage infiltration, epithelial dysplasia and invasive adenocarcinoma compared with AOM/DSS treated WT mice. Azoxymethane 16-19 glutathione S-transferase omega 1 Mus musculus 32-37 33535045-5 2021 Myofibroblast MyD88-deficient mice are resistant to azoxymethane (AOM)/dextran sodium sulfate (DSS)-induced tumorigenesis, as evidenced by the decrease in the number and sizes of tumors. Azoxymethane 52-64 myeloid differentiation primary response gene 88 Mus musculus 14-19 33535045-5 2021 Myofibroblast MyD88-deficient mice are resistant to azoxymethane (AOM)/dextran sodium sulfate (DSS)-induced tumorigenesis, as evidenced by the decrease in the number and sizes of tumors. Azoxymethane 66-69 myeloid differentiation primary response gene 88 Mus musculus 14-19 33367479-6 2021 Lastly, the suppression of ARRB2 expression was enough to attenuate the progression of CRC induced by azoxymethane/dextran sodium sulfate. Azoxymethane 102-114 arrestin beta 2 Homo sapiens 27-32 33537297-6 2020 First, AOM treatment significantly up-regulated the expression of BDNF, tropomycin receptor kinase B (TrkB), and phosphorylated AKT (p-AKT) in the hippocampus, enhanced adult hippocampal neurogenesis, and improved the spatial learning/memory and cognitive functions in the post-MCAO ischemic rats in vivo. Azoxymethane 7-10 brain-derived neurotrophic factor Rattus norvegicus 66-70 33537297-6 2020 First, AOM treatment significantly up-regulated the expression of BDNF, tropomycin receptor kinase B (TrkB), and phosphorylated AKT (p-AKT) in the hippocampus, enhanced adult hippocampal neurogenesis, and improved the spatial learning/memory and cognitive functions in the post-MCAO ischemic rats in vivo. Azoxymethane 7-10 neurotrophic receptor tyrosine kinase 2 Rattus norvegicus 72-100 33537297-6 2020 First, AOM treatment significantly up-regulated the expression of BDNF, tropomycin receptor kinase B (TrkB), and phosphorylated AKT (p-AKT) in the hippocampus, enhanced adult hippocampal neurogenesis, and improved the spatial learning/memory and cognitive functions in the post-MCAO ischemic rats in vivo. Azoxymethane 7-10 neurotrophic receptor tyrosine kinase 2 Rattus norvegicus 102-106 33537297-6 2020 First, AOM treatment significantly up-regulated the expression of BDNF, tropomycin receptor kinase B (TrkB), and phosphorylated AKT (p-AKT) in the hippocampus, enhanced adult hippocampal neurogenesis, and improved the spatial learning/memory and cognitive functions in the post-MCAO ischemic rats in vivo. Azoxymethane 7-10 AKT serine/threonine kinase 1 Rattus norvegicus 128-131 33537297-6 2020 First, AOM treatment significantly up-regulated the expression of BDNF, tropomycin receptor kinase B (TrkB), and phosphorylated AKT (p-AKT) in the hippocampus, enhanced adult hippocampal neurogenesis, and improved the spatial learning/memory and cognitive functions in the post-MCAO ischemic rats in vivo. Azoxymethane 7-10 AKT serine/threonine kinase 1 Rattus norvegicus 135-138 32468854-5 2021 C57BL6 wild-type (WT) mice and a strain defective in the DNA repair enzyme O6-methylguanine-DNA methyltransferase (MGMT) were used, in which tumors were induced by azoxymethane (AOM) followed by dextran sodium sulfate (DSS). Azoxymethane 164-176 O-6-methylguanine-DNA methyltransferase Mus musculus 115-119 33314701-5 2021 OMA1 knockout suppresses colorectal cancer development in AOM/DSS and xenograft mice models of colorectal cancer. Azoxymethane 58-61 OMA1 zinc metallopeptidase Mus musculus 0-4 33643790-7 2021 Furthermore, inhibition of CXCL12 from senescent tumor cells enhances T cell infiltration and results in reducing the number and size of tumors in azoxymethane (AOM)/dextran sulfate sodium (DSS)-induced CRC. Azoxymethane 147-159 C-X-C motif chemokine ligand 12 Homo sapiens 27-33 33643790-7 2021 Furthermore, inhibition of CXCL12 from senescent tumor cells enhances T cell infiltration and results in reducing the number and size of tumors in azoxymethane (AOM)/dextran sulfate sodium (DSS)-induced CRC. Azoxymethane 161-164 C-X-C motif chemokine ligand 12 Homo sapiens 27-33 32805281-5 2020 CCAT2 transgene and control mice were given azoxymethane and dextran sulphate sodium (DSS) to induce colon tumors. Azoxymethane 44-56 colon cancer associated transcript 2 Homo sapiens 0-5 31617778-7 2021 Immunohistochemically, CEA, COX-2, and Ki-67 immune-expressions decreased, and the immune-expression of caspase-3 increased in AOM + JB treated rats. Azoxymethane 127-130 carcinoembryonic antigen gene family 4 Rattus norvegicus 23-26 31617778-7 2021 Immunohistochemically, CEA, COX-2, and Ki-67 immune-expressions decreased, and the immune-expression of caspase-3 increased in AOM + JB treated rats. Azoxymethane 127-130 cytochrome c oxidase II, mitochondrial Rattus norvegicus 28-33 31617778-7 2021 Immunohistochemically, CEA, COX-2, and Ki-67 immune-expressions decreased, and the immune-expression of caspase-3 increased in AOM + JB treated rats. Azoxymethane 127-130 caspase 3 Rattus norvegicus 104-113 33068552-0 2020 17beta-Estradiol strongly inhibits azoxymethane/dextran sulfate sodium-induced colorectal cancer development in Nrf2 knockout male mice. Azoxymethane 35-47 nuclear factor, erythroid derived 2, like 2 Mus musculus 112-116 33110234-9 2021 We further demonstrated that Gal2-KO mice developed significantly larger tumors than WT mice using Azoxymethane (AOM)/dextran sodium sulfate (DSS)-induced colorectal cancer model. Azoxymethane 99-111 lectin, galactose-binding, soluble 2 Mus musculus 29-33 33110234-9 2021 We further demonstrated that Gal2-KO mice developed significantly larger tumors than WT mice using Azoxymethane (AOM)/dextran sodium sulfate (DSS)-induced colorectal cancer model. Azoxymethane 113-116 lectin, galactose-binding, soluble 2 Mus musculus 29-33 32749453-3 2020 Here, we demonstrate that constitutive AKT activation in intestinal epithelial cells markedly enhances tumor invasion and metastasis in Trp53DeltaIEC mice (Trp53DeltaIECAktE17K) upon challenge with the carcinogen azoxymethane. Azoxymethane 213-225 thymoma viral proto-oncogene 1 Mus musculus 39-42 32810576-7 2020 Moreover, TLR3-/-TLR7-/- mice developed colitis-associated colon cancer following AOM/DSS treatment. Azoxymethane 82-85 toll-like receptor 3 Mus musculus 10-14 32810576-7 2020 Moreover, TLR3-/-TLR7-/- mice developed colitis-associated colon cancer following AOM/DSS treatment. Azoxymethane 82-85 toll-like receptor 7 Mus musculus 17-21 32581195-8 2020 AOM/DSS-treated Pierce1 TG mice were comparable with respect to colon lengths, the number of polyps, and tumor sizes to those of the control mice. Azoxymethane 0-3 piercer of microtubule wall 1 Mus musculus 16-23 32882406-8 2020 In addition, our results showed that RNF186-/- mice exhibited significantly increased tumour burden compared to the wild type (WT) mice following treatment with azoxymethane/dextran sulfate sodium (AOM/DSS). Azoxymethane 161-173 ring finger protein 186 Mus musculus 37-43 32882406-8 2020 In addition, our results showed that RNF186-/- mice exhibited significantly increased tumour burden compared to the wild type (WT) mice following treatment with azoxymethane/dextran sulfate sodium (AOM/DSS). Azoxymethane 198-201 ring finger protein 186 Mus musculus 37-43 32758571-7 2020 Therefore, the inhibition of AOM/DSS-induced colon carcinogenesis and colon tumor growth by 2,3-, 3,4-, and 4,4"-dihydroxystilbenes appears to be due to the suppression of M2 TAM differentiation and activation and PD-1 expression (immunosuppression) via reductions in COX-2 expression levels in the colon tumor microenvironment. Azoxymethane 29-32 programmed cell death 1 Mus musculus 214-218 32758571-7 2020 Therefore, the inhibition of AOM/DSS-induced colon carcinogenesis and colon tumor growth by 2,3-, 3,4-, and 4,4"-dihydroxystilbenes appears to be due to the suppression of M2 TAM differentiation and activation and PD-1 expression (immunosuppression) via reductions in COX-2 expression levels in the colon tumor microenvironment. Azoxymethane 29-32 cytochrome c oxidase II, mitochondrial Mus musculus 268-273 32591441-8 2020 In further experiments, we found that the levels of IL-10 were elevated in the serum of Azoxymethane (AOM)/Dextran Sodium Sulfate (DSS)-treated AURKAflox/+;VillinCre+ mice. Azoxymethane 88-100 interleukin 10 Mus musculus 52-57 32653643-0 2020 Blocking NFATc3 ameliorates azoxymethane/dextran sulfate sodium induced colitis-associated colorectal cancer in mice via the inhibition of inflammatory responses and epithelial-mesenchymal transition. Azoxymethane 28-40 nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 3 Mus musculus 9-15 32591441-8 2020 In further experiments, we found that the levels of IL-10 were elevated in the serum of Azoxymethane (AOM)/Dextran Sodium Sulfate (DSS)-treated AURKAflox/+;VillinCre+ mice. Azoxymethane 102-105 interleukin 10 Mus musculus 52-57 32526927-4 2020 Resveratrol treatment in the azoxymethane (AOM) and dextran sodium sulphate (DSS) CRC murine model caused an increase in anti-inflammatory CD4 + FOXP3 + (Tregs) and CD4 + IL10 + cells, a decrease in proinflammatory Th1 and Th17 cells, and attenuated CRC development. Azoxymethane 43-46 CD4 antigen Mus musculus 139-142 32640217-3 2020 In a dextran sodium sulfate and azoxymethane (DSS/AOM) mouse model, deficiency and pharmacological inhibition of extracellular GzmA both attenuate gut inflammation and prevent CRC development, including the initial steps of cell transformation and epithelial-to-mesenchymal transition. Azoxymethane 32-44 granzyme A Mus musculus 127-131 32640217-3 2020 In a dextran sodium sulfate and azoxymethane (DSS/AOM) mouse model, deficiency and pharmacological inhibition of extracellular GzmA both attenuate gut inflammation and prevent CRC development, including the initial steps of cell transformation and epithelial-to-mesenchymal transition. Azoxymethane 50-53 granzyme A Mus musculus 127-131 32640217-5 2020 Accordingly, colon tissues from DSS/AOM-treated, GzmA-deficient animals present reduced levels of pSTAT3. Azoxymethane 36-39 granzyme A Mus musculus 49-53 32851100-7 2020 IHC staining in both human sample and AOM/DSS induced mouse CRC model revealed significant downregulation of MPC1. Azoxymethane 38-41 mitochondrial pyruvate carrier 1 Mus musculus 109-113 32630271-11 2020 In summary, we show that CerS5-ko mice were more susceptible to dextran sodium sulfate-induced colitis and azoxymethane/dextran sodium sulfate-induced colitis-associated colon cancer. Azoxymethane 107-119 ceramide synthase 5 Mus musculus 25-30 32554929-5 2020 IRF1 functions in both the myeloid and epithelial compartments to confer protection against AOM/DSS-induced colorectal tumorigenesis. Azoxymethane 92-95 interferon regulatory factor 1 Mus musculus 0-4 32526927-4 2020 Resveratrol treatment in the azoxymethane (AOM) and dextran sodium sulphate (DSS) CRC murine model caused an increase in anti-inflammatory CD4 + FOXP3 + (Tregs) and CD4 + IL10 + cells, a decrease in proinflammatory Th1 and Th17 cells, and attenuated CRC development. Azoxymethane 43-46 forkhead box P3 Mus musculus 145-150 32526927-4 2020 Resveratrol treatment in the azoxymethane (AOM) and dextran sodium sulphate (DSS) CRC murine model caused an increase in anti-inflammatory CD4 + FOXP3 + (Tregs) and CD4 + IL10 + cells, a decrease in proinflammatory Th1 and Th17 cells, and attenuated CRC development. Azoxymethane 43-46 CD4 antigen Mus musculus 165-168 32526927-4 2020 Resveratrol treatment in the azoxymethane (AOM) and dextran sodium sulphate (DSS) CRC murine model caused an increase in anti-inflammatory CD4 + FOXP3 + (Tregs) and CD4 + IL10 + cells, a decrease in proinflammatory Th1 and Th17 cells, and attenuated CRC development. Azoxymethane 43-46 interleukin 10 Mus musculus 171-175 32210144-0 2020 Alpha-Glucosidase Inhibitor Voglibose Suppresses Azoxymethane-Induced Colonic Preneoplastic Lesions in Diabetic and Obese Mice. Azoxymethane 49-61 sucrase isomaltase (alpha-glucosidase) Mus musculus 0-17 32294981-6 2020 In an azoxymethane/dextran sulfate sodium-induced, colitis-associated, CRC model, EPHB3 expression increased along with tumor development. Azoxymethane 6-18 EPH receptor B3 Homo sapiens 82-87 32276475-4 2020 Here, we analyzed whether H4R is involved in the pathogenesis of AOM/DSS-induced CRC in mice. Azoxymethane 65-68 histamine receptor H4 Mus musculus 26-29 31891805-6 2020 Data shown in this report indicates that in leptin knockdown obese mice, AOM/DSS induced polyps are smaller and lesser in numbers as compared to AOM/DSS induced polyps in diet induced obese mice. Azoxymethane 73-76 leptin Mus musculus 44-50 32266177-5 2020 The expression of COX-2 and inducible nitric oxide synthase (iNOS) was upregulated in the colon tissues of mice treated with AOM and DSS, and this was inhibited by celecoxib administration. Azoxymethane 125-128 cytochrome c oxidase II, mitochondrial Mus musculus 18-23 32266177-5 2020 The expression of COX-2 and inducible nitric oxide synthase (iNOS) was upregulated in the colon tissues of mice treated with AOM and DSS, and this was inhibited by celecoxib administration. Azoxymethane 125-128 nitric oxide synthase 2, inducible Mus musculus 28-59 32266177-5 2020 The expression of COX-2 and inducible nitric oxide synthase (iNOS) was upregulated in the colon tissues of mice treated with AOM and DSS, and this was inhibited by celecoxib administration. Azoxymethane 125-128 nitric oxide synthase 2, inducible Mus musculus 61-65 32131398-4 2020 Treatment of azoxymethane/dextran sulfate sodium (AOM/DSS) into Nudt7 knockout (Nudt7-/-) mice significantly induced lipid accumulation and the expression levels of CRC-related genes whereas xenografting of Nudt7-overexpressed LS-174T cells into mice significantly reduced lipid accumulation and the expression levels of CRC-related genes. Azoxymethane 50-53 nudix (nucleoside diphosphate linked moiety X)-type motif 7 Mus musculus 64-69 32131398-4 2020 Treatment of azoxymethane/dextran sulfate sodium (AOM/DSS) into Nudt7 knockout (Nudt7-/-) mice significantly induced lipid accumulation and the expression levels of CRC-related genes whereas xenografting of Nudt7-overexpressed LS-174T cells into mice significantly reduced lipid accumulation and the expression levels of CRC-related genes. Azoxymethane 50-53 nudix (nucleoside diphosphate linked moiety X)-type motif 7 Mus musculus 80-85 32131398-4 2020 Treatment of azoxymethane/dextran sulfate sodium (AOM/DSS) into Nudt7 knockout (Nudt7-/-) mice significantly induced lipid accumulation and the expression levels of CRC-related genes whereas xenografting of Nudt7-overexpressed LS-174T cells into mice significantly reduced lipid accumulation and the expression levels of CRC-related genes. Azoxymethane 13-25 nudix (nucleoside diphosphate linked moiety X)-type motif 7 Mus musculus 64-69 32131398-4 2020 Treatment of azoxymethane/dextran sulfate sodium (AOM/DSS) into Nudt7 knockout (Nudt7-/-) mice significantly induced lipid accumulation and the expression levels of CRC-related genes whereas xenografting of Nudt7-overexpressed LS-174T cells into mice significantly reduced lipid accumulation and the expression levels of CRC-related genes. Azoxymethane 13-25 nudix (nucleoside diphosphate linked moiety X)-type motif 7 Mus musculus 80-85 32131398-4 2020 Treatment of azoxymethane/dextran sulfate sodium (AOM/DSS) into Nudt7 knockout (Nudt7-/-) mice significantly induced lipid accumulation and the expression levels of CRC-related genes whereas xenografting of Nudt7-overexpressed LS-174T cells into mice significantly reduced lipid accumulation and the expression levels of CRC-related genes. Azoxymethane 50-53 nudix (nucleoside diphosphate linked moiety X)-type motif 7 Mus musculus 80-85 32131398-4 2020 Treatment of azoxymethane/dextran sulfate sodium (AOM/DSS) into Nudt7 knockout (Nudt7-/-) mice significantly induced lipid accumulation and the expression levels of CRC-related genes whereas xenografting of Nudt7-overexpressed LS-174T cells into mice significantly reduced lipid accumulation and the expression levels of CRC-related genes. Azoxymethane 13-25 nudix (nucleoside diphosphate linked moiety X)-type motif 7 Mus musculus 80-85 32075312-9 2020 The cancer specificity and burden correlation of plasma KARS1 level were validated using azoxymethane (AOM)/dextran sodium sulfate (DSS) model, and paired pre- and post-surgery CRC patient plasma. Azoxymethane 89-101 lysyl-tRNA synthetase 1 Homo sapiens 56-61 31988379-4 2020 Reconstitution of ApcMin/+ or azoxymethane- and dextran sulfate sodium-treated mice with an isolate of F. rodentium (F. PB1) or its metabolic products reduced tumour growth. Azoxymethane 30-42 submaxillary gland androgen regulated protein 3A Homo sapiens 120-123 32041873-7 2020 Finally, when the gut is acutely stressed by azoxymethane/dextran sulfate (AOM/DSS) exposure, both Xist-deleted and wild-type mice develop gastrointestinal tumors. Azoxymethane 45-57 inactive X specific transcripts Mus musculus 99-103 32075312-9 2020 The cancer specificity and burden correlation of plasma KARS1 level were validated using azoxymethane (AOM)/dextran sodium sulfate (DSS) model, and paired pre- and post-surgery CRC patient plasma. Azoxymethane 103-106 lysyl-tRNA synthetase 1 Homo sapiens 56-61 32075312-10 2020 In the AOM/DSS model, the plasma level of KARS1 showed high correlation with number of polyps, but not for inflammation. Azoxymethane 7-10 lysyl-tRNA synthetase 1 Homo sapiens 42-47 32024285-0 2020 High-Fat Diet Propelled AOM/DSS-Induced Colitis-Associated Colon Cancer Alleviated by Administration of Aster glehni via STAT3 Signaling Pathway. Azoxymethane 24-27 signal transducer and activator of transcription 3 Mus musculus 121-126 32050698-0 2020 Chemopreventive Effect of the Germinated Oat and its Phenolic-AVA Extract in Azoxymethane/Dextran Sulfate Sodium (AOM/DSS) Model of Colon Carcinogenesis in Mice. Azoxymethane 114-117 ornithine aminotransferase Mus musculus 41-44 32050698-4 2020 Therefore, our objective was to evaluate the chemopreventive effect of the sprouted oat (SO) and its phenolic-AVA extract (AVA) in azoxymethane (AOM)/dextran sulfate sodium (DSS)-induced CRC mouse model. Azoxymethane 131-143 ornithine aminotransferase Mus musculus 84-87 32050698-4 2020 Therefore, our objective was to evaluate the chemopreventive effect of the sprouted oat (SO) and its phenolic-AVA extract (AVA) in azoxymethane (AOM)/dextran sulfate sodium (DSS)-induced CRC mouse model. Azoxymethane 145-148 ornithine aminotransferase Mus musculus 84-87 31734229-7 2020 AOM-treated mice had increased TSP-1 and TGFbeta1 mRNA and protein expression in the liver. Azoxymethane 0-3 thrombospondin 1 Mus musculus 31-36 31734229-7 2020 AOM-treated mice had increased TSP-1 and TGFbeta1 mRNA and protein expression in the liver. Azoxymethane 0-3 transforming growth factor, beta 1 Mus musculus 41-49 31734229-8 2020 TSP-1-/- mice administered AOM had reduced liver injury as assessed by histology and serum transaminase levels compared with C57Bl/6 AOM-treated mice. Azoxymethane 27-30 thrombospondin 1 Mus musculus 0-5 31734229-10 2020 TSP-1-/- AOM-treated mice had a reduced rate of neurologic decline, less cerebral edema, and a decrease in microglia activation in comparison with C57Bl/6 mice treated with AOM. Azoxymethane 9-12 thrombospondin 1 Mus musculus 0-5 31734229-11 2020 Taken together, TSP-1 is an activator of TGFbeta1 signaling during AOM-induced acute liver failure and contributes to both liver pathology and HE progression. Azoxymethane 67-70 thrombospondin 1 Mus musculus 16-21 31734229-11 2020 Taken together, TSP-1 is an activator of TGFbeta1 signaling during AOM-induced acute liver failure and contributes to both liver pathology and HE progression. Azoxymethane 67-70 transforming growth factor, beta 1 Mus musculus 41-49 31714664-7 2020 Further, the mRNA expressions of iNOS and COX-2 were also downregulated in XHA treated rats compared to AOM-induced rats. Azoxymethane 104-107 nitric oxide synthase 2 Rattus norvegicus 33-37 31662330-9 2020 Map9 deletion accelerated colorectal cancer formation both in ApcMin /+ mice and azoxymethane-treated mice, and reduced survival in ApcMin /+ mice. Azoxymethane 81-93 microtubule-associated protein 9 Mus musculus 0-4 31714664-7 2020 Further, the mRNA expressions of iNOS and COX-2 were also downregulated in XHA treated rats compared to AOM-induced rats. Azoxymethane 104-107 cytochrome c oxidase II, mitochondrial Rattus norvegicus 42-47 31874252-9 2020 Treatment with AOM/DSS significantly increased prostaglandin (PG)E2 and 8-iso-PGF2alpha levels along with cyclooxygenase-2 (COX-2), tumor necrosis factor (TNF)-alpha, nuclear factor kappa B (NFkB) and inducible nitric oxide synthase (iNOS) gene expression, in colon specimens. Azoxymethane 15-18 prostaglandin-endoperoxide synthase 2 Mus musculus 106-122 31874252-9 2020 Treatment with AOM/DSS significantly increased prostaglandin (PG)E2 and 8-iso-PGF2alpha levels along with cyclooxygenase-2 (COX-2), tumor necrosis factor (TNF)-alpha, nuclear factor kappa B (NFkB) and inducible nitric oxide synthase (iNOS) gene expression, in colon specimens. Azoxymethane 15-18 prostaglandin-endoperoxide synthase 2 Mus musculus 124-129 31874252-9 2020 Treatment with AOM/DSS significantly increased prostaglandin (PG)E2 and 8-iso-PGF2alpha levels along with cyclooxygenase-2 (COX-2), tumor necrosis factor (TNF)-alpha, nuclear factor kappa B (NFkB) and inducible nitric oxide synthase (iNOS) gene expression, in colon specimens. Azoxymethane 15-18 tumor necrosis factor Mus musculus 132-165 31874252-9 2020 Treatment with AOM/DSS significantly increased prostaglandin (PG)E2 and 8-iso-PGF2alpha levels along with cyclooxygenase-2 (COX-2), tumor necrosis factor (TNF)-alpha, nuclear factor kappa B (NFkB) and inducible nitric oxide synthase (iNOS) gene expression, in colon specimens. Azoxymethane 15-18 nitric oxide synthase 2, inducible Mus musculus 201-232 31874252-9 2020 Treatment with AOM/DSS significantly increased prostaglandin (PG)E2 and 8-iso-PGF2alpha levels along with cyclooxygenase-2 (COX-2), tumor necrosis factor (TNF)-alpha, nuclear factor kappa B (NFkB) and inducible nitric oxide synthase (iNOS) gene expression, in colon specimens. Azoxymethane 15-18 nitric oxide synthase 2, inducible Mus musculus 234-238 31894839-8 2020 In vivo, azoxymethane/dextran sulfate sodium (AOM/DSS)-treated CRC mice, when administered EPS1-1, exhibited activation of the AMPK pathway, inhibition of mTORC1, and accumulation of p53 in tumor tissues. Azoxymethane 9-21 protein kinase AMP-activated catalytic subunit alpha 2 Homo sapiens 127-131 31894839-8 2020 In vivo, azoxymethane/dextran sulfate sodium (AOM/DSS)-treated CRC mice, when administered EPS1-1, exhibited activation of the AMPK pathway, inhibition of mTORC1, and accumulation of p53 in tumor tissues. Azoxymethane 9-21 CREB regulated transcription coactivator 1 Mus musculus 155-161 31894839-8 2020 In vivo, azoxymethane/dextran sulfate sodium (AOM/DSS)-treated CRC mice, when administered EPS1-1, exhibited activation of the AMPK pathway, inhibition of mTORC1, and accumulation of p53 in tumor tissues. Azoxymethane 9-21 transformation related protein 53, pseudogene Mus musculus 183-186 31836665-8 2020 Colon tumors from either CR-infected ApcP Min/+ or azoxymethane/dextran sodium sulfate (AOM/DSS)-treated mice had high LRP5/6 or FZD10 levels, and chronic Notch blockade through the gamma-secretase inhibitor dibenzazepine down-regulated LRP5/6 and FZD10 expression. Azoxymethane 88-91 frizzled class receptor 10 Mus musculus 129-134 31836665-8 2020 Colon tumors from either CR-infected ApcP Min/+ or azoxymethane/dextran sodium sulfate (AOM/DSS)-treated mice had high LRP5/6 or FZD10 levels, and chronic Notch blockade through the gamma-secretase inhibitor dibenzazepine down-regulated LRP5/6 and FZD10 expression. Azoxymethane 51-63 low density lipoprotein receptor-related protein 5 Mus musculus 119-125 31903123-10 2020 After AOM/DSS administration, the colorectums of CARD3-/- mice had fewer tumors than those of control mice. Azoxymethane 6-9 receptor (TNFRSF)-interacting serine-threonine kinase 2 Mus musculus 49-54 31836665-8 2020 Colon tumors from either CR-infected ApcP Min/+ or azoxymethane/dextran sodium sulfate (AOM/DSS)-treated mice had high LRP5/6 or FZD10 levels, and chronic Notch blockade through the gamma-secretase inhibitor dibenzazepine down-regulated LRP5/6 and FZD10 expression. Azoxymethane 51-63 frizzled class receptor 10 Mus musculus 129-134 31855601-4 2020 Compound H13 has a favorable PK profile and high tissue distribution specificity in the colon, as well as good efficacy in the AOM-DSS mouse model for colitis-associated colonic tumorigenesis. Azoxymethane 127-130 histocompatibility 13 Mus musculus 9-12 31968249-6 2020 Notably, compared with their wild-type littermates, MAVS knockout mice display decreased resistance to azoxymethane (AOM) or AOM/dextran sulfate sodium salt (DSS)-induced colon cancer. Azoxymethane 103-115 mitochondrial antiviral signaling protein Mus musculus 52-56 31968249-6 2020 Notably, compared with their wild-type littermates, MAVS knockout mice display decreased resistance to azoxymethane (AOM) or AOM/dextran sulfate sodium salt (DSS)-induced colon cancer. Azoxymethane 117-120 mitochondrial antiviral signaling protein Mus musculus 52-56 31968249-6 2020 Notably, compared with their wild-type littermates, MAVS knockout mice display decreased resistance to azoxymethane (AOM) or AOM/dextran sulfate sodium salt (DSS)-induced colon cancer. Azoxymethane 125-128 mitochondrial antiviral signaling protein Mus musculus 52-56 31968254-2 2020 Here, we demonstrate that periostin deficiency significantly inhibits the occurrence of colorectal cancer in azoxymethane/dextran sulfate sodium-treated mice and in ApcMin/+ mice. Azoxymethane 109-121 periostin, osteoblast specific factor Mus musculus 26-35 31836532-5 2020 The formation of colon tumours induced by AOM/DSS treatment was significantly attenuated in TRPV4-deficient mice (TRPV4KO). Azoxymethane 42-45 transient receptor potential cation channel, subfamily V, member 4 Mus musculus 92-97 31836532-7 2020 AOM/DSS treatment upregulated the expression of CD105, vascular endothelial growth factor receptor 2, and TRPV4 in wildtype, but the upregulation of CD105 was significantly attenuated in TRPV4KO. Azoxymethane 0-3 endoglin Mus musculus 48-53 31836532-7 2020 AOM/DSS treatment upregulated the expression of CD105, vascular endothelial growth factor receptor 2, and TRPV4 in wildtype, but the upregulation of CD105 was significantly attenuated in TRPV4KO. Azoxymethane 0-3 kinase insert domain protein receptor Mus musculus 55-100 31836532-7 2020 AOM/DSS treatment upregulated the expression of CD105, vascular endothelial growth factor receptor 2, and TRPV4 in wildtype, but the upregulation of CD105 was significantly attenuated in TRPV4KO. Azoxymethane 0-3 transient receptor potential cation channel, subfamily V, member 4 Mus musculus 106-111 31836532-7 2020 AOM/DSS treatment upregulated the expression of CD105, vascular endothelial growth factor receptor 2, and TRPV4 in wildtype, but the upregulation of CD105 was significantly attenuated in TRPV4KO. Azoxymethane 0-3 endoglin Mus musculus 149-154 31818852-5 2020 E1, E2 and E3 are associated with AOM exposure, walnut consumption and TWD diet, respectively. Azoxymethane 34-37 ATPase, H+ transporting, lysosomal V1 subunit E1 Mus musculus 4-13 31125123-2 2020 We report that VPS33B was downregulated in dextran sulfate sodium/azoxymethane (DSS/AOM) -induced CRC mice models and nicotine-treated CRC cells via the PI3K/AKT/c-Jun pathway. Azoxymethane 66-78 vacuolar protein sorting 33B Mus musculus 15-21 31125123-2 2020 We report that VPS33B was downregulated in dextran sulfate sodium/azoxymethane (DSS/AOM) -induced CRC mice models and nicotine-treated CRC cells via the PI3K/AKT/c-Jun pathway. Azoxymethane 84-87 vacuolar protein sorting 33B Mus musculus 15-21 31173626-4 2019 METHODS: Angiopoietin-2 wild-type, heterozygote, and knockout mice received a single injection of the procarcinogen azoxymethane and had an IBD-promoting chemical irritant (dextran sodium sulfate) added to their drinking water over a 7-week period. Azoxymethane 116-128 angiopoietin 2 Mus musculus 9-23 31628914-9 2019 KEY FINDINGS: In the AOM/DSS model of colitis-associated tumorigenesis, Nrf2-/- mice showed a phenotype similar to WT mice, but with significantly more tumors and a much higher percentage of adenocarcinomas. Azoxymethane 21-24 nuclear factor, erythroid derived 2, like 2 Mus musculus 72-76 30859181-6 2019 Most significantly, azoxymethane-treated mice with conditional Apc expression, but absent the Cre recombinase gene, demonstrated nearly 50% tumor incidence with 2 or more large colon tumors per mouse of human-like histology, but no small intestine tumors - unlike the azoxymethane-resistant C57BL/6J-background Min mouse model. Azoxymethane 20-32 APC, WNT signaling pathway regulator Mus musculus 63-66 30859181-6 2019 Most significantly, azoxymethane-treated mice with conditional Apc expression, but absent the Cre recombinase gene, demonstrated nearly 50% tumor incidence with 2 or more large colon tumors per mouse of human-like histology, but no small intestine tumors - unlike the azoxymethane-resistant C57BL/6J-background Min mouse model. Azoxymethane 268-280 APC, WNT signaling pathway regulator Mus musculus 63-66 31862898-9 2019 Accordingly, RAI16-/- mice displayed significantly increased tumor burden compared with WT mice assessed in CAC model induced by AOM/DSS. Azoxymethane 129-132 FHF complex subunit HOOK interacting protein 2B Mus musculus 13-18 30844440-4 2019 In an azoxymethane/dextran sulfate sodium model of colitis-associated tumorigenesis, Mkp-1-/- mice exhibited a phenotype similar to Nrf2-/- mice with significantly more tumors than WT mice. Azoxymethane 6-18 dual specificity phosphatase 1 Mus musculus 85-90 31195598-7 2019 First, expression of the TNIIIA2-containing TNC peptides/fragments was detected in dysplastic lesions of an azoxymethane/dextran sodium sulfate (AOM/DSS) mouse model. Azoxymethane 108-120 tenascin C Mus musculus 44-47 31195598-7 2019 First, expression of the TNIIIA2-containing TNC peptides/fragments was detected in dysplastic lesions of an azoxymethane/dextran sodium sulfate (AOM/DSS) mouse model. Azoxymethane 145-148 tenascin C Mus musculus 44-47 31432570-11 2019 IRX5 was significantly increased in azoxymethane/dextran sodium sulfate intestinal tissue of mice and IRX5-overexpressing may also enhance chemokines CXCL1 and CXCL8. Azoxymethane 36-48 Iroquois homeobox 5 Mus musculus 0-4 31681563-0 2019 Increased Incidence of Colon Tumors in AOM-Treated Apc 1638N/+ Mice Reveals Higher Frequency of Tumor Associated Neutrophils in Colon Than Small Intestine. Azoxymethane 39-42 APC, WNT signaling pathway regulator Mus musculus 51-54 31681563-4 2019 Therefore, the Apc 1638N/+ line was treated repeatedly with azoxymethane (AOM) and 90% colon tumor incidence and 4 to 5 colon tumors per mouse were achieved. Azoxymethane 60-72 APC, WNT signaling pathway regulator Mus musculus 15-18 31681563-4 2019 Therefore, the Apc 1638N/+ line was treated repeatedly with azoxymethane (AOM) and 90% colon tumor incidence and 4 to 5 colon tumors per mouse were achieved. Azoxymethane 74-77 APC, WNT signaling pathway regulator Mus musculus 15-18 31681563-9 2019 Thus, Apc 1638N/+ mice treated with AOM are a suitable and straightforward model to study the influence of immune cells and chemokines on colon carcinogenesis. Azoxymethane 36-39 APC, WNT signaling pathway regulator Mus musculus 6-9 30375302-3 2019 In this study, microRNA-array differential analysis revealed strongly enhanced expression of miR-24-1-5p in the colon tissue of azoxymethane/dextran sulphate sodium-induced mice that were fed with black raspberry anthocyanins for 9 weeks. Azoxymethane 128-140 microRNA 24-1 Mus musculus 93-101 31154022-15 2019 Fenofibrate protected human PPARA transgenic mice from azoxymethane and DSS-induced colon cancer. Azoxymethane 55-67 peroxisome proliferator activated receptor alpha Mus musculus 28-33 31480481-3 2019 However, the effect of a combined treatment of microencapsulated BF and LYC on IGF-1/IGF-1R/IGFBPs (Insulin-like growth factor-binding proteins) expression in an azoxymethane (AOM)-dextran sulfate sodium (DSS)-induced CRC model have not been demonstrated. Azoxymethane 162-174 insulin-like growth factor 1 Mus musculus 79-84 31480481-3 2019 However, the effect of a combined treatment of microencapsulated BF and LYC on IGF-1/IGF-1R/IGFBPs (Insulin-like growth factor-binding proteins) expression in an azoxymethane (AOM)-dextran sulfate sodium (DSS)-induced CRC model have not been demonstrated. Azoxymethane 162-174 insulin-like growth factor I receptor Mus musculus 85-91 31480481-3 2019 However, the effect of a combined treatment of microencapsulated BF and LYC on IGF-1/IGF-1R/IGFBPs (Insulin-like growth factor-binding proteins) expression in an azoxymethane (AOM)-dextran sulfate sodium (DSS)-induced CRC model have not been demonstrated. Azoxymethane 162-174 insulin-like growth factor binding protein 3 Mus musculus 92-98 31480481-3 2019 However, the effect of a combined treatment of microencapsulated BF and LYC on IGF-1/IGF-1R/IGFBPs (Insulin-like growth factor-binding proteins) expression in an azoxymethane (AOM)-dextran sulfate sodium (DSS)-induced CRC model have not been demonstrated. Azoxymethane 176-179 insulin-like growth factor 1 Mus musculus 79-84 31480481-3 2019 However, the effect of a combined treatment of microencapsulated BF and LYC on IGF-1/IGF-1R/IGFBPs (Insulin-like growth factor-binding proteins) expression in an azoxymethane (AOM)-dextran sulfate sodium (DSS)-induced CRC model have not been demonstrated. Azoxymethane 176-179 insulin-like growth factor I receptor Mus musculus 85-91 31480481-3 2019 However, the effect of a combined treatment of microencapsulated BF and LYC on IGF-1/IGF-1R/IGFBPs (Insulin-like growth factor-binding proteins) expression in an azoxymethane (AOM)-dextran sulfate sodium (DSS)-induced CRC model have not been demonstrated. Azoxymethane 176-179 insulin-like growth factor binding protein 3 Mus musculus 92-98 31239268-4 2019 Similarly, colon-specific knockout of Trim67 significantly accelerated azoxymethane-induced colorectal cancer in mice. Azoxymethane 71-83 tripartite motif-containing 67 Mus musculus 38-44 30973663-9 2019 Moreover, when the colorectum of azoxymethane-treated rats was observed using a thin fluorescent endoscope with AF-EGFR-Ab, all 10 small colorectal adenomas (<=3 mm) were detected with a clear fluorescence signal. Azoxymethane 33-45 epidermal growth factor receptor Mus musculus 115-119 30676667-6 2019 ESE-1 knockout in mice increased azoxymethane (AOM)-induced and dextran sulfate sodium (DSS)-promoted formation of aberrant crypt foci (ACF). Azoxymethane 33-45 E74-like factor 3 Mus musculus 0-5 30676667-6 2019 ESE-1 knockout in mice increased azoxymethane (AOM)-induced and dextran sulfate sodium (DSS)-promoted formation of aberrant crypt foci (ACF). Azoxymethane 47-50 E74-like factor 3 Mus musculus 0-5 30611867-3 2019 Heterozygous knockout IGF-1R attenuated azoxymethane (AOM)/dextran sulfate sodium (DSS)-induced colitis and colitis associated cancer (CAC) in Igf1r+/- mice. Azoxymethane 40-52 insulin-like growth factor I receptor Mus musculus 22-28 30944312-5 2019 We discovered that Ct55 deficiency alleviated inflammatory responses, decreased cell proliferation and colitis-associated tumorigenesis in an azoxymethane/dextran sulfate sodium (AOM/DSS) mouse model. Azoxymethane 142-154 cancer/testis antigen 55 Mus musculus 19-23 30913881-7 2019 In addition, MA significantly suppressed the tumorigenesis and regulated the AMPK-mTOR pathway in azoxymethane/dextran sulfate sodium mice and xenograft tumor mice. Azoxymethane 98-110 protein kinase AMP-activated catalytic subunit alpha 2 Homo sapiens 77-81 30913881-7 2019 In addition, MA significantly suppressed the tumorigenesis and regulated the AMPK-mTOR pathway in azoxymethane/dextran sulfate sodium mice and xenograft tumor mice. Azoxymethane 98-110 mechanistic target of rapamycin kinase Mus musculus 82-86 30611867-3 2019 Heterozygous knockout IGF-1R attenuated azoxymethane (AOM)/dextran sulfate sodium (DSS)-induced colitis and colitis associated cancer (CAC) in Igf1r+/- mice. Azoxymethane 40-52 insulin-like growth factor I receptor Mus musculus 143-148 30611867-3 2019 Heterozygous knockout IGF-1R attenuated azoxymethane (AOM)/dextran sulfate sodium (DSS)-induced colitis and colitis associated cancer (CAC) in Igf1r+/- mice. Azoxymethane 54-57 insulin-like growth factor I receptor Mus musculus 22-28 30611867-3 2019 Heterozygous knockout IGF-1R attenuated azoxymethane (AOM)/dextran sulfate sodium (DSS)-induced colitis and colitis associated cancer (CAC) in Igf1r+/- mice. Azoxymethane 54-57 insulin-like growth factor I receptor Mus musculus 143-148 30538296-4 2019 Here, we show that Casp11-/- mice are highly susceptible to the azoxymethane (AOM)-DSS model of colitis-associated cancer (CAC), compared to their wild type (WT) littermates. Azoxymethane 64-76 caspase 4, apoptosis-related cysteine peptidase Mus musculus 19-25 30538296-4 2019 Here, we show that Casp11-/- mice are highly susceptible to the azoxymethane (AOM)-DSS model of colitis-associated cancer (CAC), compared to their wild type (WT) littermates. Azoxymethane 78-81 caspase 4, apoptosis-related cysteine peptidase Mus musculus 19-25 31040926-5 2019 AOM/DSS treatment of Apc1638N/+ mice phenocopied CR+AOM treatment as colonic tumors exhibited pronounced changes in Ki-67, EZH2 and Dclk1 accompanied by infiltration of F4/80+ macrophages, CD3+ lymphocytes and CD3/beta-catenin co-localization. Azoxymethane 0-3 doublecortin like kinase 1 Homo sapiens 132-137 29952003-5 2018 We show here that mice lacking geminin develop a significantly higher number of tumors and bear a larger tumor burden than sham-treated controls in urethane-induced lung and azoxymethane/dextran sodium sulfate-induced colon carcinogenesis. Azoxymethane 174-186 geminin Mus musculus 31-38 30204842-9 2019 Exposure to azoxymethane/DSS resulted in extensive epithelial apoptosis in Postn-/- mice compared with that in wild-type mice. Azoxymethane 12-24 periostin, osteoblast specific factor Mus musculus 75-80 30365932-16 2019 Mice with knockdown of beta-catenin had a lower tumor burden after administration of azoxymethane and dextran sodium sulfate, regardless of Trib3 overexpression. Azoxymethane 85-97 catenin (cadherin associated protein), beta 1 Mus musculus 23-35 30099074-13 2018 CONCLUSIONS: In mice, we demonstrated that combined inactivation of Mir34a and Tp53 promotes azoxymethane-induced colorectal carcinogenesis and tumor progression and metastasis by increasing levels of IL6R and PAI1. Azoxymethane 93-105 microRNA 34a Mus musculus 68-74 30099074-13 2018 CONCLUSIONS: In mice, we demonstrated that combined inactivation of Mir34a and Tp53 promotes azoxymethane-induced colorectal carcinogenesis and tumor progression and metastasis by increasing levels of IL6R and PAI1. Azoxymethane 93-105 transformation related protein 53 Mus musculus 79-83 30099074-13 2018 CONCLUSIONS: In mice, we demonstrated that combined inactivation of Mir34a and Tp53 promotes azoxymethane-induced colorectal carcinogenesis and tumor progression and metastasis by increasing levels of IL6R and PAI1. Azoxymethane 93-105 interleukin 6 receptor, alpha Mus musculus 201-205 30099074-13 2018 CONCLUSIONS: In mice, we demonstrated that combined inactivation of Mir34a and Tp53 promotes azoxymethane-induced colorectal carcinogenesis and tumor progression and metastasis by increasing levels of IL6R and PAI1. Azoxymethane 93-105 serine (or cysteine) peptidase inhibitor, clade E, member 1 Mus musculus 210-214 30268501-8 2018 Another clone of anti-IL-11 antibodies stained stromal cells surrounding tumors of the colon of wild-type, but not Il11-deficient mice following treatment with Azoxymethane plus dextran sulfate sodium. Azoxymethane 160-172 interleukin 11 Mus musculus 22-27 30295289-4 2018 However, for the experiment that compared inflammation, invasion, and neoplasia in azoxymethane (AOM)-treated interleukin-10-deficient mice mono-associated with NC101 or NC101[Formula: see text] pks the experimental timing of the replication attempt was longer than that of the original study. Azoxymethane 83-95 interleukin 10 Mus musculus 110-124 30295289-4 2018 However, for the experiment that compared inflammation, invasion, and neoplasia in azoxymethane (AOM)-treated interleukin-10-deficient mice mono-associated with NC101 or NC101[Formula: see text] pks the experimental timing of the replication attempt was longer than that of the original study. Azoxymethane 97-100 interleukin 10 Mus musculus 110-124 30472235-8 2019 JMJD2D-knockout and wild-type (control) mice were given azoxymethane followed by dextran sodium sulfate to induce colitis-associated CRC; some mice were given the JMJD2D inhibitor 5-chloro-8-hydroxyquinoline (5-c-8HQ) or vehicle to examine the effects of 5-c-8HQ on intestinal tumor formation. Azoxymethane 56-68 lysine (K)-specific demethylase 4D Mus musculus 0-6 30457689-6 2019 The NADH fluorescence intensity measured by two-photon excitation fluorescence (TPEF) microscopy was consistently increased in CRC cell lines, azoxymethane/dextran sodium sulfate (AOM/DSS)-induced CRC tissues and tumor tissues from CRC patients. Azoxymethane 143-155 transmembrane protein with EGF like and two follistatin like domains 2 Homo sapiens 80-84 30365932-15 2019 Mice with overexpression of Trib3 developed more tumors after administration of azoxymethane and dextran sodium sulfate than BALB/c mice. Azoxymethane 80-92 tribbles pseudokinase 3 Mus musculus 28-33 30202097-3 2019 Here, we present evidence that SLC7A2 plays a role in modulating colon tumorigenesis in the azoxymethane (AOM)-DSS model of colitis-associated carcinogenesis (CAC). Azoxymethane 92-104 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 Mus musculus 31-37 30202097-3 2019 Here, we present evidence that SLC7A2 plays a role in modulating colon tumorigenesis in the azoxymethane (AOM)-DSS model of colitis-associated carcinogenesis (CAC). Azoxymethane 106-109 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 Mus musculus 31-37 30232408-7 2019 Treatment with klotho inhibited formation of colon polyps induced by the carcinogen azoxymethane, and KL1 treatment slowed growth of orthotopically-implanted colorectal tumors. Azoxymethane 84-96 klotho Homo sapiens 15-21 32566755-7 2019 Results: We found that KLF4 expression is lost in tumor sections obtained from CRC patients and in those of mouse colon following azoxymethane and dextran sodium sulfate (AOM/DSS) treatment when compared to their respective normal appearing mucosa. Azoxymethane 130-142 Kruppel like factor 4 Homo sapiens 23-27 32566755-7 2019 Results: We found that KLF4 expression is lost in tumor sections obtained from CRC patients and in those of mouse colon following azoxymethane and dextran sodium sulfate (AOM/DSS) treatment when compared to their respective normal appearing mucosa. Azoxymethane 171-174 Kruppel like factor 4 Homo sapiens 23-27 30798535-2 2019 The azoxymethane/interleukin-10 knockout (AOM/Il10-/-) model is a powerful tool for assessing the effects of intestinal microbiota and inflammation on colon tumorigenesis. Azoxymethane 4-16 interleukin 10 Mus musculus 46-50 30108164-4 2019 Mice with intestinal epithelium-specific deletion of Klf4 (Klf4DeltaIS ) and control mice (Klf4fl/fl ) were used to explore the role of KLF4 in the development of azoxymethane (AOM) and dextran sodium sulfate (DSS)-induced CAC. Azoxymethane 163-175 Kruppel-like factor 4 (gut) Mus musculus 136-140 30362310-0 2018 Effects of Grape Juice in Superoxide Dismutase and Catalase in Colorectal Cancer Carcinogenesis Induced by Azoxymethane Background: The intestinal mucosa is commonly exposed to oxidant nutrients and carcinogens, which can lead tothe generation of free radicals. Azoxymethane 107-119 catalase Rattus norvegicus 51-59 29688249-7 2018 Furthermore, in a colitis-associated colon cancer model, the PHD2-conditional knockout mice had similar susceptibility to azoxymethane (AOM)-induced colonic tumorigenesis as control mice did. Azoxymethane 122-134 egl-9 family hypoxia-inducible factor 1 Mus musculus 61-65 30232275-3 2018 Azoxymethane and dextran sodium sulfate-treated (DSS-treated) animals deficient in lipin-1 harbored fewer tumors and carcinomas than WT animals due to decreased cellular proliferation, lower expression of antiapoptotic and protumorigenic factors, and a reduced infiltration of macrophages in colon tumors. Azoxymethane 0-12 lipin 1 Homo sapiens 83-90 30143645-6 2018 Deficiency of TRIM27 significantly impairs dextran sulfate sodium (DSS)-induced STAT3 activation, inflammatory cytokine expression and colitis as well as azoxymethane (AOM)/DSS-induced colitis-associated cancer in mice. Azoxymethane 154-166 tripartite motif-containing 27 Mus musculus 14-20 29778535-5 2018 Azoxymethane-treated mice developed FHF and hepatic encephalopathy, associated with higher autotaxin (ATX) activities in serum than controls. Azoxymethane 0-12 ectonucleotide pyrophosphatase/phosphodiesterase 2 Mus musculus 91-100 29778535-5 2018 Azoxymethane-treated mice developed FHF and hepatic encephalopathy, associated with higher autotaxin (ATX) activities in serum than controls. Azoxymethane 0-12 ectonucleotide pyrophosphatase/phosphodiesterase 2 Mus musculus 102-105 30107089-13 2018 Finally, we observed enhanced association of CHIP with the UBXN2A-mot-2 complex in tumors in an azoxymethane/dextran sulfate sodium-induced mouse CRC model. Azoxymethane 96-108 UBX domain protein 2A Mus musculus 59-71 30061214-0 2018 Cannabinoid Receptor-1 Up-regulation in Azoxymethane (AOM)-treated Mice After Dietary Treatment with Quercetin. Azoxymethane 40-52 cannabinoid receptor 1 (brain) Mus musculus 0-22 29730197-8 2018 Moreover, both chemical inhibition and genetic knockout of HSF1 succeeded in increasing MIR137 expression, reducing GLS1 expression, and alleviating colorectal tumorigenesis in azoxymethane (AOM)/dextran sulfate sodium (DSS) mice. Azoxymethane 177-189 heat shock factor 1 Mus musculus 59-63 29730197-8 2018 Moreover, both chemical inhibition and genetic knockout of HSF1 succeeded in increasing MIR137 expression, reducing GLS1 expression, and alleviating colorectal tumorigenesis in azoxymethane (AOM)/dextran sulfate sodium (DSS) mice. Azoxymethane 191-194 heat shock factor 1 Mus musculus 59-63 30221056-2 2018 Here, we report that S100A4 expression was increased in azoxymethane (AOM) and dextran sulfate sodium (DSS) induced colorectal cancer (CRC) in mice. Azoxymethane 56-68 S100 calcium binding protein A4 Mus musculus 21-27 30221056-2 2018 Here, we report that S100A4 expression was increased in azoxymethane (AOM) and dextran sulfate sodium (DSS) induced colorectal cancer (CRC) in mice. Azoxymethane 70-73 S100 calcium binding protein A4 Mus musculus 21-27 29228136-4 2018 Moreover, CAC model was induced in wild-type and CD177-/- mice by azoxymethane/dextran sodium sulphate. Azoxymethane 66-78 CD177 antigen Mus musculus 49-54 29440355-2 2018 In this article, we report that mice deficient in cathelin-related antimicrobial peptide (CRAMP) were defective in the development of colon mucosa and highly sensitive to dextran sulfate sodium (DSS)-elicited colitis, as well as azoxymethane-mediated carcinogenesis. Azoxymethane 229-241 cathelicidin antimicrobial peptide Mus musculus 50-88 29440355-2 2018 In this article, we report that mice deficient in cathelin-related antimicrobial peptide (CRAMP) were defective in the development of colon mucosa and highly sensitive to dextran sulfate sodium (DSS)-elicited colitis, as well as azoxymethane-mediated carcinogenesis. Azoxymethane 229-241 cathelicidin antimicrobial peptide Mus musculus 90-95 29867954-9 2018 In mouse models of dextran sulfate sodium (DSS)-induced colitis and azoxymethane/DSS induced colon cancer, NoxO1 has a protective role and may influence the population of natural killer cells. Azoxymethane 68-80 NADPH oxidase organizer 1 Mus musculus 107-112 29748582-5 2018 Remarkably, USP49 expression was regulated by p53 and USP49 in knockout mice, which are more susceptible to azoxymethane/dextran sulfate sodium (AOM/DSS)-induced colon tumors. Azoxymethane 108-120 ubiquitin specific peptidase 49 Mus musculus 12-17 29748582-5 2018 Remarkably, USP49 expression was regulated by p53 and USP49 in knockout mice, which are more susceptible to azoxymethane/dextran sulfate sodium (AOM/DSS)-induced colon tumors. Azoxymethane 108-120 transformation related protein 53, pseudogene Mus musculus 46-49 29748582-5 2018 Remarkably, USP49 expression was regulated by p53 and USP49 in knockout mice, which are more susceptible to azoxymethane/dextran sulfate sodium (AOM/DSS)-induced colon tumors. Azoxymethane 108-120 ubiquitin specific peptidase 49 Mus musculus 54-59 29197088-6 2018 In our azoxymethane/dextran sodium sulfate (AOM/DSS) model of colitis-associated CRC, MK2 inhibitor treatment eliminated murine tumor development. Azoxymethane 7-19 MAP kinase-activated protein kinase 2 Mus musculus 86-89 29622769-11 2018 SOCS2 overexpression was detected in a murine model of azoxymethane/dextran sulfate sodium-induced colitis-associated colon cancer compared to mock-treated controls. Azoxymethane 55-67 suppressor of cytokine signaling 2 Mus musculus 0-5 29228136-9 2018 Consistently, CD177 depletion aggravated azoxymethane/dextran sodium sulphate-induced CAC in mice. Azoxymethane 41-53 CD177 antigen Mus musculus 14-19 29326691-6 2017 The protective effect of anti-S100a9 antibody treatment was also observed in azoxymethane (AOM)/DSS-induced colitis-associated cancer (CAC) mouse model. Azoxymethane 77-89 S100 calcium binding protein A9 (calgranulin B) Mus musculus 30-36 29233556-6 2018 In addition, colonic ATOH1+ IECs acquired tumor stem cell-like properties in the azoxymethane-DSS tumor model. Azoxymethane 81-93 atonal bHLH transcription factor 1 Homo sapiens 21-26 29118162-5 2018 Expression of the mutant K-ras allele accelerated azoxymethane (AOM)-induced colon carcinogenesis in C57BL/6 mice, a strain otherwise resistant to this carcinogen. Azoxymethane 50-62 Kirsten rat sarcoma viral oncogene homolog Mus musculus 25-30 29118162-5 2018 Expression of the mutant K-ras allele accelerated azoxymethane (AOM)-induced colon carcinogenesis in C57BL/6 mice, a strain otherwise resistant to this carcinogen. Azoxymethane 64-67 Kirsten rat sarcoma viral oncogene homolog Mus musculus 25-30 28875496-4 2018 Using azoxymethane (AOM)- and dextran sulfate sodium (DSS)-driven CRC mouse models, we found that GPR55 plays a tumor-promoting role that involves alterations of leukocyte populations, i.e. myeloid-derived suppressor cells and T lymphocytes, within the tumor tissues. Azoxymethane 6-18 G protein-coupled receptor 55 Mus musculus 98-103 28875496-4 2018 Using azoxymethane (AOM)- and dextran sulfate sodium (DSS)-driven CRC mouse models, we found that GPR55 plays a tumor-promoting role that involves alterations of leukocyte populations, i.e. myeloid-derived suppressor cells and T lymphocytes, within the tumor tissues. Azoxymethane 20-23 G protein-coupled receptor 55 Mus musculus 98-103 29028945-4 2017 First, we show that SphK1 deficient mice significantly attenuated azoxymethane (AOM)-induced colon carcinogenesis as measured by colon tumor incidence, multiplicity, and volume. Azoxymethane 66-78 sphingosine kinase 1 Mus musculus 20-25 29028945-4 2017 First, we show that SphK1 deficient mice significantly attenuated azoxymethane (AOM)-induced colon carcinogenesis as measured by colon tumor incidence, multiplicity, and volume. Azoxymethane 80-83 sphingosine kinase 1 Mus musculus 20-25 29070673-2 2017 Abrogation of IL-17A signaling in mice attenuated tissue repair of dextran sulfate sodium (DSS)-induced damage in colon epithelium and markedly reduced tumor development in an azoxymethane/DSS model of colitis-associated cancer. Azoxymethane 176-188 interleukin 17A Mus musculus 14-20 29416724-2 2018 The present data from azoxymethane-initiated, dextran sulfate sodium-promoted colitis associated cancer (CAC) model strongly indicate the potential of rTRAIL in cancer prevention rather than in cancer therapeutics. Azoxymethane 22-34 TNF superfamily member 10 Rattus norvegicus 151-157 28780076-5 2017 CAC was induced in cre-negative littermate mice (control) and mice with conditional disruption of Bmi1 and/or Mel18 by intraperitoneal injection of azoxymethane (AOM) followed by addition of dextran sulfate sodium (DSS) to drinking water. Azoxymethane 148-160 polycomb group ring finger 2 Mus musculus 110-115 29070673-6 2017 PLET1 deficiency impaired tissue repair of DSS-induced damage in colon epithelium and reduced tumor formation in an azoxymethane/DSS model of colitis-associated cancer. Azoxymethane 116-128 placenta expressed transcript 1 Mus musculus 0-5 28089732-4 2017 Intestinally-targeted transgenic expression of ALOX15 in mice inhibited dextran sodium sulfate-induced colitis from promoting azoxymethane- induced colorectal tumorigenesis, demonstrating that ALOX15 can suppress inflammation-driven promotion of carcinogen-induced colorectal tumorigenesis and therefore ALOX15 downregulation during tumorigenesis is likely to enhance the link between colitis and colorectal tumorigenesis. Azoxymethane 126-138 arachidonate 15-lipoxygenase Mus musculus 47-53 29017096-4 2017 METHODS: 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) or 3,3"-diindolylmethane (DIM) were used to activate aryl hydrocarbon receptor (Ahr) in azoxymethane (AOM)/dextran sodium sulfate (DSS)-induced CAC in mice. Azoxymethane 140-152 aryl-hydrocarbon receptor Mus musculus 105-130 29017096-4 2017 METHODS: 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) or 3,3"-diindolylmethane (DIM) were used to activate aryl hydrocarbon receptor (Ahr) in azoxymethane (AOM)/dextran sodium sulfate (DSS)-induced CAC in mice. Azoxymethane 154-157 aryl-hydrocarbon receptor Mus musculus 105-130 28089732-4 2017 Intestinally-targeted transgenic expression of ALOX15 in mice inhibited dextran sodium sulfate-induced colitis from promoting azoxymethane- induced colorectal tumorigenesis, demonstrating that ALOX15 can suppress inflammation-driven promotion of carcinogen-induced colorectal tumorigenesis and therefore ALOX15 downregulation during tumorigenesis is likely to enhance the link between colitis and colorectal tumorigenesis. Azoxymethane 126-138 arachidonate 15-lipoxygenase Mus musculus 193-199 28089732-4 2017 Intestinally-targeted transgenic expression of ALOX15 in mice inhibited dextran sodium sulfate-induced colitis from promoting azoxymethane- induced colorectal tumorigenesis, demonstrating that ALOX15 can suppress inflammation-driven promotion of carcinogen-induced colorectal tumorigenesis and therefore ALOX15 downregulation during tumorigenesis is likely to enhance the link between colitis and colorectal tumorigenesis. Azoxymethane 126-138 arachidonate 15-lipoxygenase Mus musculus 193-199 28718722-9 2017 These data suggest that citrus peel possesses an ability to suppress cellular oxidative stress through induction of NRF2, thereby preventing azoxymethane-induced colon carcinogenesis. Azoxymethane 141-153 NFE2 like bZIP transcription factor 2 Rattus norvegicus 116-120 28380450-9 2017 Loss of GPR56 also inhibited progastrin-dependent colonic crypt fission and colorectal carcinogenesis in the azoxymethane (AOM) mouse model of colorectal cancer. Azoxymethane 109-121 adhesion G protein-coupled receptor G1 Mus musculus 8-13 28725183-6 2017 The current study aimed to assess the role of bile-acid mediated S1PR2 signaling in neuroinflammation and disease progression during azoxymethane (AOM)-induced HE in mice. Azoxymethane 133-145 sphingosine-1-phosphate receptor 2 Mus musculus 65-70 28468928-2 2017 In this study, we investigated the cGMP-elevating ability of the phosphodiesterase-5 (PDE5) inhibitor sildenafil to prevent disease in the azoxymethane/dextran sulfate sodium (AOM/DSS) inflammation-driven colorectal cancer model. Azoxymethane 139-151 phosphodiesterase 5A, cGMP-specific Mus musculus 65-84 28468928-2 2017 In this study, we investigated the cGMP-elevating ability of the phosphodiesterase-5 (PDE5) inhibitor sildenafil to prevent disease in the azoxymethane/dextran sulfate sodium (AOM/DSS) inflammation-driven colorectal cancer model. Azoxymethane 139-151 phosphodiesterase 5A, cGMP-specific Mus musculus 86-90 28468928-2 2017 In this study, we investigated the cGMP-elevating ability of the phosphodiesterase-5 (PDE5) inhibitor sildenafil to prevent disease in the azoxymethane/dextran sulfate sodium (AOM/DSS) inflammation-driven colorectal cancer model. Azoxymethane 176-179 phosphodiesterase 5A, cGMP-specific Mus musculus 65-84 28468928-2 2017 In this study, we investigated the cGMP-elevating ability of the phosphodiesterase-5 (PDE5) inhibitor sildenafil to prevent disease in the azoxymethane/dextran sulfate sodium (AOM/DSS) inflammation-driven colorectal cancer model. Azoxymethane 176-179 phosphodiesterase 5A, cGMP-specific Mus musculus 86-90 27805617-8 2017 Furthermore, biweekly oral administration of CTBp significantly reduced disease severity and tumorigenesis in the azoxymethane/DSS model of ulcerative colitis and colon cancer. Azoxymethane 114-126 phosphate cytidylyltransferase 1B, choline Homo sapiens 45-49 28578586-2 2017 CRC induced by chemical carcinogens, such as heterocyclic aromatic amines and azoxymethane, in mice also involves dysregulation of Wnt signaling but via activating missense mutations in the beta-catenin oncogene despite the fact that genetically modified mice harboring an inactive APC allele efficiently develop CRC. Azoxymethane 78-90 catenin (cadherin associated protein), beta 1 Mus musculus 190-202 28455963-5 2017 In this study, TrkC was frequently overexpressed in CRC cells, patients" tumor samples and an azoxymethane/dextran sulphate sodium-induced mouse model of colitis-associated CRCs. Azoxymethane 94-106 neurotrophic receptor tyrosine kinase 3 Homo sapiens 15-19 28380450-9 2017 Loss of GPR56 also inhibited progastrin-dependent colonic crypt fission and colorectal carcinogenesis in the azoxymethane (AOM) mouse model of colorectal cancer. Azoxymethane 123-126 adhesion G protein-coupled receptor G1 Mus musculus 8-13 28915552-4 2017 Importantly, intestinal epithelial cell (IEC)-specific deletion of Dicer mice got more tumors after azoxymethane and dextran sulfate sodium (DSS) administration. Azoxymethane 100-112 dicer 1, ribonuclease III Homo sapiens 67-72 28410235-3 2017 In the current study, we utilized a genetic approach to investigate the effect of CysLT1R in the induced azoxymethane/dextran sulfate sodium (AOM/DSS) model of colitis-associated colon cancer. Azoxymethane 142-145 cysteinyl leukotriene receptor 1 Mus musculus 82-89 28350804-6 2017 Utilizing a mouse model of colitis-related colon carcinoma induced by the carcinogen azoxymethane (AOM), followed by the inflammatory agent dextran sodium sulfate (DSS), we found that Sdc1 deficiency results in increased susceptibility to colitis-associated tumorigenesis. Azoxymethane 85-97 syndecan 1 Mus musculus 184-188 28193514-12 2017 Colon tissues from MIR301A-knockout mice had increased epithelial barrier integrity and formed fewer tumors following administration of azoxymethane than control mice. Azoxymethane 136-148 microRNA 301 Mus musculus 19-26 28031321-7 2017 Moreover, syndecan-2 expression was detected in azoxymethane/DSS-induced colon tumors. Azoxymethane 48-60 syndecan 2 Mus musculus 10-20 28350804-6 2017 Utilizing a mouse model of colitis-related colon carcinoma induced by the carcinogen azoxymethane (AOM), followed by the inflammatory agent dextran sodium sulfate (DSS), we found that Sdc1 deficiency results in increased susceptibility to colitis-associated tumorigenesis. Azoxymethane 99-102 syndecan 1 Mus musculus 184-188 28301579-3 2017 Several mouse models of CAC have been proposed, including chemical induction through exposure to dextran sulfate sodium (DSS) with the genotoxic agents azoxymethane (AOM), 1,2-dymethylhydrazine (DHM) or targeted genetic mutations. Azoxymethane 152-164 recessive cataract Mus musculus 24-27 28405523-3 2017 Lineage tracing in Hdc-CreERT2;R26-LSL-tdTomato mice revealed that in homeostasis, there is a strong bias by HDC+ myeloid cells toward the CD11b+Ly6Ghi granulocytic lineage, which was accelerated during azoxymethane/dextran sodium sulfate (AOM/DSS)-induced colonic carcinogenesis. Azoxymethane 203-215 histidine decarboxylase Mus musculus 109-112 28039905-0 2017 Ultraviolet A eye irradiation ameliorates colon carcinoma induced by azoxymethane and dextran sodium sulfate through beta-endorphin and methionine-enkephalin. Azoxymethane 69-81 pro-opiomelanocortin-alpha Mus musculus 117-131 27876571-19 2017 miR21a-/- mice had a later appearance of fecal blood and diarrhea after administration of azoxymethane and dextran sodium sulfate, and had longer survival times compared with control mice. Azoxymethane 90-102 microRNA 21a Mus musculus 0-6 27609772-6 2016 It is noteworthy that mice lacking nCDase treated with azoxymethane were protected from tumor formation. Azoxymethane 55-67 N-acylsphingosine amidohydrolase 2 Mus musculus 35-41 28884622-2 2017 OBJECTIVE: To test whether 3-dimensional (3-D) noninvasive in vivo NIRF imaging can detect effects of epidermal growth factor receptor (EGFR) inhibitor on both polypoid and flat tumor load in azoxymethane (AOM)-induced colon tumors or tumors in ApcMin/+ mice. Azoxymethane 192-204 epidermal growth factor receptor Mus musculus 102-134 28884622-2 2017 OBJECTIVE: To test whether 3-dimensional (3-D) noninvasive in vivo NIRF imaging can detect effects of epidermal growth factor receptor (EGFR) inhibitor on both polypoid and flat tumor load in azoxymethane (AOM)-induced colon tumors or tumors in ApcMin/+ mice. Azoxymethane 192-204 epidermal growth factor receptor Mus musculus 136-140 27965594-0 2016 Lack of Adrenomedullin Results in Microbiota Changes and Aggravates Azoxymethane and Dextran Sulfate Sodium-Induced Colitis in Mice. Azoxymethane 68-80 adrenomedullin Mus musculus 8-22 27869219-7 2016 Finally, Spred2 KO mice developed significantly fewer tumors in response to azoxymethane plus DSS. Azoxymethane 76-88 sprouty-related EVH1 domain containing 2 Mus musculus 9-15 27869785-7 2016 In the azoxymethane DSS model IL-6RDeltaIEC mice were not protected from inflammation-induced carcinogenesis but showed comparable tumor load to wild-type mice. Azoxymethane 7-19 interleukin 6 receptor, alpha Mus musculus 30-48 27562646-3 2016 Consistent with this, Tnik-deficient mice are resistant to azoxymethane-induced colon tumorigenesis, and Tnik(-/-)/Apc(min/+) mutant mice develop significantly fewer intestinal tumours. Azoxymethane 59-71 TRAF2 and NCK interacting kinase Mus musculus 22-26 25994220-6 2016 Following azoxymethane and dextran sulfate sodium intervention, miR-21-knockout mice showed reduced expression of proinflammatory and procarcinogenic cytokines (interleukin (IL) 6, IL-23, IL-17A and IL-21) and a decrease in the size and number of tumours compared with the control mouse group. Azoxymethane 10-22 microRNA 21a Mus musculus 64-70 26973250-8 2016 In addition, Olfm4 deletion significantly enhanced intestinal-crypt proliferation and inflammation induced by azoxymethane/dextran sodium sulfate. Azoxymethane 110-122 olfactomedin 4 Mus musculus 13-18 27561705-14 2016 Soluble fractalkine infusion into the brain significantly reduced neurological decline in AOM-treated mice compared to saline-infused AOM-treated mice. Azoxymethane 90-93 chemokine (C-X3-C motif) ligand 1 Mus musculus 8-19 27033117-0 2016 High-fat diets rich in saturated fat protect against azoxymethane/dextran sulfate sodium-induced colon cancer. Azoxymethane 53-65 CD36 molecule Mus musculus 5-8 27561705-15 2016 Infusion of soluble fractalkine into AOM-treated mice reduced liver damage, lessened microglia activation, and suppressed expression of chemokine ligand 2, interleukin-6, and tumor necrosis factor alpha compared to saline-infused mice. Azoxymethane 37-40 chemokine (C-X3-C motif) ligand 1 Mus musculus 20-31 27561705-15 2016 Infusion of soluble fractalkine into AOM-treated mice reduced liver damage, lessened microglia activation, and suppressed expression of chemokine ligand 2, interleukin-6, and tumor necrosis factor alpha compared to saline-infused mice. Azoxymethane 37-40 interleukin 6 Mus musculus 156-169 27561705-15 2016 Infusion of soluble fractalkine into AOM-treated mice reduced liver damage, lessened microglia activation, and suppressed expression of chemokine ligand 2, interleukin-6, and tumor necrosis factor alpha compared to saline-infused mice. Azoxymethane 37-40 tumor necrosis factor Mus musculus 175-202 27300306-4 2016 EXPERIMENTAL APPROACH: Production of IL-33 from intestinal tissue was studied in a murine cancer model induced by azoxymethane (AOM) and DSS in vivo and in cultures of IEC-6 epithelial cells. Azoxymethane 114-126 interleukin 33 Mus musculus 37-42 27080303-4 2016 In this study, we found that transgenic mice overexpressing miR-17~92 specifically in epithelial cells of the small and large intestines exhibited decreased tumor size and tumor angiogenesis in azoxymethane and dextran sulfate sodium salt (AOM-DSS)-induced CRC model as compared to their littermates control. Azoxymethane 194-206 Mir17 host gene (non-protein coding) Mus musculus 60-69 27033117-0 2016 High-fat diets rich in saturated fat protect against azoxymethane/dextran sulfate sodium-induced colon cancer. Azoxymethane 53-65 CD36 molecule Mus musculus 33-36 27178440-8 2016 Olfm4 deletion in mice treated with azoxymethane/dextran sodium sulfate led to robust intestinal inflammation and intestinal crypt hyperplasia. Azoxymethane 36-48 olfactomedin 4 Mus musculus 0-5 26300003-3 2016 In this study, we provide strong evidences of enhanced CRTC1 protein content and transcriptional activity in mouse models of sporadic (APC(min/+) mice) or colitis-associated colon cancer azoxymethane/dextran sulfate sodium (AOM/DSS-treated mice), and in human colorectal tumors specimens compared with adjacent normal mucosa. Azoxymethane 187-199 CREB regulated transcription coactivator 1 Mus musculus 55-60 26983689-2 2016 However, Ptk6-null mice were also resistant to azoxymethane-induced colon tumorigenesis. Azoxymethane 47-59 PTK6 protein tyrosine kinase 6 Mus musculus 9-13 26921636-4 2016 Here we show that the cholesterol promoted colon carcinogenesis in azoxymethane (AOM)-treated mice through activating the NLRP3 inflammasome. Azoxymethane 67-79 NLR family, pyrin domain containing 3 Mus musculus 122-127 27086921-2 2016 Here, we report that the Mbd4 DNA glycosylase is protective in the azoxymethane/dextran sodium sulfate (AOM/DSS) mouse model of inflammation-driven colon cancer. Azoxymethane 67-79 methyl-CpG binding domain protein 4 Mus musculus 25-29 27086921-2 2016 Here, we report that the Mbd4 DNA glycosylase is protective in the azoxymethane/dextran sodium sulfate (AOM/DSS) mouse model of inflammation-driven colon cancer. Azoxymethane 104-107 methyl-CpG binding domain protein 4 Mus musculus 25-29 26921636-4 2016 Here we show that the cholesterol promoted colon carcinogenesis in azoxymethane (AOM)-treated mice through activating the NLRP3 inflammasome. Azoxymethane 81-84 NLR family, pyrin domain containing 3 Mus musculus 122-127 26758693-0 2016 Imaging colon cancer development in mice: IL-6 deficiency prevents adenoma in azoxymethane-treated Smad3 knockouts. Azoxymethane 78-90 SMAD family member 3 Mus musculus 99-104 26476372-3 2016 Here, under the hypothesis that Shh inhibitors can prevent CAC, mouse model was generated to develop CAC by azoxymethane (AOM)-initiated, dextran sodium sulfate-promoted carcinogenesis. Azoxymethane 108-120 sonic hedgehog Mus musculus 32-35 26476372-3 2016 Here, under the hypothesis that Shh inhibitors can prevent CAC, mouse model was generated to develop CAC by azoxymethane (AOM)-initiated, dextran sodium sulfate-promoted carcinogenesis. Azoxymethane 122-125 sonic hedgehog Mus musculus 32-35 26565021-9 2016 Despite worse colitis, p85(DeltaIEC) mice have reduced tumor burden after azoxymethane/dextran sodium sulfate treatment. Azoxymethane 74-86 extracellular matrix protein 1 Mus musculus 23-26 25772234-5 2016 In line with increased IEC proliferation, DUSP10 KO mice developed more colon tumours with increased severity compared with WT mice in response to administration of DSS and azoxymethane (AOM). Azoxymethane 173-185 dual specificity phosphatase 10 Mus musculus 42-48 26344057-14 2015 Mice that expressed SIGIRR(N86/102S) developed more inflammation and formed larger tumors after administration of azoxymethane and dextran sulfate sodium than control mice; colon tissues from these mutant mice expressed higher levels of the inflammatory cytokines IL-17A and IL-6 had activation of the transcription factors STAT3 and NFkappaB. Azoxymethane 114-126 single immunoglobulin and toll-interleukin 1 receptor (TIR) domain Mus musculus 20-26 27150094-5 2016 This review describes a common CAC model that utilizes the pro-carcinogenic compound azoxymethane (AOM) followed by dextran sulfate sodium (DSS) which induces the inflammatory insult. Azoxymethane 85-97 recessive cataract Mus musculus 31-34 27150094-5 2016 This review describes a common CAC model that utilizes the pro-carcinogenic compound azoxymethane (AOM) followed by dextran sulfate sodium (DSS) which induces the inflammatory insult. Azoxymethane 99-102 recessive cataract Mus musculus 31-34 26218141-5 2015 Starting at 10 weeks of age, wild-type or Il10 mice received 6 weekly intraperitoneal injections of azoxymethane (AOM) or phosphate-buffered saline (PBS) and were started on either a control or a curcumin-supplemented diet. Azoxymethane 100-112 interleukin 10 Mus musculus 42-46 26431492-5 2015 Here we demonstrate that CHI3L1 (aka Brp39) knockout (KO) mice treated with azoxymethane (AOM)/dextran sulphate sodium (DSS) developed severe colitis but lesser incidence of CAC as compared to that in wild-type (WT) mice. Azoxymethane 76-88 chitinase-like 1 Mus musculus 25-31 26431492-5 2015 Here we demonstrate that CHI3L1 (aka Brp39) knockout (KO) mice treated with azoxymethane (AOM)/dextran sulphate sodium (DSS) developed severe colitis but lesser incidence of CAC as compared to that in wild-type (WT) mice. Azoxymethane 76-88 chitinase-like 1 Mus musculus 37-42 26431492-5 2015 Here we demonstrate that CHI3L1 (aka Brp39) knockout (KO) mice treated with azoxymethane (AOM)/dextran sulphate sodium (DSS) developed severe colitis but lesser incidence of CAC as compared to that in wild-type (WT) mice. Azoxymethane 90-93 chitinase-like 1 Mus musculus 25-31 26431492-5 2015 Here we demonstrate that CHI3L1 (aka Brp39) knockout (KO) mice treated with azoxymethane (AOM)/dextran sulphate sodium (DSS) developed severe colitis but lesser incidence of CAC as compared to that in wild-type (WT) mice. Azoxymethane 90-93 chitinase-like 1 Mus musculus 37-42 26398937-8 2015 We also detected diminished expression of membrane-associated alpha-catenin and increased intestinal permeability in gpA33(DeltaN-Bcat) mice in challenge conditions, providing a potential explanation for the observed mild chronic intestinal inflammation and increased susceptibility to azoxymethane and mutant Apc-dependent tumorigenesis. Azoxymethane 286-298 glycoprotein A33 (transmembrane) Mus musculus 117-122 26492449-3 2015 The aim of this study was to evaluate the effect of red grape juice on the expression of COX-2 and Ki-67 expression following colon carcinogenesis induced by azoxymethane (AOM). Azoxymethane 158-170 cytochrome c oxidase II, mitochondrial Rattus norvegicus 89-94 26492449-3 2015 The aim of this study was to evaluate the effect of red grape juice on the expression of COX-2 and Ki-67 expression following colon carcinogenesis induced by azoxymethane (AOM). Azoxymethane 172-175 cytochrome c oxidase II, mitochondrial Rattus norvegicus 89-94 26055138-9 2015 A miR214 chemical inhibitor blocked this circuit and reduced the severity of DSS-induced colitis in mice, as well as the number and size of tumors that formed in mice given azoxymethane and DSS. Azoxymethane 173-185 microRNA 214 Mus musculus 2-8 26194191-4 2015 Interestingly, stromal deletion of Imp1 (Dermo1Cre;Imp1(LoxP/LoxP), or Imp1(DeltaMes)) in the azoxymethane/dextran sodium sulfate (AOM/DSS) model of colitis-associated cancer resulted in increased tumor numbers of larger size and more advanced histologic grade than controls. Azoxymethane 94-106 imprintor 1 Mus musculus 35-39 26496833-8 2015 Atg5 (flox/flox)/K19 (CreERT) mice were first treated with azoxymethane/dextran sodium sulfate and then injected with tamoxifen to inhibit autophagy in CK19-positive epithelial cells. Azoxymethane 59-71 autophagy related 5 Mus musculus 0-4 26440614-7 2015 The CHI3L1 positive colonic epithelial cells were highly proliferative and exhibited malignant transformation and expansion when exposed in vivo to azoxymethane, one of the well-known colonic carcinogens. Azoxymethane 148-160 chitinase-like 1 Mus musculus 4-10 26439841-6 2015 In the context of colitis-associated tumorigenesis, both systemic EPRAP null mutation and EPRAP-deficiency in the bone marrow enhanced intestinal polyp formation induced by azoxymethane (AOM)/DSS treatment. Azoxymethane 173-185 fem-1 homolog A Homo sapiens 66-71 26439841-6 2015 In the context of colitis-associated tumorigenesis, both systemic EPRAP null mutation and EPRAP-deficiency in the bone marrow enhanced intestinal polyp formation induced by azoxymethane (AOM)/DSS treatment. Azoxymethane 173-185 fem-1 homolog A Homo sapiens 90-95 26319614-0 2015 Probiotic Pediococcus pentosaceus strain GS4 alleviates azoxymethane-induced toxicity in mice. Azoxymethane 56-68 speedy/RINGO cell cycle regulator family, member A Mus musculus 41-44 26374068-3 2015 To address this gap in knowledge we treated M1R-deficient and WT mice with azoxymethane (AOM) for six weeks and assessed liver injury responses 14 weeks after the last dose of AOM. Azoxymethane 75-87 cholinergic receptor, muscarinic 1, CNS Mus musculus 44-47 26122663-3 2015 In this study, we show that genetic and pharmacological targeting of PLD1 disrupts spontaneous and colitis-associated intestinal tumorigenesis in Apc(Min/+) and azoxymethane/dextran sodium sulfate mice models. Azoxymethane 161-173 phospholipase D1 Mus musculus 69-73 26035389-9 2015 Gpa33(-/-) mice also exhibited rapid onset and reduced resolution of DSS-induced colitis, and a striking increase in the number of colitis-associated tumours produced by treatment with the colon-specific mutagen azoxymethane (AOM) followed by two cycles of DSS. Azoxymethane 212-224 glycoprotein A33 (transmembrane) Mus musculus 0-5 26109431-3 2015 We investigated cancer susceptibility associated with MUTYH inactivation in a mouse model of inflammation-dependent carcinogenesis induced by azoxymethane (AOM) and dextran sulphate (DSS). Azoxymethane 142-154 mutY DNA glycosylase Mus musculus 54-59 26109431-7 2015 The colon of untreated Mutyh-/- mice expressed higher basal levels of pro-inflammatory cytokines GM-CSF and IFNgamma, and treatment with AOM/DSS induced an early decrease in circulating CD4+ and CD8+ T lymphocytes and an increase in myeloid-derived suppressor cells (MDSCs). Azoxymethane 137-140 mutY DNA glycosylase Mus musculus 23-28 26196182-11 2015 CONCLUSIONS: These results indicated that GADD34 upregulated pro-inflammatory mediator production leading to a higher tumour burden following azoxymethane (AOM)/DSS treatment. Azoxymethane 142-154 protein phosphatase 1, regulatory subunit 15A Mus musculus 42-48 26107252-3 2015 We found that Aim2-deficient mice had greater tumor load than Asc-deficient mice in the azoxymethane/dextran sodium sulfate (AOM/DSS) model of colorectal cancer. Azoxymethane 88-100 absent in melanoma 2 Mus musculus 14-18 26107252-3 2015 We found that Aim2-deficient mice had greater tumor load than Asc-deficient mice in the azoxymethane/dextran sodium sulfate (AOM/DSS) model of colorectal cancer. Azoxymethane 125-128 absent in melanoma 2 Mus musculus 14-18 26463023-2 2015 METHODS: Mice with EGFR gene defects in macrophages (Egfr(fl/fl) LysM-Cre) and with EGFR gene expression in macrophages (LysM-Cre) (control group) were treated with azoxymethane (AOM) to establish colorectal tumor models. Azoxymethane 165-177 epidermal growth factor receptor Mus musculus 19-23 25804623-8 2015 To clarify its role in colon cancer in vivo, a mouse model exposed to the colon carcinogen azoxymethane and nongenotoxic carcinogen dextran sodium sulfate revealed that Spink3 (mouse homolog of SPINK1) is overexpressed in cancerous tissues. Azoxymethane 91-103 serine peptidase inhibitor, Kazal type 1 Mus musculus 169-175 25713055-5 2015 We report that intestinally targeted transgenic 15-LOX-1 expression in mice inhibited azoxymethane- and dextran sodium sulfate-induced CAC, IL-6 expression, STAT3 phosphorylation, and IL-6/STAT3 downstream target (Notch3 and MUC1) expression. Azoxymethane 86-98 arachidonate 15-lipoxygenase Homo sapiens 48-56 25713055-5 2015 We report that intestinally targeted transgenic 15-LOX-1 expression in mice inhibited azoxymethane- and dextran sodium sulfate-induced CAC, IL-6 expression, STAT3 phosphorylation, and IL-6/STAT3 downstream target (Notch3 and MUC1) expression. Azoxymethane 86-98 interleukin 6 Mus musculus 184-188 25713055-5 2015 We report that intestinally targeted transgenic 15-LOX-1 expression in mice inhibited azoxymethane- and dextran sodium sulfate-induced CAC, IL-6 expression, STAT3 phosphorylation, and IL-6/STAT3 downstream target (Notch3 and MUC1) expression. Azoxymethane 86-98 signal transducer and activator of transcription 3 Mus musculus 189-194 25713055-5 2015 We report that intestinally targeted transgenic 15-LOX-1 expression in mice inhibited azoxymethane- and dextran sodium sulfate-induced CAC, IL-6 expression, STAT3 phosphorylation, and IL-6/STAT3 downstream target (Notch3 and MUC1) expression. Azoxymethane 86-98 notch 3 Mus musculus 214-220 25713055-5 2015 We report that intestinally targeted transgenic 15-LOX-1 expression in mice inhibited azoxymethane- and dextran sodium sulfate-induced CAC, IL-6 expression, STAT3 phosphorylation, and IL-6/STAT3 downstream target (Notch3 and MUC1) expression. Azoxymethane 86-98 mucin 1, transmembrane Mus musculus 225-229 25712056-0 2015 Nrf2-dependent suppression of azoxymethane/dextran sulfate sodium-induced colon carcinogenesis by the cinnamon-derived dietary factor cinnamaldehyde. Azoxymethane 30-42 nuclear factor, erythroid derived 2, like 2 Mus musculus 0-4 25521828-7 2015 The azoxymethane (AOM)-induced colon carcinogenesis model in Erbin(DeltaC) (/) (DeltaC) mice, with the PDZ domain of Erbin deleted, demonstrated that the PDZ domain of Erbin and its regulation of EGFR signalling are necessary for the tumourigenesis and tumour growth of CRC. Azoxymethane 4-16 Erbb2 interacting protein Mus musculus 61-66 25521828-7 2015 The azoxymethane (AOM)-induced colon carcinogenesis model in Erbin(DeltaC) (/) (DeltaC) mice, with the PDZ domain of Erbin deleted, demonstrated that the PDZ domain of Erbin and its regulation of EGFR signalling are necessary for the tumourigenesis and tumour growth of CRC. Azoxymethane 4-16 Erbb2 interacting protein Mus musculus 117-122 25521828-7 2015 The azoxymethane (AOM)-induced colon carcinogenesis model in Erbin(DeltaC) (/) (DeltaC) mice, with the PDZ domain of Erbin deleted, demonstrated that the PDZ domain of Erbin and its regulation of EGFR signalling are necessary for the tumourigenesis and tumour growth of CRC. Azoxymethane 4-16 Erbb2 interacting protein Mus musculus 117-122 25521828-7 2015 The azoxymethane (AOM)-induced colon carcinogenesis model in Erbin(DeltaC) (/) (DeltaC) mice, with the PDZ domain of Erbin deleted, demonstrated that the PDZ domain of Erbin and its regulation of EGFR signalling are necessary for the tumourigenesis and tumour growth of CRC. Azoxymethane 4-16 epidermal growth factor receptor Mus musculus 196-200 25521828-7 2015 The azoxymethane (AOM)-induced colon carcinogenesis model in Erbin(DeltaC) (/) (DeltaC) mice, with the PDZ domain of Erbin deleted, demonstrated that the PDZ domain of Erbin and its regulation of EGFR signalling are necessary for the tumourigenesis and tumour growth of CRC. Azoxymethane 18-21 Erbb2 interacting protein Mus musculus 61-66 25521828-7 2015 The azoxymethane (AOM)-induced colon carcinogenesis model in Erbin(DeltaC) (/) (DeltaC) mice, with the PDZ domain of Erbin deleted, demonstrated that the PDZ domain of Erbin and its regulation of EGFR signalling are necessary for the tumourigenesis and tumour growth of CRC. Azoxymethane 18-21 Erbb2 interacting protein Mus musculus 117-122 25521828-7 2015 The azoxymethane (AOM)-induced colon carcinogenesis model in Erbin(DeltaC) (/) (DeltaC) mice, with the PDZ domain of Erbin deleted, demonstrated that the PDZ domain of Erbin and its regulation of EGFR signalling are necessary for the tumourigenesis and tumour growth of CRC. Azoxymethane 18-21 Erbb2 interacting protein Mus musculus 117-122 25521828-7 2015 The azoxymethane (AOM)-induced colon carcinogenesis model in Erbin(DeltaC) (/) (DeltaC) mice, with the PDZ domain of Erbin deleted, demonstrated that the PDZ domain of Erbin and its regulation of EGFR signalling are necessary for the tumourigenesis and tumour growth of CRC. Azoxymethane 18-21 epidermal growth factor receptor Mus musculus 196-200 25263446-8 2015 Besides that, knockout of AIB1 in mice inhibited colon carcinogenesis induced by azoxymethane/dextran sodium sulfate treatment. Azoxymethane 81-93 brain enriched myelin associated protein 1 Mus musculus 26-30 25909160-4 2015 In IL-32alpha-Tg mice, azoxymethane (AOM)-induced colon cancer incidence was decreased, whereas expression of TNFR1 and TNFR1-mediated apoptosis was increased. Azoxymethane 37-40 interleukin 32 Homo sapiens 3-13 25803810-2 2015 Its up-regulation is also important for promotion of the stage of colorectal carcinogenesis in vivo in human NEU3 transgenic mice treated with azoxymethane for the induction of aberrant crypt foci in the colon mucosa, accompanied by enhanced phosphorylation of EGF receptor (EGFR). Azoxymethane 143-155 neuraminidase 3 Homo sapiens 109-113 25881076-5 2015 METHODS: Wild-type mice and NPC1L1(-/-) (NPC1L1 knockout) mice were treated with azoxymethane (AOM)-dextran sodium sulfate (DSS) to induce colitis-associated colorectal tumorigenesis. Azoxymethane 81-93 NPC1 like intracellular cholesterol transporter 1 Mus musculus 41-47 25909160-4 2015 In IL-32alpha-Tg mice, azoxymethane (AOM)-induced colon cancer incidence was decreased, whereas expression of TNFR1 and TNFR1-mediated apoptosis was increased. Azoxymethane 23-35 interleukin 32 Homo sapiens 3-13 25740822-6 2015 Treatment with the carcinogen azoxymethane caused Sgo1(-/+) ME-CIN model mice to develop HCCs within 6 months, whereas control mice developed no HCC (P < 0.003). Azoxymethane 30-42 shugoshin 1 Mus musculus 50-54 25803810-2 2015 Its up-regulation is also important for promotion of the stage of colorectal carcinogenesis in vivo in human NEU3 transgenic mice treated with azoxymethane for the induction of aberrant crypt foci in the colon mucosa, accompanied by enhanced phosphorylation of EGF receptor (EGFR). Azoxymethane 143-155 epidermal growth factor receptor Mus musculus 261-273 25803810-2 2015 Its up-regulation is also important for promotion of the stage of colorectal carcinogenesis in vivo in human NEU3 transgenic mice treated with azoxymethane for the induction of aberrant crypt foci in the colon mucosa, accompanied by enhanced phosphorylation of EGF receptor (EGFR). Azoxymethane 143-155 epidermal growth factor receptor Mus musculus 275-279 25581824-3 2015 METHODS: TNF mice were treated with azoxymethane/dextran sulfate sodium to induce inflammation and tumorigenesis. Azoxymethane 36-48 tumor necrosis factor Mus musculus 9-12 25781343-4 2015 Arthur and colleagues identified a genotoxic island in Escherichia coli NC101 that appeared to be responsible for causing neoplastic lesions in inflammation-induced IL10-/- mice treated with azoxymethane. Azoxymethane 191-203 interleukin 10 Mus musculus 165-169 25763529-0 2015 Strawberry phytochemicals inhibit azoxymethane/dextran sodium sulfate-induced colorectal carcinogenesis in Crj: CD-1 mice. Azoxymethane 34-46 CD1 antigen complex Mus musculus 112-116 25503930-3 2015 Murine knockout of 15-PGDH increases susceptibility to azoxymethane-induced colon tumors. Azoxymethane 55-67 hydroxyprostaglandin dehydrogenase 15 (NAD) Mus musculus 19-26 26137415-3 2015 Formation of Azoxymethane/Dextransulfate (AOM/DSS)-induced CRCs was strongly suppressed in STAT3Deltam mice. Azoxymethane 13-25 signal transducer and activator of transcription 3 Mus musculus 91-96 26137415-3 2015 Formation of Azoxymethane/Dextransulfate (AOM/DSS)-induced CRCs was strongly suppressed in STAT3Deltam mice. Azoxymethane 42-45 signal transducer and activator of transcription 3 Mus musculus 91-96